0001104659-18-066115.txt : 20181106 0001104659-18-066115.hdr.sgml : 20181106 20181106060330 ACCESSION NUMBER: 0001104659-18-066115 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181106 DATE AS OF CHANGE: 20181106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MADRIGAL PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001157601 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33277 FILM NUMBER: 181161384 BUSINESS ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 BUSINESS PHONE: 404-380-9263 MAIL ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 FORMER COMPANY: FORMER CONFORMED NAME: SYNTA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20010815 10-Q 1 a18-18998_110q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-33277

MADRIGAL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		04-3508648
(State or other jurisdiction		(I.R.S. Employer Identification No.)
of incorporation or organization)

Four Tower Bridge
200 Barr Harbor Drive, Suite 400
West Conshohocken, Pennsylvania		19428
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (484) 380-9263

Former name, former address and former fiscal year, if changed since last report:

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o		Accelerated filer x

Non-accelerated filer o		Smaller reporting company o
		Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of November 01, 2018, the registrant had 15,393,309 shares of common stock outstanding.

Table of Contents

MADRIGAL PHARMACEUTICALS, INC.

TABLE OF CONTENTS

Item	Description	Page

	Part I. Financial Information

Item 1.	Financial Statements (Unaudited):	3
	Condensed Consolidated Balance Sheets at September 30, 2018 and December 31, 2017	3
	Condensed Consolidated Statements of Operations for the Three Months and Nine Months Ended September 30, 2018 and 2017	4
	Condensed Consolidated Statements of Comprehensive Loss for the Three Months and Nine Months Ended September 30, 2018 and 2017	5
	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2018 and 2017	6
	Notes to Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	19
Item 4.	Controls and Procedures	20

	Part II. Other Information

Item 1.	Legal Proceedings	21
Item 1A.	Risk Factors	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3.	Defaults Upon Senior Securities	21
Item 4.	Mine Safety Disclosures	21
Item 5.	Other Information	21
Item 6.	Exhibits	21
	Signatures	23

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

MADRIGAL PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited; in thousands, except share and per share amounts)

	September 30,			December 31,
	2018			2017
Assets
Current assets:
Cash and cash equivalents	$	38,046		$	148,627
Marketable securities	450,492			42,900
Prepaid expenses and other current assets	767			485
Total current assets	489,305			192,012
Property and equipment, net	244			301
Total assets	$	489,549		$	192,313
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	1,031		$	1,929
Accrued expenses	5,611			8,125
Total current liabilities	6,642			10,054
Total liabilities	6,642			10,054
Stockholders’ equity:
Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at September 30, 2018 and December 31, 2017; 1,969,797 shares issued and outstanding at September 30, 2018 and December 31, 2017	—			—
Common stock, par value $0.0001 per share authorized: 200,000,000 at September 30, 2018 and December 31, 2017; 15,393,309 and 14,227,634 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	2			1
Additional paid-in-capital	610,845			288,750
Accumulated other comprehensive loss	(143		)	(31		)
Accumulated deficit	(127,797		)	(106,461		)
Total stockholders’ equity	482,907			182,259
Total liabilities and stockholders’ equity	$	489,549		$	192,313

See accompanying notes to condensed consolidated financial statements.

Table of Contents

MADRIGAL PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited; in thousands, except share and per share amounts)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017

Revenues:
Total revenues	$	—		$	—		$	—		$	—
Operating expenses:
Research and development	6,211			6,682			16,518			17,878
General and administrative	5,122			1,955			9,710			5,273
Total operating expenses	11,333			8,637			26,228			23,151
Loss from operations	(11,333		)	(8,637		)	(26,228		)	(23,151		)
Interest income	2,821			174			4,692			342
Other income	—			100			200			100
Net loss	$	(8,512	)	$	(8,363	)	$	(21,336	)	$	(22,709	)
Net loss per common share:
Basic and diluted net loss per common share	$	(0.56	)	$	(0.68	)	$	(1.46	)	$	(1.87	)
Basic and diluted weighted average number of common shares outstanding	15,307,872			12,378,622			14,610,809			12,126,004

See accompanying notes to condensed consolidated financial statements.

Table of Contents

MADRIGAL PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited; in thousands)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017

Net Loss	$	(8,512	)	$	(8,363	)	$	(21,336	)	$	(22,709	)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities	(100		)	11			(112		)	22
Comprehensive loss	$	(8,612	)	$	(8,352	)	$	(21,448	)	$	(22,687	)

See accompanying notes to condensed consolidated financial statements.

Table of Contents

MADRIGAL PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited; in thousands)

	Nine Months Ended September 30,
	2018			2017

Cash flows from operating activities:
Net loss	$	(21,336	)	$	(22,709	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	8,370			2,307
Depreciation and amortization expense	71			17
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(281		)	290
Accounts payable	(898		)	638
Accrued expense	(2,514		)	3,085
Accrued interest, net of interest received on maturity of investments	(2,654		)	—
Net cash used in operating activities	(19,242		)	(16,372		)
Cash flows from investing activities:
Purchases of marketable securities	(524,935		)	(34,910		)
Sales and maturities of marketable securities	119,885			6,944
Purchases of property and equipment, net of disposals	(14		)	(125		)
Net cash used in investing activities	(405,064		)	(28,091		)
Cash flows from financing activities:
Proceeds from issuance of stock, net of transaction costs	311,825			38,278
Proceeds from exercise of common stock options	1,900			—
Net cash provided by financing activities	313,725			38,278
Net decrease in cash and cash equivalents	(110,581		)	(6,185		)
Cash and cash equivalents at beginning of period	148,627			19,145
Cash and cash equivalents at end of period	$	38,046		$	12,960

See accompanying notes to condensed consolidated financial statements.

Table of Contents

MADRIGAL PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Organization, Business, and Basis of Presentation

Organization and Business

Madrigal Pharmaceuticals, Inc. (the “Company” or “Madrigal”) is a clinical-stage pharmaceutical company developing novel, high-quality, small-molecule drugs addressing major unmet needs in cardiovascular, metabolic, and liver diseases. The Company’s lead compound, MGL-3196, is being advanced for non-alcoholic steatohepatitis (“NASH”), a liver disease that commonly affects people with metabolic diseases such as obesity and diabetes, and indications in dyslipidemia, including genetic dyslipidemias such as familial hypercholesterolemia (“FH”). The Company initiated a Phase 2 study of MGL-3196 in NASH in October 2016. In February 2017, the Company initiated a Phase 2 study of MGL-3196 in patients with Heterozygous Familial Hypercholesterolemia (“HeFH”). Both Phase 2 studies were fully enrolled in 2017, the HeFH study was completed in February 2018, and the NASH study was completed in May 2018.

Madrigal was originally incorporated as a private company (“Private Madrigal”) on August 19, 2011 and commenced operations in September 2011. On July 22, 2016, Private Madrigal completed a reverse merger (the “Merger”) into Synta Pharmaceuticals Corp. (“Synta”). Upon the consummation of the Merger, the historical financial statements of Private Madrigal became the Company’s historical financial statements. The Company, or Madrigal, as used in the accompanying notes to the unaudited condensed consolidated financial statements, refers to Private Madrigal prior to the completion of the Merger and Public Madrigal subsequent to the completion of the Merger.

Basis of Presentation

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted. Accordingly, the unaudited condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete annual financial statements. However, we believe that the disclosures included in these financial statements are adequate to make the information presented not misleading. The unaudited condensed financial statements, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of such interim results. The interim results are not necessarily indicative of the results that we will have for the full year ended December 31, 2018 or any subsequent period. These unaudited condensed financial statements should be read in conjunction with the audited consolidated financial statements and the notes to those statements for the year ended December 31, 2017.

2. Summary of Significant Accounting Policies

Principle of Consolidation

The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany balances have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank accounts, the balance of which, at times, exceeds Federal Deposit Insurance Corporation insured limits.

The primary objective of the Company’s investment activities is to preserve its capital for the purpose of funding operations and the Company does not enter into investments for trading or speculative purposes. The Company’s cash is deposited in highly rated financial institutions in the United States. The Company invests in money market funds and high-grade, short-term commercial paper and corporate bonds, which management believes are subject to minimal credit and market risk.

Table of Contents

Marketable Securities

Marketable securities consist of investments in high-grade corporate obligations and government and government agency obligations that are classified as available-for-sale. Since these securities are available to fund current operations, they are classified as current assets on the consolidated balance sheets.

The Company adjusts the cost of available-for-sale debt securities for amortization of premiums and accretion of discounts to maturity. The Company includes such amortization and accretion as a component of interest income, net. Realized gains and losses and declines in value, if any, that the Company judges to be other-than-temporary on available-for-sale securities are reported as a component of interest income, net. To determine whether an other-than-temporary impairment exists, the Company considers whether it intends to sell the debt security and, if the Company does not intend to sell the debt security, it considers available evidence to assess whether it is more likely than not that it will be required to sell the security before the recovery of its amortized cost basis. During the three and nine months ended September 30, 2018 and 2017, the Company determined it did not have any securities that were other-than-temporarily impaired.

Marketable securities are stated at fair value, including accrued interest, with their unrealized gains and losses included as a component of accumulated other comprehensive income or loss, which is a separate component of stockholders’ equity. The fair value of these securities is based on quoted prices and observable inputs on a recurring basis. Realized gains and losses are determined on the specific identification method. During the three and nine months ended September 30, 2018 and 2017, the Company did not have any realized gains or losses on marketable securities.

Fair Value of Financial Instruments

The carrying amounts of the Company’s financial instruments, which include cash equivalents, and marketable securities, approximate their fair values. The fair value of the Company’s financial instruments reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:

Level 1—quoted prices in active markets for identical assets and liabilities.

Level 2—observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.

Level 3—unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability.

Financial assets and liabilities are classified in their entirety within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The Company measures the fair value of its marketable securities by taking into consideration valuations obtained from third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker-dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs. As of September 30, 2018, the Company’s financial assets valued based on Level 1 inputs consisted of cash and cash equivalents in a money market fund and its financial assets valued based on Level 2 inputs consisted of high-grade corporate bonds and commercial paper. During the three and nine months ended September 30, 2018 and 2017, the Company did not have any transfers of financial assets between Levels 1 and 2. As of September 30, 2018 and December 31, 2017, the Company did not have any financial liabilities that were recorded at fair value on a recurring basis on the balance sheet.

Research and Development Costs

Research and development costs are expensed as incurred. Research and development costs are comprised of costs incurred in performing research and development activities, including internal costs (including stock-based compensation), costs for consultants, and other costs associated with the Company’s preclinical and clinical programs. In particular, Madrigal has conducted safety studies in animals, optimized and implemented the API manufacturing process, and conducted Phase 1 & 2 clinical trials, all of which are considered research and development expenditures.

Table of Contents

Patents

Costs to secure and defend patents are expensed as incurred and are classified as general and administrative expense in the Company’s consolidated statements of operations.

Stock-Based Compensation

The Company recognizes stock-based compensation expense based on the grant date fair value of stock options granted to employees, officers, and directors. The Company uses the Black-Scholes option pricing model to determine the grant date fair value as management believes it is the most appropriate valuation method for its option grants. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. The expected lives for options granted represent the period of time that options granted are expected to be outstanding. The Company uses the simplified method for determining the expected lives of options. Expected volatility is based upon an industry estimate or blended rate including the Company’s historical trading activity. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The Company estimates the forfeiture rate based on historical data. This analysis is re-evaluated at least annually and the forfeiture rate is adjusted as necessary.

Certain of the employee stock options granted by the Company are structured to qualify as incentive stock options (“ISOs”). Under current tax regulations, the Company does not receive a tax deduction for the issuance, exercise or disposition of ISOs if the employee meets certain holding requirements. If the employee does not meet the holding requirements, a disqualifying disposition occurs, at which time the Company may receive a tax deduction. The Company does not record tax benefits related to ISOs unless and until a disqualifying disposition is reported. In the event of a disqualifying disposition, the entire tax benefit is recorded as a reduction of income tax expense. The Company has not recognized any income tax benefit for its share-based compensation arrangements due to the fact that the Company does not believe it is more likely than not it will realize the related deferred tax assets.

Income Taxes

The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are determined based on the expected future tax consequences of temporary differences between the Company’s financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. The Company currently maintains a 100% valuation allowance on its deferred tax assets.

Comprehensive Loss

Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Changes in unrealized gains and losses on marketable securities represent the only difference between the Company’s net loss and comprehensive loss.

Basic and Diluted Loss Per Common Share

Basic net loss per share is computed using the weighted average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per common share is computed using the weighted average number of common shares outstanding and the weighted average dilutive potential common shares outstanding using the treasury stock method. However, for the three and nine months ended September 30, 2018 and 2017, diluted net loss per share is the same as basic net loss per share because the inclusion of weighted average shares of unvested restricted common stock, common stock issuable upon the exercise of stock options, and common stock issuable upon the conversion of preferred stock would be anti-dilutive.

The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive:

	Nine Months Ended September 30,
	2018	2017
Common Stock Options	1,123,582	991,711
Unvested Restricted Common Stock	52,063	105,199
Preferred Stock	1,969,797	1,969,797

Recent Accounting Pronouncements

Table of Contents

guidance and model as all other share-based payment transactions, including employees of the Company. For public business entities, ASU 2018-07 is effective for annual and interim reporting periods beginning after December 15, 2018, with early adoption permitted. The Company elected to early adopt the guidance within this accounting standard update in the second quarter of 2018. There was no significant impact from the adoption.

In May 2017, the FASB issued ASU No. 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting,” to provide clarity and reduce both diversity in practice, and cost and complexity when a change is made to the terms or conditions of a share-based payment award. For public business entities, ASU 2017-09 is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. The update should be applied prospectively to an award modified on or after the adoption date. The Company adopted ASU No. 2017-09 effective January 1, 2018. There was no significant impact from the adoption.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Clarification of Certain Cash Receipts and Cash Payments.” The objective of ASU No. 2016-15 is to eliminate the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows, by adding or clarifying guidance on eight specific cash flow issues. For public business entities, ASU 2016-15 is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. ASU 2016-15 provides that the amendments in the update should be applied retrospectively to all periods presented, unless deemed impracticable, in which case, prospective application is permitted. The Company adopted ASU No. 2016-15 effective January 1, 2018. There was no significant impact from the adoption.

In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,” which amends the guidance in U.S. generally accepted accounting principles on the classification and measurement of financial instruments. Changes to the prior guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The amendments in this ASU are effective for fiscal years and interim periods beginning after December 15, 2017, and are to be adopted by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company adopted ASU No. 2016-01 effective January 1, 2018. There was no significant impact from the adoption.

3. Liquidity and Uncertainties

The Company is subject to risks common to development stage companies in the biopharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, dependence on key personnel, uncertainty of market acceptance of products and product reimbursement, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing necessary for development and commercialization, and compliance with the U.S. Food and Drug Administration and other government regulations.

The Company has incurred losses since inception, including approximately $21.3 million for the nine months ended September 30, 2018, resulting in an accumulated deficit of approximately $127.8 million as of September 30, 2018. Management expects to incur losses for the foreseeable future. To date, the Company has funded its operations primarily through the issuance of convertible debt, the proceeds from the Merger on July 22, 2016, and proceeds from sales of the Company’s equity securities (see Note 5).

The Company believes that its cash, cash equivalents and marketable securities at September 30, 2018 will be sufficient to fund operations past one year from the issuance of these financial statements. To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. The Company has the ability to delay certain research activities and related clinical expenses if necessary due to liquidity concerns until a date when those concerns are relieved.

Table of Contents

4. Cash, Cash Equivalents and Marketable Securities

A summary of cash, cash equivalents and available-for-sale marketable securities held by the Company as of September 30, 2018 and December 31, 2017 is as follows (in thousands):

	September 30, 2018
	Cost		Unrealized gains		Unrealized losses			Fair value

Cash and cash equivalents:
Cash (Level 1)	$	2,127	$	—	$	—		$	2,127
Money market funds (Level 1)	35,919		—		—			35,919
Corporate debt securities due within 3 months of date of purchase (Level 2)	—		—		—			—
Total cash and cash equivalents	38,046		—		—			38,046
Marketable securities:
Corporate debt securities due within 1 year of date of purchase (Level 2)	437,106		13		(144		)	436,975
Corporate debt securities due between 1 and 2 years of the date of purchase (Level 2)	13,529		—		(12		)	13,517
Total cash, cash equivalents and marketable securities	$	488,681	$	13	$	(156	)	$	488,538

	December 31, 2017
	Cost		Unrealized Gains		Unrealized losses			Fair value

Cash and cash equivalents:
Cash (Level 1)	$	2,725	$	—	$	—		$	2,725
Money market funds (Level 1)	145,902		—		—			145,902
Corporate debt securities due within 3 months of date of purchase (Level 2)	—		—		—			—
Total cash and cash equivalents	148,627		—		—			148,627
Marketable securities:
Corporate debt securities due within 1 year of date of purchase (Level 2)	42,931		—		(31		)	42,900
Total cash, cash equivalents and marketable securities	$	191,558	$	—	$	(31	)	$	191,527

5. Stockholders’ Equity

Common Stock

Each common stockholder is entitled to one vote for each share of common stock held. The common stock will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders. Each share of common stock is entitled to receive dividends, as and when declared by the Company’s board of directors.

The Company has never declared cash dividends on its common stock and does not expect to do so in the foreseeable future.

June 2018 Registered Offering of Common Stock

In June 2018, the Company entered into an underwriting agreement with Goldman Sachs & Co. LLC, as representative of the several underwriters named therein (the “June 2018 Underwriters”), relating to an underwritten public offering (the “June 2018 Offering”) of 1,079,580 shares of the Company’s common stock, including 95,973 shares of the Company’s common stock purchased by the June 2018 Underwriters pursuant to a 30-day option to purchase such additional shares granted therein, at a public offering price of $305.00 per share. The June 2018 Offering resulted in net proceeds to the Company of approximately $311.8 million, after deducting the June 2018 Underwriters’ discount and other offering costs. The June 2018 Offering closed on June 11, 2018.

December 2017 Registered Offering of Common Stock

In December 2017, the Company entered into an underwriting agreement with Goldman Sachs & Co. LLC, as representative of the several underwriters named therein (the “December 2017 Underwriters”), relating to an underwritten public offering (the

Table of Contents

“December 2017 Offering”) of 1,731,929 shares of the Company’s common stock, including 225,904 shares of the Company’s common stock purchased by the December 2017 Underwriters pursuant to a 30-day option to purchase such additional shares granted therein, at a public offering price of $83.00 per share. The December 2017 Offering resulted in net proceeds to the Company of approximately $135.5 million, after deducting the December 2017 Underwriters’ discount and other offering costs. The December 2017 Offering closed on December 21, 2017.

June 2017 Private Placement Offering of Common Stock and Series A Convertible Preferred Stock

In June 2017, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement)” with a group of institutional accredited investors, who were existing, non-controlling stockholders of the Company, pursuant to which the Company sold securities to the Investors in a private placement transaction (the “June 2017 Offering”). Under the terms of the Purchase Agreement, the Company sold 328,300 shares of its common stock at a price of $15.23 per share, and 1,969,797 shares of its Series A Convertible Preferred Stock (the “Series A Preferred Stock”) at a price of $15.23 per share. The June 2017 Offering resulted in gross proceeds to the Company of approximately $35.0 million, and net proceeds to the Company of approximately $34.9 million. The June 2017 Offering closed on June 23, 2017.

The Series A Preferred Stock has a par value of $0.0001 per share and is convertible into shares of the common stock at a one-to-one ratio, subject to adjustment as provided in the Purchase Agreement. The terms of the Series A Preferred Stock are set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, that the Company filed with the Secretary of State of the State of Delaware on June 21, 2017. Each share of the Series A Preferred Stock is convertible into shares of Common Stock at any time at the holder’s option. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, after the satisfaction in full of the debts of the Company and the payment of any liquidation preference owed to the holders of shares of capital stock of the Company ranking prior to the Series A Preferred Stock upon liquidation, the holders of the Series A Preferred Stock shall participate pari passu with the holders of the Common Stock (on an as-if-converted-to-Common-Stock basis) in the net assets of the Company. Shares of the Series A Preferred Stock will generally have no voting rights, except as required by law. Shares of the Series A Preferred Stock will be entitled to receive dividends before shares of any other class or series of capital stock of the Company (other than dividends in the form of the Common Stock) equal to the dividend payable on each share of the Common Stock, on an as-converted basis.

At-The-Market Issuance Sales Agreement

In October 2015, the Company entered into an at-the-market issuance sales agreement (the “October 2015 Sales Agreement”), with Cowen and Company, LLC (“Cowen”), pursuant to which the Company may issue and sell shares of its common stock, having an aggregate offering price of up to $100 million, from time to time, at the Company’s option, through Cowen as its sales agent. Sales of common stock through Cowen may be made by any method that is deemed an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including by means of ordinary brokers’ transactions at market prices, in block transactions or as otherwise agreed by the Company and Cowen. Subject to the terms and conditions of the October 2015 Sales Agreement, Cowen will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the common stock based upon the Company’s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company is not obligated to make any sales of its common stock under the October 2015 Sales Agreement. Any shares sold will be sold pursuant to an effective shelf registration statement on Form S-3 (file no. 333-206135). The Company will pay Cowen a commission of up to 3% of the gross proceeds. The October 2015 Sales Agreement may be terminated by the Company at any time upon 10 days’ notice.

As of September 30, 2018, 597,256 shares have been sold under the October 2015 Sales Agreement for an aggregate of approximately $9.6 million in gross proceeds. Net proceeds to the Company were approximately $9.4 million after deducting commissions and other transactions costs. Of those shares sold, none were sold in 2018, and 215,539 were sold in 2017. Approximately $90.4 million remained reserved under the Company’s shelf registration statement and the applicable prospectus supplement for possible future issuance under the October 2015 Sales Agreement.

6. Stock-based Compensation

In June 2015, upon obtaining stockholder approval at its annual shareholder meeting, the Company implemented its new 2015 Stock Plan. The 2015 Stock Plan replaced the 2006 Stock Plan, which was terminated upon adoption of the 2015 Stock Plan. Shares of common stock reserved for outstanding awards under the 2006 Stock Plan that lapse or are canceled will be added back to the share reserve available for future awards under the 2015 Stock Plan. The 2015 Stock Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock and other stock-based compensation awards to employees, officers, directors, and consultants of the Company. The administration of the 2015 Stock Plan is under the general supervision of the compensation committee of the board of directors. The exercise price of the stock options is determined by the compensation committee of the board of directors, provided that incentive stock options are granted with an exercise price not less than fair market value of the common

Table of Contents

stock on the date of grant and expire no later than ten years from the date the option is granted. As of September 30, 2018, the Company had options outstanding to purchase 1,123,582 shares of its common stock, which includes options outstanding under its 2006 Stock Plan that was terminated in June 2015. As of September 30, 2018, 1,225,595 shares were available for future issuance.

The following table summarizes stock option activity during the nine months ended September 30, 2018:

	Shares		Weighted average exercise price
Outstanding at January 1, 2018	976,777		$	11.97
Options granted	241,650		173.23
Options exercised	(86,095	)	22.06
Options canceled	(8,750	)	113.81
Outstanding at September 30, 2018	1,123,582		$	45.09
Exercisable at September 30, 2018	621,000		$	10.75

The total cash received by the Company as a result of stock option exercises was $1.9 million and $0, respectively, for the nine months ended September 30, 2018 and 2017. The weighted-average grant date fair values, based on the Black-Scholes option model, of options granted during the nine months ended September 30, 2018 and 2017 were $136.43 and $13.30, respectively.

Restricted Common Stock

The Company’s share-based compensation plan provides for awards of restricted shares of common stock to employees, officers, directors and consultants to the Company. Restricted stock awards are subject to forfeiture if employment or service terminates during the prescribed retention period. Restricted shares vest over the service period.

The following table summarizes unvested restricted share activity during the nine months ended September 30, 2018:

	Shares		Weighted average exercise price
Outstanding at January 1, 2018	104,127		$	9.45
Granted	—		—
Vested	(52,064	)	9.45
Forfeited	—		—
Outstanding at September 30, 2018	52,063		$	9.45

Stock-Based Compensation Expense

Stock-based compensation expense during the three and nine months ended September 2018 and 2017 was as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Stock-based compensation expense by type of award:
Stock options	$	4,852	$	878	$	8,002	$	1,859
Restricted stock	124		151		368		448
Total stock-based compensation expense	$	4,976	$	1,029	$	8,370	$	2,307

Effect of stock-based compensation expense by line item:
Research and development	$	1,179	$	272	$	2,287	$	577
General and administrative	3,797		757		6,083		1,730
Total stock-based compensation expense included in net loss	$	4,976	$	1,029	$	8,370	$	2,307

Unrecognized stock-based compensation expense as of September 30, 2018 was as follows (in thousands):

Table of Contents

	Unrecognized stock compensation expense		Weighted average remaining period (in years)
Stock options	$	25,250	2.23
Restricted stock	396		0.80
Total	$	25,646	2.21

7. Commitments and Contingencies

The Company has a Research, Development and Commercialization Agreement with Hoffmann-La Roche (“Roche”) which grants the Company a sole and exclusive license to develop, use, sell, offer for sale and import any Licensed Product as defined by the agreement.

The agreement requires future milestone payments to Roche, the remainder of which total $10 million and are earned by the commencement of Phase 3 clinical trials as well as future regulatory approval in the United States and Europe of a product developed from MGL-3916. A single-digit royalty payment range is based on net sales of products developed from MGL-3196, subject to certain reductions. In October 2016, the Company commenced a Phase 2 study in Non-Alcoholic Steatohepatitis (NASH), which triggered a milestone payment under the agreement. Except as described above, the Company has not achieved any additional product development or regulatory milestones to date and has no Licensed Product sales for the nine months ended September 30, 2018 and 2017.

The Company has entered into customary contractual arrangements and letters of intent in preparation for and in support of the Phase 2 and 3 clinical trials.

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements that are based on our beliefs and assumptions and on information currently available to us. Forward-looking statements include information with respect to our clinical trials, research and development activities, the timing and success of future development of MGL-3196, our possible or assumed future results of operations and expenses, business strategies and plans, capital needs and financing plans, trends, market sizing, competitive position, industry environment and potential growth opportunities, among other things. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” “would” or similar expressions and the negatives of those terms.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements, including those described in “Risk Factors” and elsewhere in this report. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

Any forward-looking statement made by us in this report speaks only as of the date on which it is made. Except as required by law, we disclaim any obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The consolidated financial statements, included elsewhere in this Quarterly Report on Form 10-Q, and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read together with our audited financial statements and accompanying notes for year ended December 31, 2017 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are included in our Annual Report on Form 10-K. In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the sections entitled “Risk Factors” included elsewhere in this report. Our operating results are not necessarily indicative of results that may occur for the full fiscal year or any other future period.

About Madrigal Pharmaceuticals, Inc.

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Our lead product candidate, MGL-3196, is a proprietary, liver-directed, selective thyroid hormone receptor-ß, or THR-ß, agonist being developed as a once-daily oral pill that can potentially be used to treat a number of disease states with high unmet medical need, including non-alcoholic steatohepatitis, or NASH. For NASH, we enrolled 125 patients in a Phase 2 clinical trial. We achieved the 12-week primary endpoint for this Phase 2 clinical trial and reported the results in December 2017, and we reported positive topline 36-week results at the conclusion of the Phase 2 clinical trial in May 2018. We have an ongoing 36-week, open-label extension study in 31 participating NASH patients from the Phase 2 clinical trial, which includes 14 patients who received placebo in the main study. We are also developing MGL-3196 for dyslipidemia, including genetic dyslipidemias such as heterozygous familial hypercholesterolemia, or HeFH. We enrolled 116 patients and completed a Phase 2 clinical trial in HeFH patients, and we reported the results in February 2018. In addition to the NASH and HeFH Phase 2 clinical trials, MGL-3196 has also been studied in six completed Phase 1 trials in a total of 183 subjects. MGL-3196 appeared to be safe and was well-tolerated in these trials, which included a single ascending dose trial, a multiple ascending dose trial, two drug interaction trials with statins, a multiple dose mass balance study, and a single dose relative bioavailability study of tablet formulations versus capsule formulation.

Table of Contents

Basis of Presentation

Research and Development Expenses

Research and development expenses primarily consist of costs associated with our research activities, including the preclinical and clinical development of our product candidates. We expense our research and development expenses as incurred. We contract with clinical research organizations to manage our clinical trials under agreed upon budgets for each study, with oversight by our clinical program managers. We account for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received. Manufacturing expense includes costs associated with drug formulation development and drug production. We do not track employee and facility related research and development costs by project, as we typically use our employee and infrastructure resources across multiple research and development programs. We believe that the allocation of such costs would be arbitrary and not be meaningful.

Our research and development expenses consist primarily of:

· external expenses paid to clinical trial sites, contract research organizations, laboratories, database software providers and consultants that conduct clinical trials;

· expenses related to development and production of nonclinical and clinical trial supplies, including fees paid to contract manufacturers;

· expenses related to preclinical studies;

· expenses related to compliance with drug development regulatory requirements; and

· other allocated expenses, which include direct and allocated expenses for depreciation of equipment and other supplies.

We expect to continue to incur substantial expenses related to our development activities for the foreseeable future as we initiate our Phase 3 clinical program and continue to conduct our Phase 2 clinical program and manufacturing and toxicology studies. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, due primarily to the increased size and duration of later-stage clinical trials, additional drug manufacturing requirements, and later stage toxicology studies such as carcinogenicity studies. Our research and development expenses increased between 2017 and 2018, and we expect that our research and development expenses will increase substantially in the future. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time consuming. The probability of success for each product candidate is affected by numerous factors, including preclinical data, clinical data, competition, manufacturing capability and commercial viability. Accordingly, we may never succeed in achieving marketing approval for any of our product candidates.

Completion dates and costs for our clinical development programs as well as our research program can vary significantly for each current and future product candidate and are difficult to predict. As a result, we cannot estimate with any degree of certainty the costs we will incur in connection with the development of our product candidates at this point in time. We expect that we will make determinations as to which programs and product candidates to pursue and how much funding to direct to each program and product candidate on an ongoing basis in response to the scientific success of early research programs, results of ongoing and future clinical trials, our ability to enter into collaborative agreements with respect to programs or potential product candidates, as well as ongoing assessments as to each current or future product candidate’s commercial potential.

General and Administrative Expenses

General and administrative expenses consist primarily of management costs, costs associated with obtaining and maintaining our patent portfolio, professional fees for accounting, auditing, consulting and legal services, and allocated overhead expenses.

We expect that our general and administrative expenses may increase in the future as we expand our operating activities, maintain and expand our patent portfolio and incur additional costs associated with being a public company and maintaining compliance with exchange listing and U.S. Securities and Exchange Commission, or SEC, requirements. We expect these potential increases will likely include management costs, legal fees, accounting fees, directors’ and officers’ liability insurance premiums and expenses associated with investor relations.

Critical Accounting Policies and Estimates

Our management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amount of assets, liabilities, and expenses

Table of Contents

and the disclosure of contingent assets and liabilities as of the date of the financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued research and development expenses and stock-based compensation expense. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions. There have been no material changes in our critical accounting policies and significant judgments and estimates during the nine months ended September 30, 2018, as compared to those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed with the SEC on March 13, 2018.

Results of Operations

Three Months Ended September 30, 2018 and 2017

The following table provides comparative unaudited results of operations for the three months ended September 30, 2018 and 2017 (in thousands):

	Three Months Ended September 30,						Increase / (Decrease)
	2018			2017			$		%

Research and Development Expenses	$	6,211		$	6,682		(471	)	(7	)%
General and Administrative Expenses	5,122			1,955			3,167		162	%
Interest Income	(2,821		)	(174		)	2,647		1521	%
Other Income	—			(100		)	(100	)	(100	)%
	$	8,512		$	8,363

Revenue

We had no revenue for the three months ended September 30, 2018 and 2017.

Research and Development Expenses

Our research and development expenses were $6.2 million for the three months ended September 30, 2018, compared to $6.7 million in the corresponding period in 2017. Research and development expenses decreased by $0.5 million in the 2018 period due primarily to the completion of treatment in our Phase 2 clinical trials in 2018. We expect our research and development expenses to increase over time as we advance our clinical and preclinical development programs for MGL-3196.

General and Administrative Expenses

Our general and administrative expenses were $5.1 million for the three months ended September 30, 2018, compared to $2.0 million in the corresponding period in 2017. General and administrative expenses increased by $3.1 million in the 2018 period due primarily to an increase in non-cash stock compensation from stock option awards. We believe our general and administrative expenses may increase over time as we advance our clinical and preclinical development programs for MGL-3196, which will likely result in an increase in our headcount, consulting services, and related overhead needed to support those efforts.

Interest Income

Our net interest income was $2.8 million for the three months ended September 30, 2018, compared to $0.2 million for the three months ended September 30, 2017. The increase in interest income was due primarily to a higher average principal balance in our investment account in 2018, and increased interest rates.

Table of Contents

Nine Months Ended September 30, 2018 and 2017

The following table provides comparative unaudited results of operations for the nine months ended September 30, 2018 and 2017 (in thousands):

	Nine Months Ended September 30,						Increase / (Decrease)
	2018			2017			$		%

Research and Development Expenses	$	16,518		$	17,878		(1,360	)	(8	)%
General and Administrative Expenses	9,710			5,273			4,437		84	%
Interest Income	(4,692		)	(342		)	4,350		1272	%
Other Income	(200		)	(100		)	100		100	%
	$	21,336		$	22,709

Revenue

We had no revenue for the nine months ended September 30, 2018 and 2017.

Research and Development Expenses

Our research and development expenses were $16.5 million for the nine months ended September 30, 2018, compared to $17.9 million in the corresponding period in 2017. Research and development expenses decreased by $1.4 million in the 2018 period due primarily to the completion of treatment in our Phase 2 clinical trials in 2018. We expect our research and development expenses to increase over time as we advance our clinical and preclinical development programs for MGL-3196.

General and Administrative Expenses

Our general and administrative expenses were $9.7 million for the nine months ended September 30, 2018, compared to $5.3 million in the corresponding period in 2017. General and administrative expenses increased by $4.4 million in the 2018 period due primarily to an increase in non-cash stock compensation from stock option awards. We believe our general and administrative expenses may increase over time as we advance our clinical and preclinical development programs for MGL-3196, which will likely result in an increase in our headcount, consulting services, and related overhead needed to support those efforts.

Interest Income

Our net interest income was $4.7 million for the nine months ended September 30, 2018, compared to $0.3 million for the nine months ended September 30, 2017. The increase in interest income was due primarily to a higher average principal balance in our investment account in 2018, and increased interest rates.

Liquidity and Capital Resources

As of September 30, 2018, we had cash, cash equivalents and marketable securities totaling $488.5 million compared to $191.5 million as of December 31, 2017, with the increase primarily attributable to the proceeds from the June 2018 Offering, partially offset by our cash used in operating activities. To date, we have funded our operations primarily through the issuance of convertible debt, the issuance of shares of common stock and preferred stock, and the proceeds from the merger with Synta.

Our most significant use of capital pertains to salaries and benefits for our employees, including clinical, scientific, operational, financial and management personnel, and external research and development expenses, such as clinical trials and preclinical activity related to our product candidates. Our cash and investment balances are held in a variety of interest bearing instruments, including obligations of U.S. government agencies, U.S. Treasury debt securities, corporate debt securities and money market funds. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital preservation and liquidity.

We anticipate continuing to incur operating losses for the foreseeable future. While our rate of cash usage may increase in the future, in particular to support our product development and clinical trial efforts, we believe our available cash resources as of September 30,

Table of Contents

2018 will be sufficient to fund our operations past one year from the issuance of the financial statements contained herein. Future capital requirements will be substantial and will depend on many factors. To meet future capital requirements, we will need to raise additional capital to fund our operations through equity or debt financing. We regularly consider fundraising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of operation. Additional capital may not be available on terms acceptable to us, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, our business and our ability to develop our product candidates would be harmed. Furthermore, any sales of additional equity securities may result in dilution to our stockholders, and any debt financing may include covenants that restrict our business.

Cash Flows

The following table provides a summary of our net cash flow activity (in thousands):

	Nine Months Ended September 30,
	2018			2017
Net cash used in operating activities	$	(19,242	)	$	(16,372	)
Net cash used by investing activities	(405,064		)	(28,091		)
Net cash provided by financing activities	313,725			38,278
Net decrease in cash and cash equivalents	$	(110,581	)	$	(6,185	)

Net cash used in operating activities was $19.2 million for the nine months ended September 30, 2018, compared to $16.4 million for the nine months ended September 30, 2017. The use of cash in these periods resulted primarily from our losses from operations, as adjusted for non-cash charges for stock-based compensation, and changes in our working capital accounts.

Net cash used in investing activities was $405.1 million for the nine months ended September 30, 2018, compared to $28.1 million used in investing activities for the nine months ended September 30, 2017. Net cash used by investing activities for the nine months ended September 30, 2018 consisted of $524.9 million of purchases of marketable securities for our investment portfolio, partially offset by $119.9 million from sales and maturities of marketable securities. Net cash used by investing activities for the nine months ended September 30, 2017 consisted of $34.9 million of purchases of marketable securities for our investment portfolio, partially offset by $6.9 million from sales and maturities of marketable securities.

Net cash provided by financing activities was $313.7 million for the nine months ended September 30, 2018, compared to $38.3 million for the nine months ended September 30, 2017. Net cash provided by financing activities for the nine months ended September 30, 2018 consisted of net proceeds from the issuance of common stock pursuant to the June 2018 Offering and the exercise of stock options. Net cash provided by financing activities for the nine months ended September 30, 2017 consisted of net proceeds from the sale of common stock under the October 2015 Sales Agreement and net proceeds from the sale of preferred stock and common stock in the June 2017 Offering.

Contractual Obligations and Commitments

No significant changes to contractual obligations and commitments occurred during the nine months ended September 30, 2018, as compared to those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the SEC on March 13, 2018.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements as defined in the rules and regulations of the SEC.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Risk

Our cash, cash equivalents and marketable securities as of September 30, 2018 consisted of readily available checking account balances, money market funds, and high-grade corporate and government obligations that are classified as available-for-sale. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. However, because of the short-term nature of the instruments in our portfolio, a sudden change in market interest rates would not be expected to have a material impact on our financial condition and/or results of operations. We do not believe that our cash, cash

Table of Contents

equivalents and marketable securities have a significant risk of default or illiquidity. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits.

Effects of Inflation

Inflation generally affects us with increased cost of labor and clinical trial costs. We do not believe that inflation and changing prices had a significant impact on our results of operations for any periods presented herein.

Item 4. Controls and Procedures.

Definition and Limitations of Disclosure Controls

Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file under the Exchange Act, such as this Quarterly Report, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management evaluates these controls and procedures on an ongoing basis.

We carried out an evaluation, under the supervision of and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

Limitations on the Effectiveness of Controls and Procedures

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

We are not party to any material pending legal proceedings. From time to time, we may be involved in legal proceedings arising in the ordinary course of business.

Item 1A. Risk Factors.

There have been no material changes to the risk factors included in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2018.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.

EXHIBIT INDEX

Exhibit

Incorporated by Reference

Filed

Number

Exhibit Description

Form

File No.

Exhibit

Filing Date

Herewith

31.1

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*

Certifications of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

XBRL Instance Document.

101.SCH

XBRL Taxonomy Extension Schema Document.

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document.

Table of Contents

101.LAB

XBRL Taxonomy Extension Label Linkbase Document.

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document.

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document.

* The certifications attached as Exhibit 32.1 that accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, shall not be deemed “filed” by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrant’s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MADRIGAL PHARMACEUTICALS, INC.


Date: November 6, 2018	By:	/s/ Paul A. Friedman, M.D.
		Paul A. Friedman, M.D.
		Chief Executive Officer
		(Principal Executive Officer)


Date: November 6, 2018	By:	/s/ Marc R. Schneebaum
		Marc R. Schneebaum
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-31.1 2 a18-18998_1ex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a)

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Paul A. Friedman, M.D., certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Madrigal Pharmaceuticals, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Paul A. Friedman, M.D.
Paul A. Friedman, M.D.
Chief Executive Officer and Chairman of the Board
(Principal Executive Officer)
Date: November 6, 2018

EX-31.2 3 a18-18998_1ex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO

EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a)

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Marc R. Schneebaum, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Madrigal Pharmaceuticals, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Marc R. Schneebaum
Marc R. Schneebaum
Senior Vice President and Chief Financial Officer
(Principal Financial Officer)
Date: November 6, 2018

EX-32.1 4 a18-18998_1ex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350)), each of the undersigned officers of Madrigal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2018 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 6, 2018	/s/ Paul A. Friedman, M.D.
	Paul A. Friedman, M.D.
	Chief Executive Officer and Chairman of the Board
	(Principal Executive Officer)

Dated: November 6, 2018	/s/ Marc R. Schneebaum
	Marc R. Schneebaum
	Senior Vice President and Chief Financial Officer
	(Principal Accounting and Financial Officer)

These certifications accompany the Form 10-Q, are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.INS 5 mdgl-20180930.xml XBRL INSTANCE DOCUMENT 0001157601 mdgl:GoldmanSachsCoMember us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember mdgl:UnderwritingAgreementMember 2018-06-01 2018-06-30 0001157601 mdgl:AtTheMarketIssuanceSalesAgreementMember 2018-01-01 2018-09-30 0001157601 mdgl:GoldmanSachsCoMember us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember mdgl:UnderwritingAgreementMember 2017-12-01 2017-12-31 0001157601 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember mdgl:SecuritiesPurchaseAgreementMember 2017-06-01 2017-06-30 0001157601 mdgl:ConvertibleSeriesPreferredStockMember us-gaap:PrivatePlacementMember mdgl:SecuritiesPurchaseAgreementMember 2017-06-01 2017-06-30 0001157601 mdgl:AtTheMarketIssuanceSalesAgreementMember 2017-01-01 2017-12-31 0001157601 mdgl:GoldmanSachsCoMember us-gaap:CommonStockMember mdgl:RegisteredOfferingMember mdgl:UnderwritingAgreementMember 2018-06-30 0001157601 mdgl:GoldmanSachsCoMember us-gaap:CommonStockMember mdgl:RegisteredOfferingMember mdgl:UnderwritingAgreementMember 2017-12-31 0001157601 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember mdgl:SecuritiesPurchaseAgreementMember 2017-06-30 0001157601 mdgl:ConvertibleSeriesPreferredStockMember us-gaap:PrivatePlacementMember mdgl:SecuritiesPurchaseAgreementMember 2017-06-30 0001157601 us-gaap:EmployeeStockOptionMember 2017-12-31 0001157601 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001157601 mdgl:HoffmanLaRocheMember mdgl:ResearchDevelopmentAndCommercializationAgreementMember 2018-01-01 2018-09-30 0001157601 mdgl:HoffmanLaRocheMember mdgl:ResearchDevelopmentAndCommercializationAgreementMember 2017-01-01 2017-09-30 0001157601 mdgl:AtTheMarketIssuanceSalesAgreementMember 2015-10-01 2018-09-30 0001157601 mdgl:ConvertibleSeriesPreferredStockMember 2017-09-30 0001157601 us-gaap:RestrictedStockMember 2018-09-30 0001157601 us-gaap:EmployeeStockOptionMember 2018-09-30 0001157601 mdgl:ConvertibleSeriesPreferredStockMember 2017-06-01 2017-06-30 0001157601 2017-09-30 0001157601 2016-12-31 0001157601 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-09-30 0001157601 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-09-30 0001157601 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-09-30 0001157601 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-09-30 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-09-30 0001157601 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0001157601 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-12-31 0001157601 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0001157601 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-12-31 0001157601 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2018-09-30 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember mdgl:CorporateDebtSecurities3Member 2018-09-30 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2018-09-30 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember mdgl:CorporateDebtSecurities3Member 2018-09-30 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0001157601 us-gaap:FairValueInputsLevel2Member mdgl:CorporateDebtSecurities3Member 2018-09-30 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0001157601 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2018-09-30 0001157601 us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0001157601 us-gaap:PreferredStockMember 2018-01-01 2018-09-30 0001157601 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001157601 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0001157601 us-gaap:PreferredStockMember 2017-01-01 2017-09-30 0001157601 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001157601 us-gaap:RestrictedStockMember 2018-07-01 2018-09-30 0001157601 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001157601 us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0001157601 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0001157601 2018-07-01 2018-09-30 0001157601 us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0001157601 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001157601 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0001157601 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001157601 us-gaap:RestrictedStockMember 2017-07-01 2017-09-30 0001157601 us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-01 2017-09-30 0001157601 us-gaap:GeneralAndAdministrativeExpenseMember 2017-07-01 2017-09-30 0001157601 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0001157601 2017-07-01 2017-09-30 0001157601 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0001157601 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0001157601 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-09-30 0001157601 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001157601 mdgl:GoldmanSachsCoMember us-gaap:CommonStockMember mdgl:RegisteredOfferingMember mdgl:UnderwritingAgreementMember 2018-06-01 2018-06-30 0001157601 mdgl:GoldmanSachsCoMember us-gaap:CommonStockMember mdgl:RegisteredOfferingMember mdgl:UnderwritingAgreementMember 2017-12-01 2017-12-31 0001157601 mdgl:AtTheMarketIssuanceSalesAgreementMember 2018-09-30 0001157601 mdgl:HoffmanLaRocheMember mdgl:ResearchDevelopmentAndCommercializationAgreementMember 2018-09-30 0001157601 us-gaap:PrivatePlacementMember mdgl:SecuritiesPurchaseAgreementMember 2017-06-01 2017-06-30 0001157601 2017-01-01 2017-09-30 0001157601 mdgl:ConvertibleSeriesPreferredStockMember 2017-06-30 0001157601 srt:MinimumMember mdgl:CorporateDebtSecurities3Member 2018-01-01 2018-09-30 0001157601 srt:MaximumMember mdgl:CorporateDebtSecurities3Member 2018-01-01 2018-09-30 0001157601 us-gaap:CorporateDebtSecuritiesMember 2018-01-01 2018-09-30 0001157601 mdgl:CorporateDebtSecurities2Member 2018-01-01 2018-09-30 0001157601 us-gaap:CorporateDebtSecuritiesMember 2017-01-01 2017-12-31 0001157601 mdgl:CorporateDebtSecurities2Member 2017-01-01 2017-12-31 0001157601 mdgl:CowenCo.LlcMember srt:MaximumMember mdgl:AtTheMarketIssuanceSalesAgreementMember 2015-10-01 2015-10-31 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-09-30 0001157601 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-12-31 0001157601 2017-12-31 0001157601 2018-09-30 0001157601 2018-11-01 0001157601 2018-01-01 2018-09-30 iso4217:USD xbrli:shares xbrli:pure mdgl:Vote iso4217:USD xbrli:shares false --12-31 Q3 2018 2018-09-30 10-Q 0001157601 15393309 Yes false Accelerated Filer MADRIGAL PHARMACEUTICALS, INC. false 13000 31000 156000 191558000 488681000 100000000 1 1.00 -2654000 P3M P1Y P3M P1Y P2Y P1Y <div> <div> Patents Costs to secure and defend patents are expensed as incurred and are classified as general and administrative expense in the Company's consolidated statements of operations. <div /></div> </div> 0.03 0 38278000 34900000 311825000 10000000 90400000 P30D P30D P10D <div> <div> Stock-based compensation expense during the three and nine months ended September 2018 and 2017 was as follows (in thousands):     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended September 30, </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:25.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine Months Ended September 30, </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock-based compensation expense by type of award: </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  4,852 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  878 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  8,002 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  1,859 </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Restricted stock </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  124 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  151 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  368 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  448 </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total stock-based compensation expense </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  4,976 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  1,029 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  8,370 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  2,307 </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Effect of stock-based compensation expense by line item: </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  1,179 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  272 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  2,287 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  577 </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  3,797 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  757 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  6,083 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  1,730 </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total stock-based compensation expense included in net loss </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  4,976 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  1,029 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  8,370 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  2,307 </td> </tr> </table></div>   <div /></div> </div>

1929000

1031000

8125000

5611000

-31000

-143000

288750000

610845000

2307000

1859000

1730000

577000

448000

1029000

878000

757000

272000

151000

8370000

8002000

6083000

2287000

368000

4976000

4852000

3797000

1179000

124000

991711

1969797

105199

1123582

1969797

52063

192313000

489549000

192012000

489305000

13000

31000

12000

144000

42931000

13529000

437106000

42900000

13517000

436975000

42900000

450492000

148627000

38046000

148627000

2725000

145902000

38046000

2127000

35919000

<div> <div> Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank accounts, the balance of which, at times, exceeds Federal Deposit Insurance Corporation insured limits. The primary objective of the Company's investment activities is to preserve its capital for the purpose of funding operations and the Company does not enter into investments for trading or speculative purposes. The Company's cash is deposited in highly rated financial institutions in the United States. The Company invests in money market funds and high-grade, short-term commercial paper and corporate bonds, which management believes are subject to minimal credit and market risk. <div /></div> </div>

<div> <div> 4. Cash, Cash Equivalents and Marketable Securities   A summary of cash, cash equivalents and available-for-sale marketable securities held by the Company as of September 30, 2018 and December 31, 2017 is as follows (in thousands):     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:41.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2018 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> gains </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> losses </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> value </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash and cash equivalents: </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cash (Level 1) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,127 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,127 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Money market funds (Level 1) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 35,919 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 35,919 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate debt securities due within 3 months of date of purchase (Level 2) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total cash and cash equivalents </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 38,046 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 38,046 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Marketable securities: </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Corporate debt securities due within 1 year of date of purchase (Level 2) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 437,106 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (144) </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 436,975 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate debt securities due between 1 and 2 years of the date of purchase (Level 2) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 13,529 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (12) </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 13,517 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total cash, cash equivalents and marketable securities </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 488,681 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (156) </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 488,538 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:37.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, 2017 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gains </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> losses </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> value </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash and cash equivalents: </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cash (Level 1) </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,725 </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,725 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Money market funds (Level 1) </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 145,902 </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 145,902 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate debt securities due within 3 months of date of purchase (Level 2) </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total cash and cash equivalents </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 148,627 </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 148,627 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Marketable securities: </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Corporate debt securities due within 1 year of date of purchase (Level 2) </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 42,931 </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (31) </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 42,900 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total cash, cash equivalents and marketable securities </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 191,558 </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (31) </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 191,527 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

191527000

488538000

19145000

12960000

148627000

38046000

-6185000

-110581000

<div> <div> 7. Commitments and Contingencies   The Company has a Research, Development and Commercialization Agreement with Hoffmann-La Roche (“Roche”) which grants the Company a sole and exclusive license to develop, use, sell, offer for sale and import any Licensed Product as defined by the agreement.   The agreement requires future milestone payments to Roche, the remainder of which total $10 million and are earned by the commencement of Phase 3 clinical trials as well as future regulatory approval in the United States and Europe of a product developed from MGL-3916. A single-digit royalty payment range is based on net sales of products developed from MGL-3196, subject to certain reductions.  In October 2016, the Company commenced a Phase 2 study in Non-Alcoholic Steatohepatitis (NASH), which triggered a milestone payment under the agreement. Except as described above, the Company has not achieved any additional product development or regulatory milestones to date and has no Licensed Product sales for the nine months ended September 30, 2018 and 2017.   The Company has entered into customary contractual arrangements and letters of intent in preparation for and in support of the Phase 2 and 3 clinical trials. <div /></div> </div>

0.0001

200000000

14227634

15393309

14227634

15393309

1000

2000

-22687000

-8352000

-21448000

-8612000

<div> <div> Comprehensive Loss Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Changes in unrealized gains and losses on marketable securities represent the only difference between the Company's net loss and comprehensive loss. <div /></div> </div>

<div> <div> Principle of Consolidation   The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany balances have been eliminated in consolidation. <div /></div> </div>

17000

71000

<div> <div> 6. Stock-based Compensation   In June 2015, upon obtaining stockholder approval at its annual shareholder meeting, the Company implemented its new 2015 Stock Plan. The 2015 Stock Plan replaced the 2006 Stock Plan, which was terminated upon adoption of the 2015 Stock Plan. Shares of common stock reserved for outstanding awards under the 2006 Stock Plan that lapse or are canceled will be added back to the share reserve available for future awards under the 2015 Stock Plan. The 2015 Stock Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock and other stock-based compensation awards to employees, officers, directors, and consultants of the Company. The administration of the 2015 Stock Plan is under the general supervision of the compensation committee of the board of directors. The exercise price of the stock options is determined by the compensation committee of the board of directors, provided that incentive stock options are granted with an exercise price not less than fair market value of the common stock on the date of grant and expire no later than ten years from the date the option is granted. As of September 30, 2018, the Company had options outstanding to purchase 1,123,582 shares of its common stock, which includes options outstanding under its 2006 Stock Plan that was terminated in June 2015. As of September 30, 2018, 1,225,595 shares were available for future issuance.   The following table summarizes stock option activity during the nine months ended September 30, 2018:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> average </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> exercise </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> price </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at January 1, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  976,777 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11.97 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Options granted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  241,650 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 173.23 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Options exercised </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (86,095) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 22.06 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Options canceled </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (8,750) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 113.81 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at September 30, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  1,123,582 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 45.09 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exercisable at September 30, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  621,000 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10.75 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   The total cash received by the Company as a result of stock option exercises was $1.9 million and $0,  respectively, for the nine months ended September 30, 2018 and 2017. The weighted-average grant date fair values, based on the Black-Scholes option model, of options granted during the nine months ended September 30, 2018 and 2017 were $136.43 and $13.30, respectively.   Restricted Common Stock   The Company’s share-based compensation plan provides for awards of restricted shares of common stock to employees, officers, directors and consultants to the Company. Restricted stock awards are subject to forfeiture if employment or service terminates during the prescribed retention period. Restricted shares vest over the service period.   The following table summarizes unvested restricted share activity during the nine months ended September 30, 2018:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> </tr> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> average </td> </tr> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> exercise </td> </tr> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> price </td> </tr> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at January 1, 2018 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 104,127 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9.45 </td> </tr> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> </tr> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (52,064) </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9.45 </td> </tr> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> </tr> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at September 30, 2018 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 52,063 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9.45 </td> </tr> </table></div>   Stock-Based Compensation Expense   Stock-based compensation expense during the three and nine months ended September 2018 and 2017 was as follows (in thousands):     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended September 30, </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:25.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine Months Ended September 30, </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock-based compensation expense by type of award: </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  4,852 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  878 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  8,002 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  1,859 </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Restricted stock </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  124 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  151 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  368 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  448 </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total stock-based compensation expense </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  4,976 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  1,029 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  8,370 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  2,307 </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Effect of stock-based compensation expense by line item: </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  1,179 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  272 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  2,287 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  577 </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  3,797 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  757 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  6,083 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  1,730 </td> </tr> <tr> <td valign="bottom" style="width:44.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total stock-based compensation expense included in net loss </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  4,976 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  1,029 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  8,370 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  2,307 </td> </tr> </table></div>   Unrecognized stock-based compensation expense as of September 30, 2018 was as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrecognized </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> average </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> stock </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> remaining </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> compensation </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> period </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> expense </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in years) </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  25,250 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.23 </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Restricted stock </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  396 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.80 </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  25,646 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.21 </td> </tr> </table></div>   <div /></div> </div>

-1.87

-0.68

-1.46

-0.56

<div> <div> Basic and Diluted Loss Per Common Share   Basic net loss per share is computed using the weighted average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per common share is computed using the weighted average number of common shares outstanding and the weighted average dilutive potential common shares outstanding using the treasury stock method. However, for the three and nine months ended September 30, 2018 and 2017, diluted net loss per share is the same as basic net loss per share because the inclusion of weighted average shares of unvested restricted common stock, common stock issuable upon the exercise of stock options, and common stock issuable upon the conversion of preferred stock would be anti-dilutive. The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive:                                                                                                                                                                                                  <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:32.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine Months Ended September 30, </td> <td valign="bottom" style="width:00.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Common Stock Options </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,123,582 </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 991,711 </td> <td valign="bottom" style="width:00.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unvested Restricted Common Stock </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 52,063 </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 105,199 </td> <td valign="bottom" style="width:00.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Preferred Stock </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,969,797 </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,969,797 </td> <td valign="bottom" style="width:00.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

25646000

25250000

396000

P2Y2M16D

P2Y2M23D

P9M18D

<div> <div> Fair Value of Financial Instruments The carrying amounts of the Company's financial instruments, which include cash equivalents, and marketable securities, approximate their fair values. The fair value of the Company's financial instruments reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels: Level 1—quoted prices in active markets for identical assets and liabilities. Level 2—observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3—unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The Company measures the fair value of its marketable securities by taking into consideration valuations obtained from third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker-dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs. As of September 30, 2018, the Company's financial assets valued based on Level 1 inputs consisted of cash and cash equivalents in a money market fund and its financial assets valued based on Level 2 inputs consisted of high-grade corporate bonds and commercial paper. During the three and nine months ended September 30, 2018 and 2017, the Company did not have any transfers of financial assets between Levels 1 and 2. As of September 30, 2018 and December 31, 2017, the Company did not have any financial liabilities that were recorded at fair value on a recurring basis on the balance sheet. <div /></div> </div>

5273000

1955000

9710000

5122000

<div> <div> Income Taxes The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are determined based on the expected future tax consequences of temporary differences between the Company's financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. The Company currently maintains a 100% valuation allowance on its deferred tax assets. <div /></div> </div>

638000

-898000

3085000

-2514000

-290000

281000

342000

174000

4692000

2821000

10054000

6642000

192313000

489549000

10054000

6642000

<div> <div> Marketable Securities Marketable securities consist of investments in high-grade corporate obligations and government and government agency obligations that are classified as available-for-sale. Since these securities are available to fund current operations, they are classified as current assets on the consolidated balance sheets. The Company adjusts the cost of available-for-sale debt securities for amortization of premiums and accretion of discounts to maturity. The Company includes such amortization and accretion as a component of interest income, net. Realized gains and losses and declines in value, if any, that the Company judges to be other-than-temporary on available-for-sale securities are reported as a component of interest income, net. To determine whether an other-than-temporary impairment exists, the Company considers whether it intends to sell the debt security and, if the Company does not intend to sell the debt security, it considers available evidence to assess whether it is more likely than not that it will be required to sell the security before the recovery of its amortized cost basis. During the three and nine months ended September 30, 2018 and 2017, the Company determined it did not have any securities that were other-than-temporarily impaired. Marketable securities are stated at fair value, including accrued interest, with their unrealized gains and losses included as a component of accumulated other comprehensive income or loss, which is a separate component of stockholders' equity. The fair value of these securities is based on quoted prices and observable inputs on a recurring basis. Realized gains and losses are determined on the specific identification method. During the three and nine months ended September 30, 2018 and 2017, the Company did not have any realized gains or losses on marketable securities. <div /></div> </div>

38278000

313725000

-28091000

-405064000

-16372000

-19242000

-22709000

-8363000

-21336000

-8512000

<div> <div> Recent Accounting Pronouncements   In June 2018, The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-07, “Improvements to Nonemployee Share-Based Payment Accounting” to simplify the accounting for share-based payment transactions with non-employees of the Company. The guidance within this accounting standard update generally requires that share-based payment transactions for acquiring goods or services from non-employees of the Company be accounted for under the same guidance and model as all other share-based payment transactions, including employees of the Company. For public business entities, ASU 2018-07 is effective for annual and interim reporting periods beginning after December 15, 2018, with early adoption permitted.  The Company elected to early adopt the guidance within this accounting standard update in the second quarter of 2018.  There was no significant impact from the adoption. In May 2017, the FASB issued ASU No. 2017-09, "Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting," to provide clarity and reduce both diversity in practice, and cost and complexity when a change is made to the terms or conditions of a share-based payment award. For public business entities, ASU 2017-09 is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. The update should be applied prospectively to an award modified on or after the adoption date. The Company adopted ASU No. 2017-09 effective January 1, 2018. There was no significant impact from the adoption. In August 2016, the FASB issued ASU No. 2016-15, "Statement of Cash Flows (Topic 230): Clarification of Certain Cash Receipts and Cash Payments." The objective of ASU No. 2016-15 is to eliminate the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows, by adding or clarifying guidance on eight specific cash flow issues. For public business entities, ASU 2016-15 is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. ASU 2016-15 provides that the amendments in the update should be applied retrospectively to all periods presented, unless deemed impracticable, in which case, prospective application is permitted. The Company adopted ASU No. 2016-15 effective January 1, 2018. There was no significant impact from the adoption. In January 2016, the FASB issued ASU No. 2016-01, "Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities," which amends the guidance in U.S. generally accepted accounting principles on the classification and measurement of financial instruments. Changes to the prior guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The amendments in this ASU are effective for fiscal years and interim periods beginning after December 15, 2017, and are to be adopted by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company adopted ASU No. 2016-01 effective January 1, 2018. There was no significant impact from the adoption. <div /></div> </div>

23151000

8637000

26228000

11333000

-23151000

-8637000

-26228000

-11333000

<div> <div> 1. Organization, Business, and Basis of Presentation   Organization and Business   Madrigal Pharmaceuticals, Inc. (the “Company” or “Madrigal”) is a clinical-stage pharmaceutical company developing novel, high-quality, small-molecule drugs addressing major unmet needs in cardiovascular, metabolic, and liver diseases. The Company’s lead compound, MGL-3196, is being advanced for non-alcoholic steatohepatitis (“NASH”), a liver disease that commonly affects people with metabolic diseases such as obesity and diabetes, and indications in dyslipidemia, including genetic dyslipidemias such as familial hypercholesterolemia (“FH”). The Company initiated a Phase 2 study of MGL-3196 in NASH in October 2016. In February 2017, the Company initiated a Phase 2 study of MGL-3196 in patients with Heterozygous Familial Hypercholesterolemia (“HeFH”). Both Phase 2 studies were fully enrolled in 2017, the HeFH study was completed in February 2018, and the NASH study was completed in May 2018. Madrigal was originally incorporated as a private company (“Private Madrigal”) on August 19, 2011 and commenced operations in September 2011. On July 22, 2016, Private Madrigal completed a reverse merger (the “Merger”) into Synta Pharmaceuticals Corp. (“Synta”). Upon the consummation of the Merger, the historical financial statements of Private Madrigal became the Company’s historical financial statements. The Company, or Madrigal, as used in the accompanying notes to the unaudited condensed consolidated financial statements, refers to Private Madrigal prior to the completion of the Merger and Public Madrigal subsequent to the completion of the Merger. Basis of Presentation   Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted. Accordingly, the unaudited condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete annual financial statements. However, we believe that the disclosures included in these financial statements are adequate to make the information presented not misleading. The unaudited condensed financial statements, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of such interim results. The interim results are not necessarily indicative of the results that we will have for the full year ended December 31, 2018 or any subsequent period. These unaudited condensed financial statements should be read in conjunction with the audited consolidated financial statements and the notes to those statements for the year ended December 31, 2017.   <div /></div> </div>

<div> <div> 2. Summary of Significant Accounting Policies   Principle of Consolidation   The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany balances have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank accounts, the balance of which, at times, exceeds Federal Deposit Insurance Corporation insured limits. The primary objective of the Company's investment activities is to preserve its capital for the purpose of funding operations and the Company does not enter into investments for trading or speculative purposes. The Company's cash is deposited in highly rated financial institutions in the United States. The Company invests in money market funds and high-grade, short-term commercial paper and corporate bonds, which management believes are subject to minimal credit and market risk. Marketable Securities Marketable securities consist of investments in high-grade corporate obligations and government and government agency obligations that are classified as available-for-sale. Since these securities are available to fund current operations, they are classified as current assets on the consolidated balance sheets. The Company adjusts the cost of available-for-sale debt securities for amortization of premiums and accretion of discounts to maturity. The Company includes such amortization and accretion as a component of interest income, net. Realized gains and losses and declines in value, if any, that the Company judges to be other-than-temporary on available-for-sale securities are reported as a component of interest income, net. To determine whether an other-than-temporary impairment exists, the Company considers whether it intends to sell the debt security and, if the Company does not intend to sell the debt security, it considers available evidence to assess whether it is more likely than not that it will be required to sell the security before the recovery of its amortized cost basis. During the three and nine months ended September 30, 2018 and 2017, the Company determined it did not have any securities that were other-than-temporarily impaired. Marketable securities are stated at fair value, including accrued interest, with their unrealized gains and losses included as a component of accumulated other comprehensive income or loss, which is a separate component of stockholders' equity. The fair value of these securities is based on quoted prices and observable inputs on a recurring basis. Realized gains and losses are determined on the specific identification method. During the three and nine months ended September 30, 2018 and 2017, the Company did not have any realized gains or losses on marketable securities. Fair Value of Financial Instruments The carrying amounts of the Company's financial instruments, which include cash equivalents, and marketable securities, approximate their fair values. The fair value of the Company's financial instruments reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels: Level 1—quoted prices in active markets for identical assets and liabilities. Level 2—observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3—unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The Company measures the fair value of its marketable securities by taking into consideration valuations obtained from third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker-dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs. As of September 30, 2018, the Company's financial assets valued based on Level 1 inputs consisted of cash and cash equivalents in a money market fund and its financial assets valued based on Level 2 inputs consisted of high-grade corporate bonds and commercial paper. During the three and nine months ended September 30, 2018 and 2017, the Company did not have any transfers of financial assets between Levels 1 and 2. As of September 30, 2018 and December 31, 2017, the Company did not have any financial liabilities that were recorded at fair value on a recurring basis on the balance sheet.   Research and Development Costs Research and development costs are expensed as incurred. Research and development costs are comprised of costs incurred in performing research and development activities, including internal costs (including stock-based compensation), costs for consultants, and other costs associated with the Company's preclinical and clinical programs. In particular, Madrigal has conducted safety studies in animals, optimized and implemented the API manufacturing process, and conducted Phase 1 & 2 clinical trials, all of which are considered research and development expenditures.   Patents Costs to secure and defend patents are expensed as incurred and are classified as general and administrative expense in the Company's consolidated statements of operations. Stock-Based Compensation The Company recognizes stock-based compensation expense based on the grant date fair value of stock options granted to employees, officers, and directors. The Company uses the Black-Scholes option pricing model to determine the grant date fair value as management believes it is the most appropriate valuation method for its option grants. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. The expected lives for options granted represent the period of time that options granted are expected to be outstanding. The Company uses the simplified method for determining the expected lives of options. Expected volatility is based upon an industry estimate or blended rate including the Company’s historical trading activity. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The Company estimates the forfeiture rate based on historical data. This analysis is re-evaluated at least annually and the forfeiture rate is adjusted as necessary. Certain of the employee stock options granted by the Company are structured to qualify as incentive stock options (“ISOs”). Under current tax regulations, the Company does not receive a tax deduction for the issuance, exercise or disposition of ISOs if the employee meets certain holding requirements. If the employee does not meet the holding requirements, a disqualifying disposition occurs, at which time the Company may receive a tax deduction. The Company does not record tax benefits related to ISOs unless and until a disqualifying disposition is reported. In the event of a disqualifying disposition, the entire tax benefit is recorded as a reduction of income tax expense. The Company has not recognized any income tax benefit for its share-based compensation arrangements due to the fact that the Company does not believe it is more likely than not it will realize the related deferred tax assets. Income Taxes The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are determined based on the expected future tax consequences of temporary differences between the Company's financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. The Company currently maintains a 100% valuation allowance on its deferred tax assets. Comprehensive Loss Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Changes in unrealized gains and losses on marketable securities represent the only difference between the Company's net loss and comprehensive loss. Basic and Diluted Loss Per Common Share   Basic net loss per share is computed using the weighted average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per common share is computed using the weighted average number of common shares outstanding and the weighted average dilutive potential common shares outstanding using the treasury stock method. However, for the three and nine months ended September 30, 2018 and 2017, diluted net loss per share is the same as basic net loss per share because the inclusion of weighted average shares of unvested restricted common stock, common stock issuable upon the exercise of stock options, and common stock issuable upon the conversion of preferred stock would be anti-dilutive. The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive:                                                                                                                                                                                                  <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:32.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine Months Ended September 30, </td> <td valign="bottom" style="width:00.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Common Stock Options </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,123,582 </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 991,711 </td> <td valign="bottom" style="width:00.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unvested Restricted Common Stock </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 52,063 </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 105,199 </td> <td valign="bottom" style="width:00.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Preferred Stock </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,969,797 </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,969,797 </td> <td valign="bottom" style="width:00.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   Recent Accounting Pronouncements   In June 2018, The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-07, “Improvements to Nonemployee Share-Based Payment Accounting” to simplify the accounting for share-based payment transactions with non-employees of the Company. The guidance within this accounting standard update generally requires that share-based payment transactions for acquiring goods or services from non-employees of the Company be accounted for under the same guidance and model as all other share-based payment transactions, including employees of the Company. For public business entities, ASU 2018-07 is effective for annual and interim reporting periods beginning after December 15, 2018, with early adoption permitted.  The Company elected to early adopt the guidance within this accounting standard update in the second quarter of 2018.  There was no significant impact from the adoption. In May 2017, the FASB issued ASU No. 2017-09, "Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting," to provide clarity and reduce both diversity in practice, and cost and complexity when a change is made to the terms or conditions of a share-based payment award. For public business entities, ASU 2017-09 is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. The update should be applied prospectively to an award modified on or after the adoption date. The Company adopted ASU No. 2017-09 effective January 1, 2018. There was no significant impact from the adoption. In August 2016, the FASB issued ASU No. 2016-15, "Statement of Cash Flows (Topic 230): Clarification of Certain Cash Receipts and Cash Payments." The objective of ASU No. 2016-15 is to eliminate the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows, by adding or clarifying guidance on eight specific cash flow issues. For public business entities, ASU 2016-15 is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. ASU 2016-15 provides that the amendments in the update should be applied retrospectively to all periods presented, unless deemed impracticable, in which case, prospective application is permitted. The Company adopted ASU No. 2016-15 effective January 1, 2018. There was no significant impact from the adoption. In January 2016, the FASB issued ASU No. 2016-01, "Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities," which amends the guidance in U.S. generally accepted accounting principles on the classification and measurement of financial instruments. Changes to the prior guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The amendments in this ASU are effective for fiscal years and interim periods beginning after December 15, 2017, and are to be adopted by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company adopted ASU No. 2016-01 effective January 1, 2018. There was no significant impact from the adoption.  <div /></div> </div>

22000

11000

-112000

-100000

100000

200000

34910000

524935000

125000

14000

0.0001

5000000

1969797

485000

767000

9400000

135500000

311800000

6944000

119885000

1900000

-22709000

-21336000

301000

244000

17878000

6682000

16518000

6211000

<div> <div> Research and Development Costs Research and development costs are expensed as incurred. Research and development costs are comprised of costs incurred in performing research and development activities, including internal costs (including stock-based compensation), costs for consultants, and other costs associated with the Company's preclinical and clinical programs. In particular, Madrigal has conducted safety studies in animals, optimized and implemented the API manufacturing process, and conducted Phase 1 & 2 clinical trials, all of which are considered research and development expenditures. <div /></div> </div>

-106461000

-127797000

<div> <div>                                                                                                                                                                                                  <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:32.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Nine Months Ended September 30, </td> <td valign="bottom" style="width:00.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:00.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Common Stock Options </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,123,582 </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 991,711 </td> <td valign="bottom" style="width:00.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unvested Restricted Common Stock </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 52,063 </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 105,199 </td> <td valign="bottom" style="width:00.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Preferred Stock </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,969,797 </td> <td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,969,797 </td> <td valign="bottom" style="width:00.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> A summary of cash, cash equivalents and available-for-sale marketable securities held by the Company as of September 30, 2018 and December 31, 2017 is as follows (in thousands):     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:41.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> September 30, 2018 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> gains </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> losses </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> value </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash and cash equivalents: </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cash (Level 1) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,127 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,127 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Money market funds (Level 1) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 35,919 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 35,919 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate debt securities due within 3 months of date of purchase (Level 2) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total cash and cash equivalents </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 38,046 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 38,046 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Marketable securities: </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Corporate debt securities due within 1 year of date of purchase (Level 2) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 437,106 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (144) </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 436,975 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate debt securities due between 1 and 2 years of the date of purchase (Level 2) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 13,529 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (12) </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 13,517 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total cash, cash equivalents and marketable securities </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 488,681 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (156) </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 488,538 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:37.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, 2017 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gains </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> losses </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> value </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash and cash equivalents: </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Cash (Level 1) </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,725 </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,725 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Money market funds (Level 1) </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 145,902 </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 145,902 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate debt securities due within 3 months of date of purchase (Level 2) </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total cash and cash equivalents </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 148,627 </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 148,627 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Marketable securities: </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Corporate debt securities due within 1 year of date of purchase (Level 2) </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 42,931 </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (31) </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 42,900 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:60.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total cash, cash equivalents and marketable securities </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 191,558 </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (31) </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 191,527 </td> <td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> </tr> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> average </td> </tr> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> exercise </td> </tr> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> price </td> </tr> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at January 1, 2018 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 104,127 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9.45 </td> </tr> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> </tr> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (52,064) </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9.45 </td> </tr> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> — </td> </tr> <tr> <td valign="bottom" style="width:74.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at September 30, 2018 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 52,063 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9.45 </td> </tr> </table></div>   <div /></div> </div>

<div> <div>     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> average </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> exercise </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> price </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at January 1, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  976,777 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11.97 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Options granted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  241,650 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 173.23 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Options exercised </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (86,095) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 22.06 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Options canceled </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (8,750) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 113.81 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at September 30, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  1,123,582 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 45.09 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exercisable at September 30, 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  621,000 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10.75 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Unrecognized stock-based compensation expense as of September 30, 2018 was as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrecognized </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> average </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> stock </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> remaining </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> compensation </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> period </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> expense </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in years) </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  25,250 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.23 </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Restricted stock </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  396 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.80 </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  25,646 </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.21 </td> </tr> </table></div>   <div /></div> </div>

2307000

8370000

104127

52063

9.45

52064

9.45

P10Y

1225595

621000

10.75

8750

241650

13.30

136.43

976777

1123582

11.97

45.09

22.06

113.81

173.23

<div> <div> Stock-Based Compensation The Company recognizes stock-based compensation expense based on the grant date fair value of stock options granted to employees, officers, and directors. The Company uses the Black-Scholes option pricing model to determine the grant date fair value as management believes it is the most appropriate valuation method for its option grants. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. The expected lives for options granted represent the period of time that options granted are expected to be outstanding. The Company uses the simplified method for determining the expected lives of options. Expected volatility is based upon an industry estimate or blended rate including the Company’s historical trading activity. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The Company estimates the forfeiture rate based on historical data. This analysis is re-evaluated at least annually and the forfeiture rate is adjusted as necessary. Certain of the employee stock options granted by the Company are structured to qualify as incentive stock options (“ISOs”). Under current tax regulations, the Company does not receive a tax deduction for the issuance, exercise or disposition of ISOs if the employee meets certain holding requirements. If the employee does not meet the holding requirements, a disqualifying disposition occurs, at which time the Company may receive a tax deduction. The Company does not record tax benefits related to ISOs unless and until a disqualifying disposition is reported. In the event of a disqualifying disposition, the entire tax benefit is recorded as a reduction of income tax expense. The Company has not recognized any income tax benefit for its share-based compensation arrangements due to the fact that the Company does not believe it is more likely than not it will realize the related deferred tax assets. <div /></div> </div>

15.23

83.00

305.00

182259000

482907000

<div> <div> 5. Stockholders’ Equity   Common Stock   Each common stockholder is entitled to one vote for each share of common stock held. The common stock will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders. Each share of common stock is entitled to receive dividends, as and when declared by the Company’s board of directors.   The Company has never declared cash dividends on its common stock and does not expect to do so in the foreseeable future.   June 2018 Registered Offering of Common Stock   In June 2018, the Company entered into an underwriting agreement with Goldman Sachs & Co. LLC, as representative of the several underwriters named therein (the "June 2018 Underwriters"), relating to an underwritten public offering (the "June 2018 Offering") of 1,079,580 shares of the Company's common stock, including 95,973 shares of the Company's common stock purchased by the June 2018 Underwriters pursuant to a 30-day option to purchase such additional shares granted therein, at a public offering price of $305.00 per share. The June 2018 Offering resulted in net proceeds to the Company of approximately $311.8 million, after deducting the June 2018 Underwriters' discount and other offering costs. The June 2018 Offering closed on June 11, 2018.   December 2017 Registered Offering of Common Stock In December 2017, the Company entered into an underwriting agreement with Goldman Sachs & Co. LLC, as representative of the several underwriters named therein (the " December 2017 Underwriters"), relating to an underwritten public offering (the "December 2017 Offering") of 1,731,929 shares of the Company's common stock, including 225,904 shares of the Company's common stock purchased by the December 2017 Underwriters pursuant to a 30-day option to purchase such additional shares granted therein, at a public offering price of $83.00 per share. The December 2017 Offering resulted in net proceeds to the Company of approximately $135.5 million, after deducting the December 2017 Underwriters' discount and other offering costs. The December 2017 Offering closed on December 21, 2017. June 2017 Private Placement Offering of Common Stock and Series A Convertible Preferred Stock   In June 2017, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement)” with a group of institutional accredited investors, who were existing, non-controlling stockholders of the Company, pursuant to which the Company sold securities to the Investors in a private placement transaction (the “June 2017 Offering”). Under the terms of the Purchase Agreement, the Company sold 328,300 shares of its common stock at a price of $15.23 per share, and 1,969,797 shares of its Series A Convertible Preferred Stock (the “Series A Preferred Stock”) at a price of $15.23 per share.  The June 2017 Offering resulted in gross proceeds to the Company of approximately $35.0 million, and net proceeds to the Company of approximately $34.9 million. The June 2017 Offering closed on June 23, 2017.   The Series A Preferred Stock has a par value of $0.0001 per share and is convertible into shares of the common stock at a one-to-one ratio, subject to adjustment as provided in the Purchase Agreement.  The terms of the Series A Preferred Stock are set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, that the Company filed with the Secretary of State of the State of Delaware on June 21, 2017.  Each share of the Series A Preferred Stock is convertible into shares of Common Stock at any time at the holder’s option. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, after the satisfaction in full of the debts of the Company and the payment of any liquidation preference owed to the holders of shares of capital stock of the Company ranking prior to the Series A Preferred Stock upon liquidation, the holders of the Series A Preferred Stock shall participate pari passu with the holders of the Common Stock (on an as-if-converted-to-Common-Stock basis) in the net assets of the Company.  Shares of the Series A Preferred Stock will generally have no voting rights, except as required by law. Shares of the Series A Preferred Stock will be entitled to receive dividends before shares of any other class or series of capital stock of the Company (other than dividends in the form of the Common Stock) equal to the dividend payable on each share of the Common Stock, on an as-converted basis.   At-The-Market Issuance Sales Agreement In October 2015, the Company entered into an at-the-market issuance sales agreement (the "October 2015 Sales Agreement"), with Cowen and Company, LLC ("Cowen"), pursuant to which the Company may issue and sell shares of its common stock, having an aggregate offering price of up to $100 million, from time to time, at the Company's option, through Cowen as its sales agent. Sales of common stock through Cowen may be made by any method that is deemed an "at-the-market" offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including by means of ordinary brokers' transactions at market prices, in block transactions or as otherwise agreed by the Company and Cowen. Subject to the terms and conditions of the October 2015 Sales Agreement, Cowen will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the common stock based upon the Company's instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company is not obligated to make any sales of its common stock under the October 2015 Sales Agreement. Any shares sold will be sold pursuant to an effective shelf registration statement on Form S-3 (file no. 333-206135). The Company will pay Cowen a commission of up to 3% of the gross proceeds. The October 2015 Sales Agreement may be terminated by the Company at any time upon 10 days' notice. As of September 30, 2018, 597,256 shares have been sold under the October 2015 Sales Agreement for an aggregate of approximately $9.6 million in gross proceeds. Net proceeds to the Company were approximately $9.4 million after deducting commissions and other transactions costs. Of those shares sold, none were sold in 2018, and 215,539 were sold in 2017. Approximately $90.4 million remained reserved under the Company's shelf registration statement and the applicable prospectus supplement for possible future issuance under the October 2015 Sales Agreement.   <div /></div> </div>

597256

215539

1969797

328300

1731929

225904

1079580

95973

86095

9600000

35000000

<div> <div> 3. Liquidity and Uncertainties   The Company is subject to risks common to development stage companies in the biopharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, dependence on key personnel, uncertainty of market acceptance of products and product reimbursement, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing necessary for development and commercialization, and compliance with the U.S. Food and Drug Administration and other government regulations. The Company has incurred losses since inception, including approximately $21.3 million for the nine months ended September 30, 2018, resulting in an accumulated deficit of approximately $127.8 million as of September 30, 2018. Management expects to incur losses for the foreseeable future. To date, the Company has funded its operations primarily through the issuance of convertible debt, the proceeds from the Merger on July 22, 2016, and proceeds from sales of the Company's equity securities (see Note 5). The Company believes that its cash, cash equivalents and marketable securities at September 30, 2018 will be sufficient to fund operations past one year from the issuance of these financial statements. To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company's business, results of operations and financial condition. The Company has the ability to delay certain research activities and related clinical expenses if necessary due to liquidity concerns until a date when those concerns are relieved.   <div /></div> </div>

<div> <div> Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. <div /></div> </div>

12126004

12378622

14610809

15307872

EX-101.SCH 6 mdgl-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization, Business, and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Liquidity and Uncertainties link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Cash, Cash Equivalents and Marketable Securities link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of Significant Accounting Policies - Basic and Diluted Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Liquidity and Uncertainties (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Stockholders' Equity - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Stockholders' Equity - Registered Offering (Details) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Stockholders' Equity - June 2017 Private Placement (Details) link:presentationLink link:calculationLink link:definitionLink 40504 - Disclosure - Stockholders' Equity - At The Market Issuances (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Stock-based Compensation - Stock Option (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Stock-based Compensation - Restricted Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - Stock-based Compensation - Expense (Details) link:presentationLink link:calculationLink link:definitionLink 40604 - Disclosure - Stock-based Compensation - Unrecognized Expense (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 mdgl-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 mdgl-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 mdgl-20180930_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Document and Entity Information Statement [Table] Statement [Line Items] Statement Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Emerging Growth Company Entity Small Business Entity Common Stock, Shares Outstanding Condensed Consolidated Balance Sheets Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Debt Securities, Available-for-sale, Current Marketable securities Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Liabilities, Current Total current liabilities Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at June 30, 2018 and December 31, 2017; 1,969,797 shares issued and outstanding at June 30, 2018 and December 31, 2017 Common Stock, Value, Issued Common stock, par value $0.0001 per share authorized: 200,000,000 at June 30, 2018 and December 31, 2017; 15,393,309 and 14,227,634 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively Additional Paid in Capital, Common Stock Additional paid-in-capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Condensed Consolidated Statements of Operations Costs and Expenses [Abstract] Operating expenses: Research and Development Expense (Excluding Acquired in Process Cost) Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Interest Income, Operating Interest income Other Income Other income Net Income (Loss) Attributable to Parent Net loss Net loss Net Loss Earnings Per Share [Abstract] Net loss per common share: Earnings Per Share, Basic and Diluted Basic and diluted net loss per common share (in dollars per share) Weighted Average Number of Shares Outstanding, Basic and Diluted Basic and diluted weighted average number of common shares outstanding Condensed Consolidated Statements of Comprehensive Loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive income (loss): Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Unrealized gain (loss) on available-for-sale securities Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-based Compensation Stock-based compensation expense Depreciation, Depletion and Amortization Depreciation and amortization expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Accounts Payable, Trade Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expense The increase (decrease) during the reporting period in the aggregate amount of accrued interest expense incurred but not yet paid, net of interest received on maturity of investments. Increase (Decrease) In Accrued Interest, Net Of Interest Received Accrued interest, net of interest received on maturity of investments Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities: Payments to Acquire Marketable Securities Purchases of marketable securities Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities Sales and maturities of marketable securities Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment, net of disposals Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities: The cash inflow from the issuance of common stock, preferred stock, treasury stock, and other types of equity, net of transaction costs. Proceeds From Issuance Or Sale Of Equity, Net Proceeds from issuance of stock, net of transaction costs Net proceeds after deducting commissions and other transactions costs Proceeds from Stock Options Exercised Proceeds resulting from exercise of stock options Proceeds from exercise of common stock options Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Organization, Business, and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization, Business, and Basis of Presentation Summary of Significant Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Summary of Significant Accounting Policies Liquidity And Uncertainties Disclosure Abstract Liquidity and Uncertainties Substantial Doubt about Going Concern [Text Block] Liquidity and Uncertainties Cash, Cash Equivalents and Marketable Securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Cash, Cash Equivalents and Marketable Securities Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Stock-based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-based Compensation Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Consolidation, Policy [Policy Text Block] Principle of Consolidation Use of Estimates, Policy [Policy Text Block] Use of Estimates Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Marketable Securities, Policy [Policy Text Block] Marketable Securities Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Disclosure of accounting policy for patents. Patents [Policy Text Block] Patents Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock-Based Compensation Income Tax, Policy [Policy Text Block] Income Taxes Comprehensive Income, Policy [Policy Text Block] Comprehensive Loss Earnings Per Share, Policy [Policy Text Block] Basic and Diluted Loss Per Common Share New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Summary of the outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive Cash, Cash Equivalents and Investments [Table Text Block] Summary of cash, cash equivalents and available-for-sale marketable securities Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of stock option activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Summary of unvested restricted share activity Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the income statement for the period. This may include the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits. It includes the reporting line for the costs expensed. Schedule of Share Based Compensation Expense Allocation of Compensation Costs and Recognized Period Costs [Table Text Block] Schedule of stock-based compensation expense Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block] Schedule of unrecognized stock-based compensation expense Income Taxes Income Taxes The percentage of valuation allowance on the deferred tax assets. Deferred Tax Assets, Percentage Of Valuation Allowance Valuation allowance on deferred tax assets (as a percent) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Employee Stock Option [Member] Stock options Restricted Stock [Member] Unvested Restricted Common Stock Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive (in shares) Schedule of Investments [Table] Financial Instrument [Axis] Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain] Major Types of Debt and Equity Securities [Domain] Debt securities due within 3 months issued by domestic or foreign corporate business, banks and other entities with a promise of repayment. Corporate Debt Securities2 [Member] Corporate debt securities due within 3 months of date of purchase Corporate Debt Securities [Member] Corporate debt securities due within 1 year of date of purchase Debt securities due within between 1 and 2 years of date purchase issued by domestic or foreign corporate business, banks and other entities with a promise of repayment. Corporate Debt Securities3 [Member] Corporate debt securities due between 1 and 2 years of the date of purchase Measurement Basis [Axis] Portion At Fair Value Fair Value Disclosure [Member] Portion at Fair Value Measurement [Member] Carrying Reported Amount Fair Value Disclosure [Member] Carrying value Estimate Of Fair Value Fair Value Disclosure [Member] Fair value Fair Value, Hierarchy [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Inputs Level1 [Member] Level 1 Fair Value Inputs Level2 [Member] Level 2 Schedule of Investments [Line Items] Cash, Cash Equivalents and Marketable Securities Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents Represents the maturity period from date of purchase to classify an investment as marketable securities. Maturity Period from Date of Purchase to Classify Investment as Marketable Securities Maturity period from date of purchase to classify an investment as marketable securities Debt Securities, Available-for-sale, Amortized Cost Marketable securities, cost Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Marketable securities, unrealized gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Marketable securities, unrealized losses Debt Securities, Available-for-sale Marketable securities, fair value This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings, and cash and cash equivalents. Cash, Cash Equivalents, and Short-term Investments, At Cost Total cash, cash equivalents and marketable securities, Cost This item represents the gross unrealized gains for cash and cash equivalents securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities. Cash and Cash Equivalents and Available for Sale Securities, Gross Unrealized Gains Total cash, cash equivalents and marketable securities, Unrealized gains This item represents the gross unrealized losses for cash and cash equivalents securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities. Cash and Cash Equivalents and Available for Sale Securities, Gross Unrealized Losses Total cash, cash equivalents and marketable securities, Unrealized losses Cash, Cash Equivalents, and Short-term Investments Total cash, cash equivalents and marketable securities, Fair value Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Stockholders' Equity Represents the number of votes per share that common stockholders are entitled to receive. Common Stock Voting Rights Number Number of votes per share that common stockholders are entitled to receive Sale of Stock [Axis] Sale Of Stock Name Of Transaction [Domain] Sale of Stock [Domain] Over Allotment Option [Member] Additional Shares Represents registered offering. Registered Offering [Member] Registered Offering Counterparty Name [Axis] Repurchase Agreement Counterparty Name [Domain] Counterparty Name [Domain] Represents Goldman Sachs & Co. Goldman Sachs Co [Member] Goldman Sachs & Co. LLC Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements And Nonarrangement Transactions [Member] Arrangements and Non-arrangement Transactions [Domain] Represents Underwriting agreement. Underwriting Agreement [Member] Underwriting Agreement Stock Issued During Period, Shares, New Issues Number of shares sold by the entity Period granted to purchase additional shares. Sale of Stock, Period Granted to Purchase Additional Shares Number of days granted to purchase additional shares Shares Issued, Price Per Share Issue price of stock Proceeds from Issuance of Common Stock Net proceeds after deducting commissions and other transactions costs Represents information pertaining to private placement offering to sell its securities Securities Purchase Agreement [Member] Purchase Agreement Stock Issued During Period, Value, New Issues Value of shares sold by the entity Conversion of Stock, Shares Converted Preferred stock conversion ratio Number of voting rights of preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights. Preferred Stock, Number Of Voting Rights Preferred shares number voting rights Represent of Cowen & Co. LLC Member. Cowen Co. Llc [Member] Cowen & Co. LLC Range [Axis] Range [Member] Range [Domain] Maximum [Member] Maximum Represents information pertaining to at-the-market issuance sales agreement for the sale of the entity's common shares. At The Market Issuance Sales Agreement [Member] At-The-Market Issuance Sales Agreement Value of common stock and preferred stock, debt securities and/or warrants, rights or purchase contracts that remain reserved for future issuances under shelf registration with the Securities and Exchange Commission of the United States. Remaining Securities Under Shelf Registration, Value Remaining reserved amount under shelf registration Represents the maximum aggregate offering price the entity may issue and sell shares of its common stock from time to time, at the entity's option, according to at-the-market issuance sales agreement with third party. Common Stock Aggregate Offering Price Maximum aggregate offering price Represents the percentage of gross proceeds payable as commission during the period. Percentage of Gross Proceeds Payable as Commission Percentage of gross proceeds payable as commission Represents number of days of notice period for termination of sales agreement. Sales Agreement Termination Notice Period Days Notice period of termination of sales agreement Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Equity Award [Domain] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Unrecognized stock-based compensation expense Stock-based compensation expense Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Shares available for future issuance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding at the end of the period (in shares) Outstanding at the beginning of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Options canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Exercisable at the end of the period (in shares) EX-101.PRE 10 mdgl-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Nov. 01, 2018
Document and Entity Information
Entity Registrant Name	MADRIGAL PHARMACEUTICALS, INC.
Entity Central Index Key	0001157601
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2018
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		15,393,309

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 38,046	$ 148,627
Marketable securities	450,492	42,900
Prepaid expenses and other current assets	767	485
Total current assets	489,305	192,012
Property and equipment, net	244	301
Total assets	489,549	192,313
Current liabilities:
Accounts payable	1,031	1,929
Accrued expenses	5,611	8,125
Total current liabilities	6,642	10,054
Total liabilities	6,642	10,054
Stockholders' equity:
Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at June 30, 2018 and December 31, 2017; 1,969,797 shares issued and outstanding at June 30, 2018 and December 31, 2017
Common stock, par value $0.0001 per share authorized: 200,000,000 at June 30, 2018 and December 31, 2017; 15,393,309 and 14,227,634 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively	2	1
Additional paid-in-capital	610,845	288,750
Accumulated other comprehensive loss	(143)	(31)
Accumulated deficit	(127,797)	(106,461)
Total stockholders' equity	482,907	182,259
Total liabilities and stockholders' equity	$ 489,549	$ 192,313

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Condensed Consolidated Balance Sheets
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	1,969,797	1,969,797
Preferred stock, shares outstanding	1,969,797	1,969,797
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	15,393,309	14,227,634
Common stock, shares outstanding	15,393,309	14,227,634

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Operating expenses:
Research and development	$ 6,211	$ 6,682	$ 16,518	$ 17,878
General and administrative	5,122	1,955	9,710	5,273
Total operating expenses	11,333	8,637	26,228	23,151
Loss from operations	(11,333)	(8,637)	(26,228)	(23,151)
Interest income	2,821	174	4,692	342
Other income		100	200	100
Net loss	$ (8,512)	$ (8,363)	$ (21,336)	$ (22,709)
Net loss per common share:
Basic and diluted net loss per common share (in dollars per share)	$ (0.56)	$ (0.68)	$ (1.46)	$ (1.87)
Basic and diluted weighted average number of common shares outstanding	15,307,872	12,378,622	14,610,809	12,126,004

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Condensed Consolidated Statements of Comprehensive Loss
Net Loss	$ (8,512)	$ (8,363)	$ (21,336)	$ (22,709)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities	(100)	11	(112)	22
Comprehensive loss	$ (8,612)	$ (8,352)	$ (21,448)	$ (22,687)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (21,336)	$ (22,709)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	8,370	2,307
Depreciation and amortization expense	71	17
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(281)	290
Accounts payable	(898)	638
Accrued expense	(2,514)	3,085
Accrued interest, net of interest received on maturity of investments	(2,654)
Net cash used in operating activities	(19,242)	(16,372)
Cash flows from investing activities:
Purchases of marketable securities	(524,935)	(34,910)
Sales and maturities of marketable securities	119,885	6,944
Purchases of property and equipment, net of disposals	(14)	(125)
Net cash used in investing activities	(405,064)	(28,091)
Cash flows from financing activities:
Proceeds from issuance of stock, net of transaction costs	311,825	38,278
Proceeds from exercise of common stock options	1,900
Net cash provided by financing activities	313,725	38,278
Net decrease in cash and cash equivalents	(110,581)	(6,185)
Cash and cash equivalents at beginning of period	148,627	19,145
Cash and cash equivalents at end of period	$ 38,046	$ 12,960

XML 17 R7.htm IDEA: XBRL DOCUMENT

Organization, Business, and Basis of Presentation	9 Months Ended
Organization, Business, and Basis of Presentation	Sep. 30, 2018
Organization, Business, and Basis of Presentation
Organization, Business, and Basis of Presentation	1. Organization, Business, and Basis of Presentation Organization and Business Madrigal Pharmaceuticals, Inc. (the “Company” or “Madrigal”) is a clinical-stage pharmaceutical company developing novel, high-quality, small-molecule drugs addressing major unmet needs in cardiovascular, metabolic, and liver diseases. The Company’s lead compound, MGL-3196, is being advanced for non-alcoholic steatohepatitis (“NASH”), a liver disease that commonly affects people with metabolic diseases such as obesity and diabetes, and indications in dyslipidemia, including genetic dyslipidemias such as familial hypercholesterolemia (“FH”). The Company initiated a Phase 2 study of MGL-3196 in NASH in October 2016. In February 2017, the Company initiated a Phase 2 study of MGL-3196 in patients with Heterozygous Familial Hypercholesterolemia (“HeFH”). Both Phase 2 studies were fully enrolled in 2017, the HeFH study was completed in February 2018, and the NASH study was completed in May 2018. Madrigal was originally incorporated as a private company (“Private Madrigal”) on August 19, 2011 and commenced operations in September 2011. On July 22, 2016, Private Madrigal completed a reverse merger (the “Merger”) into Synta Pharmaceuticals Corp. (“Synta”). Upon the consummation of the Merger, the historical financial statements of Private Madrigal became the Company’s historical financial statements. The Company, or Madrigal, as used in the accompanying notes to the unaudited condensed consolidated financial statements, refers to Private Madrigal prior to the completion of the Merger and Public Madrigal subsequent to the completion of the Merger. Basis of Presentation Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted. Accordingly, the unaudited condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete annual financial statements. However, we believe that the disclosures included in these financial statements are adequate to make the information presented not misleading. The unaudited condensed financial statements, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of such interim results. The interim results are not necessarily indicative of the results that we will have for the full year ended December 31, 2018 or any subsequent period. These unaudited condensed financial statements should be read in conjunction with the audited consolidated financial statements and the notes to those statements for the year ended December 31, 2017.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2018

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Principle of Consolidation

The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany balances have been eliminated in consolidation.

Use of Estimates

Cash and Cash Equivalents

The primary objective of the Company's investment activities is to preserve its capital for the purpose of funding operations and the Company does not enter into investments for trading or speculative purposes. The Company's cash is deposited in highly rated financial institutions in the United States. The Company invests in money market funds and high-grade, short-term commercial paper and corporate bonds, which management believes are subject to minimal credit and market risk.

Marketable Securities

Marketable securities are stated at fair value, including accrued interest, with their unrealized gains and losses included as a component of accumulated other comprehensive income or loss, which is a separate component of stockholders' equity. The fair value of these securities is based on quoted prices and observable inputs on a recurring basis. Realized gains and losses are determined on the specific identification method. During the three and nine months ended September 30, 2018 and 2017, the Company did not have any realized gains or losses on marketable securities.

Fair Value of Financial Instruments

The carrying amounts of the Company's financial instruments, which include cash equivalents, and marketable securities, approximate their fair values. The fair value of the Company's financial instruments reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:

Level 1—quoted prices in active markets for identical assets and liabilities.

Level 3—unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability.

Financial assets and liabilities are classified in their entirety within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The Company measures the fair value of its marketable securities by taking into consideration valuations obtained from third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker-dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs. As of September 30, 2018, the Company's financial assets valued based on Level 1 inputs consisted of cash and cash equivalents in a money market fund and its financial assets valued based on Level 2 inputs consisted of high-grade corporate bonds and commercial paper. During the three and nine months ended September 30, 2018 and 2017, the Company did not have any transfers of financial assets between Levels 1 and 2. As of September 30, 2018 and December 31, 2017, the Company did not have any financial liabilities that were recorded at fair value on a recurring basis on the balance sheet.

Research and Development Costs

Research and development costs are expensed as incurred. Research and development costs are comprised of costs incurred in performing research and development activities, including internal costs (including stock-based compensation), costs for consultants, and other costs associated with the Company's preclinical and clinical programs. In particular, Madrigal has conducted safety studies in animals, optimized and implemented the API manufacturing process, and conducted Phase 1 & 2 clinical trials, all of which are considered research and development expenditures.

Patents

Costs to secure and defend patents are expensed as incurred and are classified as general and administrative expense in the Company's consolidated statements of operations.

Stock-Based Compensation

Income Taxes

The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are determined based on the expected future tax consequences of temporary differences between the Company's financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. The Company currently maintains a 100% valuation allowance on its deferred tax assets.

Comprehensive Loss

Basic and Diluted Loss Per Common Share

The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive:


	Nine Months Ended September 30,
	2018	2017
Common Stock Options	1,123,582	991,711
Unvested Restricted Common Stock	52,063	105,199
Preferred Stock	1,969,797	1,969,797

Recent Accounting Pronouncements

In June 2018, The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-07, “Improvements to Nonemployee Share-Based Payment Accounting” to simplify the accounting for share-based payment transactions with non-employees of the Company. The guidance within this accounting standard update generally requires that share-based payment transactions for acquiring goods or services from non-employees of the Company be accounted for under the same guidance and model as all other share-based payment transactions, including employees of the Company. For public business entities, ASU 2018-07 is effective for annual and interim reporting periods beginning after December 15, 2018, with early adoption permitted. The Company elected to early adopt the guidance within this accounting standard update in the second quarter of 2018. There was no significant impact from the adoption.

In May 2017, the FASB issued ASU No. 2017-09, "Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting," to provide clarity and reduce both diversity in practice, and cost and complexity when a change is made to the terms or conditions of a share-based payment award. For public business entities, ASU 2017-09 is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. The update should be applied prospectively to an award modified on or after the adoption date. The Company adopted ASU No. 2017-09 effective January 1, 2018. There was no significant impact from the adoption.

In August 2016, the FASB issued ASU No. 2016-15, "Statement of Cash Flows (Topic 230): Clarification of Certain Cash Receipts and Cash Payments." The objective of ASU No. 2016-15 is to eliminate the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows, by adding or clarifying guidance on eight specific cash flow issues. For public business entities, ASU 2016-15 is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. ASU 2016-15 provides that the amendments in the update should be applied retrospectively to all periods presented, unless deemed impracticable, in which case, prospective application is permitted. The Company adopted ASU No. 2016-15 effective January 1, 2018. There was no significant impact from the adoption.

In January 2016, the FASB issued ASU No. 2016-01, "Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities," which amends the guidance in U.S. generally accepted accounting principles on the classification and measurement of financial instruments. Changes to the prior guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The amendments in this ASU are effective for fiscal years and interim periods beginning after December 15, 2017, and are to be adopted by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company adopted ASU No. 2016-01 effective January 1, 2018. There was no significant impact from the adoption.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Liquidity and Uncertainties	9 Months Ended
Liquidity and Uncertainties	Sep. 30, 2018
Liquidity and Uncertainties
Liquidity and Uncertainties	3. Liquidity and Uncertainties The Company is subject to risks common to development stage companies in the biopharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, dependence on key personnel, uncertainty of market acceptance of products and product reimbursement, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing necessary for development and commercialization, and compliance with the U.S. Food and Drug Administration and other government regulations. The Company has incurred losses since inception, including approximately $21.3 million for the nine months ended September 30, 2018, resulting in an accumulated deficit of approximately $127.8 million as of September 30, 2018. Management expects to incur losses for the foreseeable future. To date, the Company has funded its operations primarily through the issuance of convertible debt, the proceeds from the Merger on July 22, 2016, and proceeds from sales of the Company's equity securities (see Note 5). The Company believes that its cash, cash equivalents and marketable securities at September 30, 2018 will be sufficient to fund operations past one year from the issuance of these financial statements. To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company's business, results of operations and financial condition. The Company has the ability to delay certain research activities and related clinical expenses if necessary due to liquidity concerns until a date when those concerns are relieved.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Marketable Securities

9 Months Ended

Sep. 30, 2018

Cash, Cash Equivalents and Marketable Securities

Cash, Cash Equivalents and Marketable Securities

4. Cash, Cash Equivalents and Marketable Securities

A summary of cash, cash equivalents and available-for-sale marketable securities held by the Company as of September 30, 2018 and December 31, 2017 is as follows (in thousands):


	September 30, 2018
			Unrealized		Unrealized		Fair
	Cost		gains		losses		value

Cash and cash equivalents:
Cash (Level 1)	$	2,127	$	—	$	—	$	2,127
Money market funds (Level 1)		35,919		—		—		35,919
Corporate debt securities due within 3 months of date of purchase (Level 2)		—		—		—		—
Total cash and cash equivalents		38,046		—		—		38,046
Marketable securities:
Corporate debt securities due within 1 year of date of purchase (Level 2)		437,106		13		(144)		436,975
Corporate debt securities due between 1 and 2 years of the date of purchase (Level 2)		13,529		—		(12)		13,517
Total cash, cash equivalents and marketable securities	$	488,681	$	13	$	(156)	$	488,538


	December 31, 2017
			Unrealized		Unrealized		Fair
	Cost		Gains		losses		value

Cash and cash equivalents:
Cash (Level 1)	$	2,725	$	—	$	—	$	2,725
Money market funds (Level 1)		145,902		—		—		145,902
Corporate debt securities due within 3 months of date of purchase (Level 2)		—		—		—		—
Total cash and cash equivalents		148,627		—		—		148,627
Marketable securities:
Corporate debt securities due within 1 year of date of purchase (Level 2)		42,931		—		(31)		42,900
Total cash, cash equivalents and marketable securities	$	191,558	$	—	$	(31)	$	191,527

XML 21 R11.htm IDEA: XBRL DOCUMENT

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2018
Stockholders' Equity
Stockholders' Equity	5. Stockholders’ Equity Common Stock Each common stockholder is entitled to one vote for each share of common stock held. The common stock will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders. Each share of common stock is entitled to receive dividends, as and when declared by the Company’s board of directors. The Company has never declared cash dividends on its common stock and does not expect to do so in the foreseeable future. June 2018 Registered Offering of Common Stock In June 2018, the Company entered into an underwriting agreement with Goldman Sachs & Co. LLC, as representative of the several underwriters named therein (the "June 2018 Underwriters"), relating to an underwritten public offering (the "June 2018 Offering") of 1,079,580 shares of the Company's common stock, including 95,973 shares of the Company's common stock purchased by the June 2018 Underwriters pursuant to a 30-day option to purchase such additional shares granted therein, at a public offering price of $305.00 per share. The June 2018 Offering resulted in net proceeds to the Company of approximately $311.8 million, after deducting the June 2018 Underwriters' discount and other offering costs. The June 2018 Offering closed on June 11, 2018. December 2017 Registered Offering of Common Stock In December 2017, the Company entered into an underwriting agreement with Goldman Sachs & Co. LLC, as representative of the several underwriters named therein (the " December 2017 Underwriters"), relating to an underwritten public offering (the "December 2017 Offering") of 1,731,929 shares of the Company's common stock, including 225,904 shares of the Company's common stock purchased by the December 2017 Underwriters pursuant to a 30-day option to purchase such additional shares granted therein, at a public offering price of $83.00 per share. The December 2017 Offering resulted in net proceeds to the Company of approximately $135.5 million, after deducting the December 2017 Underwriters' discount and other offering costs. The December 2017 Offering closed on December 21, 2017. June 2017 Private Placement Offering of Common Stock and Series A Convertible Preferred Stock In June 2017, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement)” with a group of institutional accredited investors, who were existing, non-controlling stockholders of the Company, pursuant to which the Company sold securities to the Investors in a private placement transaction (the “June 2017 Offering”). Under the terms of the Purchase Agreement, the Company sold 328,300 shares of its common stock at a price of $15.23 per share, and 1,969,797 shares of its Series A Convertible Preferred Stock (the “Series A Preferred Stock”) at a price of $15.23 per share. The June 2017 Offering resulted in gross proceeds to the Company of approximately $35.0 million, and net proceeds to the Company of approximately $34.9 million. The June 2017 Offering closed on June 23, 2017. The Series A Preferred Stock has a par value of $0.0001 per share and is convertible into shares of the common stock at a one-to-one ratio, subject to adjustment as provided in the Purchase Agreement. The terms of the Series A Preferred Stock are set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, that the Company filed with the Secretary of State of the State of Delaware on June 21, 2017. Each share of the Series A Preferred Stock is convertible into shares of Common Stock at any time at the holder’s option. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, after the satisfaction in full of the debts of the Company and the payment of any liquidation preference owed to the holders of shares of capital stock of the Company ranking prior to the Series A Preferred Stock upon liquidation, the holders of the Series A Preferred Stock shall participate pari passu with the holders of the Common Stock (on an as-if-converted-to-Common-Stock basis) in the net assets of the Company. Shares of the Series A Preferred Stock will generally have no voting rights, except as required by law. Shares of the Series A Preferred Stock will be entitled to receive dividends before shares of any other class or series of capital stock of the Company (other than dividends in the form of the Common Stock) equal to the dividend payable on each share of the Common Stock, on an as-converted basis. At-The-Market Issuance Sales Agreement In October 2015, the Company entered into an at-the-market issuance sales agreement (the "October 2015 Sales Agreement"), with Cowen and Company, LLC ("Cowen"), pursuant to which the Company may issue and sell shares of its common stock, having an aggregate offering price of up to $100 million, from time to time, at the Company's option, through Cowen as its sales agent. Sales of common stock through Cowen may be made by any method that is deemed an "at-the-market" offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including by means of ordinary brokers' transactions at market prices, in block transactions or as otherwise agreed by the Company and Cowen. Subject to the terms and conditions of the October 2015 Sales Agreement, Cowen will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the common stock based upon the Company's instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company is not obligated to make any sales of its common stock under the October 2015 Sales Agreement. Any shares sold will be sold pursuant to an effective shelf registration statement on Form S-3 (file no. 333-206135). The Company will pay Cowen a commission of up to 3% of the gross proceeds. The October 2015 Sales Agreement may be terminated by the Company at any time upon 10 days' notice. As of September 30, 2018, 597,256 shares have been sold under the October 2015 Sales Agreement for an aggregate of approximately $9.6 million in gross proceeds. Net proceeds to the Company were approximately $9.4 million after deducting commissions and other transactions costs. Of those shares sold, none were sold in 2018, and 215,539 were sold in 2017. Approximately $90.4 million remained reserved under the Company's shelf registration statement and the applicable prospectus supplement for possible future issuance under the October 2015 Sales Agreement.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Stock-based Compensation

9 Months Ended

Sep. 30, 2018

Stock-based Compensation

Stock-based Compensation

6. Stock-based Compensation

The following table summarizes stock option activity during the nine months ended September 30, 2018:


		Weighted
		average
		exercise
	Shares	price
Outstanding at January 1, 2018	976,777	$	11.97
Options granted	241,650		173.23
Options exercised	(86,095)		22.06
Options canceled	(8,750)		113.81
Outstanding at September 30, 2018	1,123,582	$	45.09
Exercisable at September 30, 2018	621,000	$	10.75

Restricted Common Stock

The following table summarizes unvested restricted share activity during the nine months ended September 30, 2018:


		Weighted
		average
		exercise
	Shares	price
Outstanding at January 1, 2018	104,127	$	9.45
Granted	—		—
Vested	(52,064)		9.45
Forfeited	—		—
Outstanding at September 30, 2018	52,063	$	9.45

Stock-Based Compensation Expense

Stock-based compensation expense during the three and nine months ended September 2018 and 2017 was as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Stock-based compensation expense by type of award:
Stock options	$	4,852	$	878	$	8,002	$	1,859
Restricted stock		124		151		368		448
Total stock-based compensation expense	$	4,976	$	1,029	$	8,370	$	2,307

Effect of stock-based compensation expense by line item:
Research and development	$	1,179	$	272	$	2,287	$	577
General and administrative		3,797		757		6,083		1,730
Total stock-based compensation expense included in net loss	$	4,976	$	1,029	$	8,370	$	2,307

Unrecognized stock-based compensation expense as of September 30, 2018 was as follows (in thousands):


			Weighted
	Unrecognized		average
	stock		remaining
	compensation		period
	expense		(in years)
Stock options	$	25,250	2.23
Restricted stock		396	0.80
Total	$	25,646	2.21

XML 23 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2018
Commitments and Contingencies
Commitments and Contingencies	7. Commitments and Contingencies The Company has a Research, Development and Commercialization Agreement with Hoffmann-La Roche (“Roche”) which grants the Company a sole and exclusive license to develop, use, sell, offer for sale and import any Licensed Product as defined by the agreement. The agreement requires future milestone payments to Roche, the remainder of which total $10 million and are earned by the commencement of Phase 3 clinical trials as well as future regulatory approval in the United States and Europe of a product developed from MGL-3916. A single-digit royalty payment range is based on net sales of products developed from MGL-3196, subject to certain reductions. In October 2016, the Company commenced a Phase 2 study in Non-Alcoholic Steatohepatitis (NASH), which triggered a milestone payment under the agreement. Except as described above, the Company has not achieved any additional product development or regulatory milestones to date and has no Licensed Product sales for the nine months ended September 30, 2018 and 2017. The Company has entered into customary contractual arrangements and letters of intent in preparation for and in support of the Phase 2 and 3 clinical trials.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2018

Summary of Significant Accounting Policies

Principle of Consolidation

The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany balances have been eliminated in consolidation.

Use of Estimates

Cash and Cash Equivalents

Marketable Securities

Marketable securities are stated at fair value, including accrued interest, with their unrealized gains and losses included as a component of accumulated other comprehensive income or loss, which is a separate component of stockholders' equity. The fair value of these securities is based on quoted prices and observable inputs on a recurring basis. Realized gains and losses are determined on the specific identification method. During the three and nine months ended September 30, 2018 and 2017, the Company did not have any realized gains or losses on marketable securities.

Fair Value of Financial Instruments

Level 1—quoted prices in active markets for identical assets and liabilities.

Level 3—unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability.

Financial assets and liabilities are classified in their entirety within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The Company measures the fair value of its marketable securities by taking into consideration valuations obtained from third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker-dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs. As of September 30, 2018, the Company's financial assets valued based on Level 1 inputs consisted of cash and cash equivalents in a money market fund and its financial assets valued based on Level 2 inputs consisted of high-grade corporate bonds and commercial paper. During the three and nine months ended September 30, 2018 and 2017, the Company did not have any transfers of financial assets between Levels 1 and 2. As of September 30, 2018 and December 31, 2017, the Company did not have any financial liabilities that were recorded at fair value on a recurring basis on the balance sheet.

Research and Development Costs

Research and development costs are expensed as incurred. Research and development costs are comprised of costs incurred in performing research and development activities, including internal costs (including stock-based compensation), costs for consultants, and other costs associated with the Company's preclinical and clinical programs. In particular, Madrigal has conducted safety studies in animals, optimized and implemented the API manufacturing process, and conducted Phase 1 & 2 clinical trials, all of which are considered research and development expenditures.

Patents

Costs to secure and defend patents are expensed as incurred and are classified as general and administrative expense in the Company's consolidated statements of operations.

Stock-Based Compensation

Income Taxes

The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are determined based on the expected future tax consequences of temporary differences between the Company's financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. The Company currently maintains a 100% valuation allowance on its deferred tax assets.

Comprehensive Loss

Basic and Diluted Loss Per Common Share

The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive:


	Nine Months Ended September 30,
	2018	2017
Common Stock Options	1,123,582	991,711
Unvested Restricted Common Stock	52,063	105,199
Preferred Stock	1,969,797	1,969,797

Recent Accounting Pronouncements

XML 25 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2018

Summary of Significant Accounting Policies

Summary of the outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive


	Nine Months Ended September 30,
	2018	2017
Common Stock Options	1,123,582	991,711
Unvested Restricted Common Stock	52,063	105,199
Preferred Stock	1,969,797	1,969,797

XML 26 R16.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Marketable Securities (Tables)

9 Months Ended

Sep. 30, 2018

Cash, Cash Equivalents and Marketable Securities

Summary of cash, cash equivalents and available-for-sale marketable securities

A summary of cash, cash equivalents and available-for-sale marketable securities held by the Company as of September 30, 2018 and December 31, 2017 is as follows (in thousands):


	September 30, 2018
			Unrealized		Unrealized		Fair
	Cost		gains		losses		value

Cash and cash equivalents:
Cash (Level 1)	$	2,127	$	—	$	—	$	2,127
Money market funds (Level 1)		35,919		—		—		35,919
Corporate debt securities due within 3 months of date of purchase (Level 2)		—		—		—		—
Total cash and cash equivalents		38,046		—		—		38,046
Marketable securities:
Corporate debt securities due within 1 year of date of purchase (Level 2)		437,106		13		(144)		436,975
Corporate debt securities due between 1 and 2 years of the date of purchase (Level 2)		13,529		—		(12)		13,517
Total cash, cash equivalents and marketable securities	$	488,681	$	13	$	(156)	$	488,538


	December 31, 2017
			Unrealized		Unrealized		Fair
	Cost		Gains		losses		value

Cash and cash equivalents:
Cash (Level 1)	$	2,725	$	—	$	—	$	2,725
Money market funds (Level 1)		145,902		—		—		145,902
Corporate debt securities due within 3 months of date of purchase (Level 2)		—		—		—		—
Total cash and cash equivalents		148,627		—		—		148,627
Marketable securities:
Corporate debt securities due within 1 year of date of purchase (Level 2)		42,931		—		(31)		42,900
Total cash, cash equivalents and marketable securities	$	191,558	$	—	$	(31)	$	191,527

XML 27 R17.htm IDEA: XBRL DOCUMENT

Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2018

Stock-based Compensation

Summary of stock option activity


		Weighted
		average
		exercise
	Shares	price
Outstanding at January 1, 2018	976,777	$	11.97
Options granted	241,650		173.23
Options exercised	(86,095)		22.06
Options canceled	(8,750)		113.81
Outstanding at September 30, 2018	1,123,582	$	45.09
Exercisable at September 30, 2018	621,000	$	10.75

Summary of unvested restricted share activity


		Weighted
		average
		exercise
	Shares	price
Outstanding at January 1, 2018	104,127	$	9.45
Granted	—		—
Vested	(52,064)		9.45
Forfeited	—		—
Outstanding at September 30, 2018	52,063	$	9.45

Schedule of stock-based compensation expense

Stock-based compensation expense during the three and nine months ended September 2018 and 2017 was as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Stock-based compensation expense by type of award:
Stock options	$	4,852	$	878	$	8,002	$	1,859
Restricted stock		124		151		368		448
Total stock-based compensation expense	$	4,976	$	1,029	$	8,370	$	2,307

Effect of stock-based compensation expense by line item:
Research and development	$	1,179	$	272	$	2,287	$	577
General and administrative		3,797		757		6,083		1,730
Total stock-based compensation expense included in net loss	$	4,976	$	1,029	$	8,370	$	2,307

Schedule of unrecognized stock-based compensation expense

Unrecognized stock-based compensation expense as of September 30, 2018 was as follows (in thousands):


			Weighted
	Unrecognized		average
	stock		remaining
	compensation		period
	expense		(in years)
Stock options	$	25,250	2.23
Restricted stock		396	0.80
Total	$	25,646	2.21

XML 28 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Income Taxes (Details)	9 Months Ended
	Sep. 30, 2018
Income Taxes
Valuation allowance on deferred tax assets (as a percent)	100.00%

XML 29 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Basic and Diluted Loss Per Common Share (Details) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Stock options
Anti-dilutive securities
Outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive (in shares)	1,123,582	991,711
Unvested Restricted Common Stock
Anti-dilutive securities
Outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive (in shares)	52,063	105,199
Preferred Stock
Anti-dilutive securities
Outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive (in shares)	1,969,797	1,969,797

XML 30 R20.htm IDEA: XBRL DOCUMENT

Liquidity and Uncertainties (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Liquidity and Uncertainties
Net loss	$ 8,512	$ 8,363	$ 21,336	$ 22,709
Accumulated deficit	$ 127,797		$ 127,797		$ 106,461

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 31 R21.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Cash, Cash Equivalents and Marketable Securities
Total cash, cash equivalents and marketable securities, Unrealized gains	$ 13
Total cash, cash equivalents and marketable securities, Unrealized losses	(156)	$ (31)
Carrying value
Cash, Cash Equivalents and Marketable Securities
Cash and cash equivalents	38,046	148,627
Total cash, cash equivalents and marketable securities, Cost	488,681	191,558
Fair value
Cash, Cash Equivalents and Marketable Securities
Cash and cash equivalents	38,046	148,627
Total cash, cash equivalents and marketable securities, Fair value	$ 488,538	$ 191,527
Corporate debt securities due within 3 months of date of purchase
Cash, Cash Equivalents and Marketable Securities
Maturity period from date of purchase to classify an investment as marketable securities	3 months	3 months
Corporate debt securities due within 1 year of date of purchase
Cash, Cash Equivalents and Marketable Securities
Maturity period from date of purchase to classify an investment as marketable securities	1 year	1 year
Corporate debt securities due within 1 year of date of purchase \| Level 2
Cash, Cash Equivalents and Marketable Securities
Marketable securities, unrealized gains	$ 13
Marketable securities, unrealized losses	(144)	$ (31)
Corporate debt securities due within 1 year of date of purchase \| Carrying value \| Level 2
Cash, Cash Equivalents and Marketable Securities
Marketable securities, cost	437,106	42,931
Corporate debt securities due within 1 year of date of purchase \| Fair value \| Level 2
Cash, Cash Equivalents and Marketable Securities
Marketable securities, fair value	$ 436,975	42,900
Corporate debt securities due between 1 and 2 years of the date of purchase \| Minimum
Cash, Cash Equivalents and Marketable Securities
Maturity period from date of purchase to classify an investment as marketable securities	1 year
Corporate debt securities due between 1 and 2 years of the date of purchase \| Maximum
Cash, Cash Equivalents and Marketable Securities
Maturity period from date of purchase to classify an investment as marketable securities	2 years
Corporate debt securities due between 1 and 2 years of the date of purchase \| Level 2
Cash, Cash Equivalents and Marketable Securities
Marketable securities, unrealized losses	$ (12)
Corporate debt securities due between 1 and 2 years of the date of purchase \| Carrying value \| Level 2
Cash, Cash Equivalents and Marketable Securities
Marketable securities, cost	13,529
Corporate debt securities due between 1 and 2 years of the date of purchase \| Fair value \| Level 2
Cash, Cash Equivalents and Marketable Securities
Marketable securities, fair value	13,517
Cash \| Carrying value \| Level 1
Cash, Cash Equivalents and Marketable Securities
Cash and cash equivalents	2,127	2,725
Cash \| Fair value \| Level 1
Cash, Cash Equivalents and Marketable Securities
Cash and cash equivalents	2,127	2,725
Money market funds \| Carrying value \| Level 1
Cash, Cash Equivalents and Marketable Securities
Cash and cash equivalents	35,919	145,902
Money market funds \| Fair value \| Level 1
Cash, Cash Equivalents and Marketable Securities
Cash and cash equivalents	$ 35,919	$ 145,902

XML 32 R22.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Common Stock (Details)	9 Months Ended
Stockholders' Equity - Common Stock (Details)	Sep. 30, 2018 Vote
Stockholders' Equity
Number of votes per share that common stockholders are entitled to receive	1

XML 33 R23.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Registered Offering (Details) - Common stock - Goldman Sachs & Co. LLC - Underwriting Agreement - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Registered Offering
Stockholders' Equity
Number of shares sold by the entity	1,079,580	1,731,929
Number of days granted to purchase additional shares	30 days	30 days
Issue price of stock	$ 305.00	$ 83.00
Net proceeds after deducting commissions and other transactions costs	$ 311.8	$ 135.5
Additional Shares
Stockholders' Equity
Number of shares sold by the entity	95,973	225,904

XML 34 R24.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - June 2017 Private Placement (Details) $ / shares in Units, $ in Thousands	1 Months Ended	9 Months Ended
	Jun. 30, 2017 USD ($) Vote $ / shares shares	Sep. 30, 2018 USD ($) $ / shares	Sep. 30, 2017 USD ($) $ / shares	Dec. 31, 2017 $ / shares
Stockholders' Equity
Net proceeds after deducting commissions and other transactions costs \| $		$ 311,825	$ 38,278
Preferred Stock, Par or Stated Value Per Share		$ 0.0001		$ 0.0001
Series A Convertible Preferred Stock
Stockholders' Equity
Preferred Stock, Par or Stated Value Per Share			$ 0.0001
Preferred stock conversion ratio \| shares	1
Preferred shares number voting rights \| Vote	0
Private Placement Offering \| Purchase Agreement
Stockholders' Equity
Value of shares sold by the entity \| $	$ 35,000
Net proceeds after deducting commissions and other transactions costs \| $	$ 34,900
Private Placement Offering \| Common stock \| Purchase Agreement
Stockholders' Equity
Number of shares sold by the entity \| shares	328,300
Issue price of stock	$ 15.23
Private Placement Offering \| Series A Convertible Preferred Stock \| Purchase Agreement
Stockholders' Equity
Number of shares sold by the entity \| shares	1,969,797
Issue price of stock	$ 15.23

XML 35 R25.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - At The Market Issuances (Details) - At-The-Market Issuance Sales Agreement - USD ($) $ in Millions	1 Months Ended	9 Months Ended	12 Months Ended	36 Months Ended
	Oct. 31, 2015	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2018
Stockholders' Equity
Number of shares sold by the entity		0	215,539	597,256
Value of shares sold by the entity				$ 9.6
Net proceeds after deducting commissions and other transactions costs				9.4
Remaining reserved amount under shelf registration		$ 90.4		$ 90.4
Cowen & Co. LLC \| Maximum
Stockholders' Equity
Maximum aggregate offering price	$ 100.0
Percentage of gross proceeds payable as commission	3.00%
Notice period of termination of sales agreement	10 days

XML 36 R26.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Stock Option (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Additional disclosures
Proceeds resulting from exercise of stock options	$ 1,900,000
Stock options
Stock-based compensation expense
Shares available for future issuance	1,225,595
Shares
Outstanding at the beginning of the period (in shares)	976,777
Options granted (in shares)	241,650
Options exercised (in shares)	(86,095)
Options canceled (in shares)	(8,750)
Outstanding at the end of the period (in shares)	1,123,582
Exercisable at the end of the period (in shares)	621,000
Weighted average exercise price
Outstanding at the beginning of the period (in dollars per share)	$ 11.97
Options granted (in dollars per share)	173.23
Options exercised (in dollars per share)	22.06
Options cancelled (in dollars per share)	113.81
Outstanding at the end of the period (in dollars per share)	45.09
Exercisable at the end of the period (in dollars per share)	$ 10.75
Additional disclosures
Proceeds resulting from exercise of stock options	$ 1,900,000	$ 0
Weighted-average grant date fair value of options (in dollars per share)	$ 136.43	$ 13.30
Stock options \| Maximum
Stock-based compensation expense
Expiration period	10 years

XML 37 R27.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Restricted Common Stock (Details)	9 Months Ended
	Sep. 30, 2018 $ / shares shares
Shares
Outstanding at January 1, 2018 \| shares	104,127
Vested (in shares) \| shares	(52,064)
Outstanding at September 30,2018 \| shares	52,063
Weighted average grant date fair value
Outstanding at January 1, 2018 (in dollars per share) \| $ / shares	$ 9.45
Vested (in dollars per share) \| $ / shares	9.45
Outstanding at September 30,2018 (in dollars per share) \| $ / shares	$ 9.45

XML 38 R28.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Stock-based compensation expense
Stock-based compensation expense	$ 4,976	$ 1,029	$ 8,370	$ 2,307
Research and development
Stock-based compensation expense
Stock-based compensation expense	1,179	272	2,287	577
General and administrative
Stock-based compensation expense
Stock-based compensation expense	3,797	757	6,083	1,730
Stock options
Stock-based compensation expense
Stock-based compensation expense	4,852	878	8,002	1,859
Unvested Restricted Common Stock
Stock-based compensation expense
Stock-based compensation expense	$ 124	$ 151	$ 368	$ 448

XML 39 R29.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Unrecognized Expense (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2018 USD ($)
Unrecognized stock-based compensation expense
Unrecognized stock compensation expense	$ 25,646
Weighted average remaining period (in years)	2 years 2 months 16 days
Stock options
Unrecognized stock-based compensation expense
Unrecognized stock compensation expense	$ 25,250
Weighted average remaining period (in years)	2 years 2 months 23 days
Unvested Restricted Common Stock
Unrecognized stock-based compensation expense
Unrecognized stock compensation expense	$ 396
Weighted average remaining period (in years)	9 months 18 days

XML 40 R30.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) - Research, Development and Commercialization Agreement - Hoffmann-La Roche ("Roche") - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Commitments and Contingencies
Remainder of future milestone payments	$ 10,000,000
Licensed product sales	$ 0	$ 0

EXCEL 41 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 42 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 43 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 84 137 1 false 30 0 false 5 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.madrigalpharma.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.madrigalpharma.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.madrigalpharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.madrigalpharma.com/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.madrigalpharma.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 00400 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.madrigalpharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 10101 - Disclosure - Organization, Business, and Basis of Presentation Sheet http://www.madrigalpharma.com/role/DisclosureOrganizationBusinessAndBasisOfPresentation Organization, Business, and Basis of Presentation Notes 7 false false R8.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.madrigalpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 10301 - Disclosure - Liquidity and Uncertainties Sheet http://www.madrigalpharma.com/role/DisclosureLiquidityAndUncertainties Liquidity and Uncertainties Notes 9 false false R10.htm 10401 - Disclosure - Cash, Cash Equivalents and Marketable Securities Sheet http://www.madrigalpharma.com/role/DisclosureCashCashEquivalentsAndMarketableSecurities Cash, Cash Equivalents and Marketable Securities Notes 10 false false R11.htm 10501 - Disclosure - Stockholders' Equity Sheet http://www.madrigalpharma.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 11 false false R12.htm 10601 - Disclosure - Stock-based Compensation Sheet http://www.madrigalpharma.com/role/DisclosureStockBasedCompensation Stock-based Compensation Notes 12 false false R13.htm 10701 - Disclosure - Commitments and Contingencies Sheet http://www.madrigalpharma.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.madrigalpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.madrigalpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies 14 false false R15.htm 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.madrigalpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.madrigalpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies 15 false false R16.htm 30403 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables) Sheet http://www.madrigalpharma.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables Cash, Cash Equivalents and Marketable Securities (Tables) Tables http://www.madrigalpharma.com/role/DisclosureCashCashEquivalentsAndMarketableSecurities 16 false false R17.htm 30603 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.madrigalpharma.com/role/DisclosureStockBasedCompensationTables Stock-based Compensation (Tables) Tables http://www.madrigalpharma.com/role/DisclosureStockBasedCompensation 17 false false R18.htm 40201 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details) Sheet http://www.madrigalpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIncomeTaxesDetails Summary of Significant Accounting Policies - Income Taxes (Details) Details 18 false false R19.htm 40202 - Disclosure - Summary of Significant Accounting Policies - Basic and Diluted Loss Per Common Share (Details) Sheet http://www.madrigalpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedLossPerCommonShareDetails Summary of Significant Accounting Policies - Basic and Diluted Loss Per Common Share (Details) Details 19 false false R20.htm 40301 - Disclosure - Liquidity and Uncertainties (Details) Sheet http://www.madrigalpharma.com/role/DisclosureLiquidityAndUncertaintiesDetails Liquidity and Uncertainties (Details) Details http://www.madrigalpharma.com/role/DisclosureLiquidityAndUncertainties 20 false false R21.htm 40401 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Details) Sheet http://www.madrigalpharma.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesDetails Cash, Cash Equivalents and Marketable Securities (Details) Details http://www.madrigalpharma.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables 21 false false R22.htm 40501 - Disclosure - Stockholders' Equity - Common Stock (Details) Sheet http://www.madrigalpharma.com/role/DisclosureStockholdersEquityCommonStockDetails Stockholders' Equity - Common Stock (Details) Details 22 false false R23.htm 40502 - Disclosure - Stockholders' Equity - Registered Offering (Details) Sheet http://www.madrigalpharma.com/role/DisclosureStockholdersEquityRegisteredOfferingDetails Stockholders' Equity - Registered Offering (Details) Details 23 false false R24.htm 40503 - Disclosure - Stockholders' Equity - June 2017 Private Placement (Details) Sheet http://www.madrigalpharma.com/role/DisclosureStockholdersEquityJune2017PrivatePlacementDetails Stockholders' Equity - June 2017 Private Placement (Details) Details 24 false false R25.htm 40504 - Disclosure - Stockholders' Equity - At The Market Issuances (Details) Sheet http://www.madrigalpharma.com/role/DisclosureStockholdersEquityAtMarketIssuancesDetails Stockholders' Equity - At The Market Issuances (Details) Details 25 false false R26.htm 40601 - Disclosure - Stock-based Compensation - Stock Option (Details) Sheet http://www.madrigalpharma.com/role/DisclosureStockBasedCompensationStockOptionDetails Stock-based Compensation - Stock Option (Details) Details 26 false false R27.htm 40602 - Disclosure - Stock-based Compensation - Restricted Common Stock (Details) Sheet http://www.madrigalpharma.com/role/DisclosureStockBasedCompensationRestrictedCommonStockDetails Stock-based Compensation - Restricted Common Stock (Details) Details 27 false false R28.htm 40603 - Disclosure - Stock-based Compensation - Expense (Details) Sheet http://www.madrigalpharma.com/role/DisclosureStockBasedCompensationExpenseDetails Stock-based Compensation - Expense (Details) Details 28 false false R29.htm 40604 - Disclosure - Stock-based Compensation - Unrecognized Expense (Details) Sheet http://www.madrigalpharma.com/role/DisclosureStockBasedCompensationUnrecognizedExpenseDetails Stock-based Compensation - Unrecognized Expense (Details) Details 29 false false R30.htm 40701 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.madrigalpharma.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.madrigalpharma.com/role/DisclosureCommitmentsAndContingencies 30 false false All Reports Book All Reports mdgl-20180930.xml mdgl-20180930.xsd mdgl-20180930_cal.xml mdgl-20180930_def.xml mdgl-20180930_lab.xml mdgl-20180930_pre.xml http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 47 0001104659-18-066115-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-18-066115-xbrl.zip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
WP>).ISRD)-?'.N.B72U,N"WX)L MTJJSU)9>U87:%'U]NY'IV8DB,L2>'R,P!3E;D#6FZUU[V HKZ"^5].4]H-G& M6 =DPZE_*9A/I#)EE7Z*AJ=Y7C3XZ_"4 _JF8%LEDOIOY.1&:W_ [DM MR#=$:4D];9_6J=6:2:@"/G]*SP<^5=05S<_"Y7D=GBJ6'#Z-_%WP;B$OPKO_,D['^^LF@[\O9Z$%[VG7Z#VV=)>>C6W M0?OQ=<\_P-W!8\!B$B._Y+ZKQ70S0I'B6 26WI:4K8NP($2LB#1;D04=IZM5ZW_H1G6)XUM0I8"'L>?QY/]R\%QP]6;\_;&\/ M@VM":L1SK_67W$!W'P6X%)Z55X^K;RXW]T>'_='; >B.#=[)CNR]\F:V"/YY M7^9L7]:N90N3RRRGS2H$P?+8OZ5W/8WD1B; M2#0Q(_\;##4-B!F,YC=K.@OU93\)8&!4E:&/C=2G#,HW5Q>:2>*/(@(WM[BO:!SK^/F%)H$ICL##<*8TU:'Q[Y,4X>JD9[\H M'#.3_3EES+Q,<]+3,C2SE26&68(*_\[J\D,9O3%=Z,UO M8CX/,+_$-P(U2-W7CI[ MS&X77WQ?)TW/]$-&KN?VM8:B;: )8]$@<9?XX^8SH>P2\R99X$^M?OO/'QR=G^4(CB'\7T]GX;26T(T[L09PTK1.72B>Z+LJGNB MBN^BV*CN4VBVF\;^?.>8F9I+X]:(81S#U.#T$F2P6TA;?\5L(4U@0&.4NVC4(-ZQL%8.R457D?OO"A4C/ M;($LP#4+[%0*CQ!?3?&3\6RB[+ZA4C2^8^7*F49L40Z'!+YR?-\T%97U@-^% MV0.]H8NE5K @M(7,%OJY1"7(4Z[)@LC] -\:X8F^@R)M[8C?C&56]F?HIAYQ MU<,Y?E*Q\TT82GIUXS+B6:-0_(YILHF>%NTN#LU82B+1LNY_UKB<$YB@8':X MPX\3F)>URF;JWS$+W7H&*O,'MT43K94:L^4/GQU2_+.&XX8H@J%\/B?WA(E5 MM+XSN1VLI*: <8YM9C87E9VY7VINN2'&-NC<5Q1RAH8*!N9S>V28AJ2$XGFK MH:2RVU,Q5.Q]6NM^X3Z1MTO"YNZ=51=I,R#(5D3JL0O-ABYUT%OET+::B/=K5 3;?9X>IGE M;$.^[S-VXB5[VT#%BR2SMQ-7UM=V=7T]=R?\GTD2G;K$WVD)NK^89,>"6UY! MR9%9O$6T6UX7M+]5EEYQM>G*KZD\2T@6L MJD12 ?F^?84%,WMRLK9&;\SY8A;K!7EL7"O;C5]\M[C@YO_L8=[-=7]?$GG M@5K_@IO^KS1,Y-?S^!\WQ"/TWKQ%XL*R,_<+*@S5OK0S-9$')FD'4)R-YE)FDR2Z]S;C; %J"=;5+()Z5]? M29AO"\L&S@KIP^7 K':UOUUI5]):YW],? +&B'%,@XM2K5PM 12XU,/!X*(4 M<0=R%^/2'[__^,/Y3XX#N@S!$'F@]PKN$&.8$-"E;$09# 4#X#@QX9?+QUO@ M43?R41 "-V[U@L/AO-TEP]X ?"A7"]7R\W:HO$EY()8L%-9>!J< M@5JMD(DF'!\QMTA\N$M M=95"%Z5A&([.*I67EY?RI,=(F;*!8%5M5.:MM!3RFS,C<^0CIU9W&K7RA'LE M(' /N))M(&1&+GJX0OW2F-'6*E_N;I]4YQT<\! &[J+5AI2X7:W=;E?4KW-2 M(1YOZ="!+2*24IR%"(2\!*>;SX\U*OWSH,3R M9#2$S(=EE_H525;)Q%@I;81_Y; *SW_E]_W[$9H.I[UJKI-@)01=ZH\8&@H: M/$:WE!\,B01!=@("^? CH2^' V(AX#L"<(6Y2RB/&)+RY;_K?R(\AD1VJA-X M=Y!]0R'L$?2$W(CA$"-^)1Y@DA&(G01E!L2%Q(V(&F&WXK<8!-F1 TQA2Z"C M28A$"V_^%(=2I(@.U2IPP)RO^#QG#99Y@Y@YR#Q!*L6%ZH2Z*UTB,I)2MNH( M,3O%J@]Y3_$3R<8 PI$*U!5$0CY[HES&J=;BT/ES_/AKA_,E! CL(:)2EI4? M*X5UK!LQ)K#>VK^8YFNST6RUJM56_:35:C;:C>;I4L^7O*G#5I6 S)WQ%Q\W M'&S55C%%A4>^K[@Y6+C#K'V?47\3OE@8S=)QRCS$1"Y9 A$7_:$C*0N2$GA! M># ,U2]%F$6.>C'4UP=_V(6,O8I\]R]((J0QEU%;6\VXS5B;!LZOJJV&[XS% M/"[G]H^4/<'5*;X7+KZEC-AL7([#&?:A=.P6==O]60D Z%P^?MP MB)C)Y&W0\CC,GU?1V.0-^TQ.Q=(G?'T064XHU)$3W$AF1'\BO:WU36PU52I?!58\>T9@*#TY/&:;W:KITV3S_4 MFNUJX?JEJV*?!^;">=-=TW2T-==8ZO?V&+)):+4M#0.&H5:V6J_CNC02V>X# M?)5)3TI"F$ALM14S)G_F"EIL4!8ASWA4:NF/RZP9=#1) T8,4[$.>%5D19C9 M. M(C$?V&G:7"&JHJJUIGEAZ])%PRRD V_9F$BCM,ZJA-1*78$;:V3H#=ZGO MTR#5B.MD1V1!(]5L'88=S\/3KCQ [-T$73C"(21+.NDB:6K#(S)Q3F5MW281 M&4+D2_#1=,-GY93T)G"IK\Y*_T3A??\93O2Y5!8NQ^0.>] \]HT3VWSC49Z* M!LB[ABS P8 OZ7J%^MC%NM0ZO>$1>4!.96.CGZ8;_;RR=LC\'4Z>M24D)D?0 M==,CZ(440/L@5ZE* <-"C.7%P-:,@#6:(D9O#&AZ9:V)H]S_L?'\&D6FM&9Y^M3$VQQ8A;E4LUH5-8Q.1( "4/U:_0&!&J MCEUB7:XG+HEDM6W'%?%%+/-N@@=&7<1YEW)]*,W-T6*_V&K=I!"[7Q!LG0(^ MH4 1(2:'<_' >:AA&N,8DTU+I+2ZGC<((^BMBZV;X(0,<3CF*:6#AKS)E#: M9]+4Z&RJQ9O8@U;=GVJB"](+BC=HK+3>FVQF+(S4L&4ADU0!;K*>:>1;SZR( M QDKSHO9OEW?NDC9]MG28G9R4:NVFZU:J]YJ%#319EZMV3=>L\*\.:#3%;0U M)=)MJLVK%?N4\95JQ8[W=\3#N-Q)@?1 F;)7&#+25!>Y-G%%5KW<;@ENUH0 MV.8P!#[1_- *>OF32'RB;Z[LX,DM6TSTUV--+:NBL_"&_BZ&A9/?5&U;WJ)K^>(.9BOK%"-VYWQ'ZQ&P8Y M"V8/4Q"SV]VKZ84Q)]63:@TX8"%'5L8(,;]-2U^6I $8>& A#RP$@E]BD;\> MJDA&,W,F8_(TI"Q\1LR?IB=^? 7CYBLA.7GL9=+7W!09>/IT^1.CG'\.1%PD M^%_D?8(X6,\B]LG:G@EB)UO/ \4A83EP*#F8#\FRBHU4=*^\__>B#+BDAA[' MAI3$'$/S.D$-@R/RGCTIGVV)4I"'K(^%U?MNX^H-6>;#PTO(L?8>\LQL;%!6 M=\VOH9*ZYO8,A5VMG.>.Y+>[@$M!:7&W14*R<2EK_-&66V+VP?M].-;^H'D; M03JO_C([.93;K?#^W^VR09,S\"=M2YQ7IE:-E^*__P=02P,$% @ CS!F M327E'?I.$P <4\! !4 !M9&=L+3(P,3@P.3,P7V1E9BYX;6SM7>EOX[@5 M_UZ@_X.:?F@+U'$VG 2/1-C$Z7%)RXOGK2U(^9)N2 M*)NRGCT"VD7&XO&.'_D>'Q_)3_]Y]UQKB"DC@?]YK[5_L&=AWPX.%>7.RE;'YN%!Z\0Z/6M_.#LXL3IWTX)WG(,NR2WI$O_[F?C/*^_2>F?D MC-E][*';P)8,?=[KA^'@K-E\>WO;?W^E[GY >[RI@W9S6BNUA/A78U*L(7YJ MM X;[=;^.W/V+"YWG\F^-3J9%.<4SI5^:T_*MII_WMT^2^(;Q& MQO5:IZ>G3?EU6I1W3S((6FJ:?W7":85DX8_-^.,>%[1E?:*!BY]PUY+=G86C M ?Z\QX@W<$5;\K<^Q=WYEKJ(O_ M8^QX>Y;X]/7I9MK:4D.B0%.4;5Z]A]AGY-7%5SY':PSD6\)"-N912SW-8DQZ M3L^5E!^$V6[ (HJ?(\]#=/30?28]GX/81G[8L>T@\D,^*!\#E]@$ M,SY&B-WQG4OB1GQ$W :,/6)Z$7A>X#_W$<67.$3$9S]P'3[A"UK#T1/N<:QCBIV';A=3KMMU@5.D"R!"^"WR,2]\_$BY M]D+\Z"(;"\-E7!2Y'0$12">,L7O#6"2F^W7'1Y$>JA.!]#OXY#7@!D&: ?GK MPT#\:4( 6NT#8O_J7?RYMB71:AL0VU]]BNV 6[T?V"E3!%G]5&,NN=TFH3>V M7A>!-/5\-6# /FJT7)AER16B]H3U\9])ZJ8M$#]L.L1KCLLTG,V!WX@Y-BG"I:8-T-OG M=%$[>L6-:?,&25:V;E;*N(LB-RQ'S).VQQ3S?Q.?Q,L@__NX=4'/VLNI!.U8 ME'.P,_V5A**#674K4=^ZE$BP[N2P6F6NR.>IHF51OD@^'!P>'%H-:T8$_\>8 M#BOH6@E*K!DIUH067EB28R'?L<8$68(BBY-DQ319DBCKGV.R_E5 P%*\ N:! M/<>,*R(H 56"4V-M+WY97-J/?_XFHAQ.Y.*';H>SZ@B6R#"QQ+IZM]V(R_&: M!IZPMU$H0?30O4+4YZ(1NI ,OXBEV81"%[UB5X:\2NFD68&@UJ3\?*1NH/-. M6(K42NUQ*L+98.[0>6'RB7-"V7@.7=$T!)0O53[OM2:M=3GIY8%CS$*P(4%& MC(LED,L.Y$*"YCWR\.64]&4J)Z7L1A5S:$XQ*>P 4,HC;PM3 MJJ,3==&-JJ1M3B5J;@!H9,WIGJ]-\4V(O9+AI=*M8A+(DKBPK1? MOH"H.(1R9@=^R-?J5Z[O/FG6X?>&J&W_(?0FY"Z(7>EJN4,5L(E0B=FT68) >!Q?X>!3[.M>1[V2/R[3"$!QKTWI*XQ6 SJZ)CWR; M(/?&YSS+=/<,SRBU= 5N48KNBKE%J0P!4,T+13[K8BI6+,^8#HG-5U@/707) M[(73PM2?,O M>8P!4-EC0*4\PRFQTS]FL?_LC>LB+4!QH/6 .K>C783-GTVQ\Q[=,??H3@%Y MN:4J6\DZ /U?($I'W!8]86Y"0NS$^Y5%,5"X%0@.\@K0GX\Y%N09@+:O6$@\ M[BAP]V+5X5ZL"0A.\IIZ+L8P "4G)K+IG[\23+GP^J-;/,2NGI>56;D"9^N# M86DR8([9,=&:,JF ;\/PN#00KU:O'[\^HY6UQPLK4/%1O;$KOC3^( M0B89;F6:X\P:$+RLE?"M5*R*0Z Z4X>.M6I \)A*T=EA>3IC-$SHB_]K45?\ MIV]/R.]AA>>S\*T"Q^;C.H[- OE5"E<)^J6O%?L82BC,"1("3G5$.6_$3D[; MQP?5&W)=\2J)KTCB=UQ07N2ERGSA>Y56-04@$P$O4%J5/-%[MCSGOU=I\?+D M.4\I &]#:11N->N PU=YG<%+^(2L++PLM#V1O%R5#5>%IB'CI?D&=XD@YJ02*^^ M4:T?EZ7U=/Y*]QG5IZ^?^]R&O6#J)3CJA,*@*=,<"[>Q4;6=&/'_BC.Y$=TI MCA?Z3CJ^%&9'Z>P;:WJCFCXUIFDCO&\! (0=42_WS+6]V:CD 1 ,3+B'9IKU MY[&,D(YN YM5O;%(7A$6J[X^I=AC& G!IUZ<\E%Q%W"BDW]8<3?\YUE/UJ2K M[;LRY2)P.<+E\U)#W*%4Q-PGU\C?![Z=\EF>FT"V4*#F52OF.JKDV"+OX*&; MH"LC52^E+,2+64QK?^[(H5H, (S ,J-(S5MFMDCA5H D\65">6Z=5I3!GU6U MX@T>9=K/#%$ 4&R2J,P<:%5!()8P M%YQSJR(%']NM!]!F:TW=F+=.INX[D$_4Y%XGK2@'P7:EHVW^=H(EX@&(_CEZ M9<0AB(Y$Y$K#%*67AWBBO513E"X*"(J=T21N-7_H)GC*G!)U*D(Q57G@G5.7 M!E^[K;?YZ;_%I_\V(--F5I=*7LM8B"U'5M-78>EE(9@Q?>1-5UWI#$%;VX;B!#]!I/O624!Y&46DA7&DQ5E'Q_(6XAP'2 :#@2C*2<>%(7@WBJNPR' M(UT"51WZP8-QANLTU+)(G])4%:P+X.Q5%CZGYX3T.=IE?8'T+HSK<&-^Q9? M=3SD/R.[SRZ"=)]"7:[R4U]%$3=U*=3\0',G#$SSMSG'H,QV4=VAJ3)$I3YB M9<[V;NO1+.D0WC 68>CI? MPM&/2?C"60BQ\Q),#AEU'(?$7<;4J8S$*JU .(]5EII7%@HT.Q33%0/UD1(; M3U[R2AOCZ>4AG+LJ?5BGLP]-LX\TL#%VF#A5* A&OBU-W'03(47#&O4@'*,J M6],:8H"7I?E;Y&,.AV,.S2$*\:.+;,EUT5S-MF:NINC/$AU:XQZM:9=USF:= MLUGG;-8YFW7.IC%/?GHJY'$Q-)(>W=&H!&'K:-WL/0TVH?EG=0Y?G<-7Y_#5 M26&PDL)2GZGQAYB&1-XY0\4TRTMC2K&3+M\B%4&$!#,%7H0; ."OT_+JM+PZ M+0^0-5H,R60_,I-2&()=6BUS*(TC )JIMV+KK=AZ*[;>B@47(-C2K;D-;\5N MX=9<"B+EY:XKCNS%NC_%9JR>*$I/L5!N%=+83XJWRNZQ\HXSS8J[O-U:1 [0 MAO'\XO\144ZSB)O%",R9K74K0[B"LOR]=CU90 - ' X2"]OQ@BBV0>,H$79: MJ=;. M%P*\%)E.&%^?/K$SK&ANS ?-W)A.:+WTL17W9DV[J_-BZKR8.B^FSHNI\V), MF?!.R.?9^4E=+!V81G:,=E4(@?=U0O%2?KH:;E52?KJY/ M5V=ESKQA_R+8OW7MK"R9I4+;>P!7P4S)@9LM?Q"WDFR7^B'='7M(%_(SI 6? M=07W#&F=(E*GB-0I(G6*"+0-J%U+)*@J=633B03U"6\ Z2-&3GBO??FC$ A' MW"P&)"^B?^YCMQM?CB@8#'R)1=72L6@+.Y],4E0@Y3^H-D-4I\?7TCWYQ'-\ MVZ5,5%-'!'(K[7)FB*X,RL\/X*MV3C#J\9[E8VR36>,1C83SV&&"2L+B!;TB M4Z!0_5W.^EA!'!NY'&FV_R&>82.^G!ON@S#.(.5NP"4:I=Z)I%EYYW-!"L@" M1$K(.6+B+75O@#ESHDWY:WRC;;&$D*.#EC(AI"$2-QPKV,W1!V]!)"UVZ\D54#VSWO)R/=8* ,QS\.0;N>R ^:Y M!K!B6IW)&2^^\^@B/W43K=RN@"2(*#&_=!C#./KM MYGJ[N=YN-N5DI V[O$UF$PU7M[5L3BSJ#>6UI[NMW4<63+WF"_9UD>^K]P&) M@^EQA"<+=F;:A[ ;71(.S0D)VD;ER@*;'"J+-^([0T1<,=*N RJO6C<]R^5V M!V$SO$3TE2*SG0%CO)I@#U'(0N0[XI1CX+J<4?'1-!1S.H.P/P\,B#D2VV$8 MQD.P? 1.^MF*>,):H[@D0$X$N&M8E#,]N_$GKZ $S/@")*NGK?8)-XY'I0C! M(3(K(3,1VV-7[YC:A.%4 [Q"0UOMY17'TPH2 @>7-:7%Q=/%)(S$!6(:2UG3 M/6VU-[?Q"4PIPEU#Y'BPB:54J>Z=HA$&:+;@T:% '<-BPEA_H'%Q3[8Z0PQ M13T\,0DR&U,(NKNIU; V(5N-YDVME+6E^9-"NUH\[]R*N^ L4@'HMQ#IJ9M3 MRG5?&6@W2<&.K>G+1+Q)L>\JH'Q\;9'O&M([CD-B^F?GT5CG51QX MMHTGR^CU">&0,LSP2X[@H&$S>5M"D0TXC7J[$-W0&GIIMT_$+MLF0M1^?$2 MA?@:$:JZ[:(R*G8A%%$8GAN7,LQCX5?OXD]<]$AXN\"1\'$7]6EPX^W7I\'K MT^#E1%= G.6M_(Q:)N9_BM/@]2%=^(=T"ROU"7.WB-AAUMOV.66WPF4TI,P4 M$0!0Y(W/_3PL7Y(3O-V*GH0(TBUS9HT=/Z&M)0.X6LTTOSEU@-A1#;QJ* J0 M>32NJKG+.DX.3]LG'^!<7V)2?4I& 6B43_:8"ZC/+<,E'F(W& C:QTO8/$N9 M7Q."$Z0%V@4#F,\9 -U]P3ZFR.5D=AR/2S>^!W6(=;2G61>"WU-8?YJ\ ="@ MN8V,^EZ(^EX(C6"6*QO'CEH"XP&2%N72K QASB@'0;H2@!GZ_NI3; <]G_S MSHIAHP>+*[.B9>Q\3KF#A,%Z..B=)2QER!$;O+[1<#"^R#\+PZ?IFN$/&MBOK^MF,!6 MPFF)0H.6PU@:JW&BVW5 QS^)9=,J;*U6H(0H5@1L8D',U?C MO6373NL5@HL@XBL@.D T'(DE>D<##R*.&&[CIZA8 MI$\9^BU8%\ ;'%D FS['H<]1&;/@KT&WZR'_%CT%=E^=QI%1KO*'.8I":3IO MJ?D!X$+,C^:\P%EJZ>JB83D,)/T Y%,<1_R!A_R+B='/_X\:WW4A<)]!A#//_ M.2_H/77;8866($1&"HRVE7A<*6;QJ1G+>+R4_^7_4$L#!!0 ( (\P9DU? MF=;M@#P *+: P 5 ;61G;"TR,#$X,#DS,%]L86(N>&UL[7U[<^,X=N__ MM^I^!V1R*SM3)?=C>K.;GNPFI;:[)\YUMUUM]R:IKEM;, E)W*%(+4G9UGSZ MBP/P 4I\@. #A^ZIRF;<$G!>.N>'U\'!G_[]:>N3!Q;%7AC\^;O7+UY]1UC@ MA*X7K/_\W3X^H['C>=_]^[_][__UIW\X.R/G$:,)<\G]@7QD4>3Y/CD/HUT8 MT803(&=G:1YZX9(?_RXL<7KU[\X771 M^1V->6-.3E#Y\<7K_)N,?1C\1%Z_?OG/+W]\]?I?R-N?WOS^IU?_0I8?\X8? MN08KK[6E[P6__ 3_[YZS)$^Q]U/L;-B67H6.4.C/WVV29/?3RY>/CX\OGNXC M_T48K3FI5V]>YKUJ6\"_SK)F9_#1V>L?S]Z\?O$4N]\1;O<@%KPUF&3-N82E MUH]OLK:O7_[WQZM;(?R9%\0)#9RBUPF7M-_KMV_?OA3?YDTY>Z]!H)PTMQXA M?XI"GWUF*R)H_)0<=NS/W\7>=N<#;_'9)F*K:GI^%+V$_B\#MH8?%2ST%BST M^@]@H7],/[ZB]\S_CD#++Y\O:T5[6Z*5=A(Z:9GWI=1'^@-TON)_E=1B3PD+ M7.9FB@&[!M)"&F%901EHATZ)H \^%D9E0VW=M7\&KOKJ[9M7P@SPR5\OTDA: M!N[[(/&2PV6P"J.M\-'E?9Q$U$DR0D)\24FW7T=]P2@9L'9E]L.ROQ;QH30P"62#5'X_$F*U\EU4ZZ"XXK&]X(M'T'6 ME.X$^KYD?A)GGP@G/WOU.L7#?TP__NMMPN,7)+NC]P6*I/:I;834@9N5 F^M M;H'0-5L$-?7#G!SY*@C^/P2>QZ&?7?(_XS83J WGXH$GRE5Z8=YJ#IYX*NP MW@A$B:!ZXI*#:);P*3>[LJ2>:9#%693%S'FQ#A]>NLR3 <;_.(XK_M%?Y"Y!/='F-Z0S.D,=6F&$1471N$\=0JJJF[I=.*@BH!LA/[WCEW]XCZ MEWSJ_O1_V:%6]]-VZ+VO1K6R^QTU0NU_=;+V=,"4+!%T"2<\F0MFL^P[3K=" MZZ.O$3M"C^4-JAZWFX%S5:IV M[&6E1LC=K5K6WGXGR?)5NTN \&0NN.3<79#@@T_7%6H??X_8Y2I5R5RM]"52 M%ZN6T=2UR0;0IF'EG7#JE+MHIKZI,IX9)+3CXA3%?M4I3/;!=&B1>L89>Q$BE; MFB/V3AU%C[9=*MLB]5(MD?MNPJ0.FY,GDO[$SOK!\UETSH-D'4;UFX''K="[ M9J5:98\L-4'MB-62]O0_091D5"?VNO=;%JVYS_\KNEOO]N'WL!B^L'\.-6Z-VR4JVR M.Y::H';#:DE[NI\@2C*J4\\?P^TV#&Z3T/GE=D.YQ:[W"2090@IJ_62EN1-Z MG]11^FA&V= #M<=J"=YW=BEX$,%D020;HO!!D%5TO?K@!31P/.K?A+'7D+G9 ML2M27S1PPEAC# M>7_?7\8QY]_BY2>-D/MSM5*JYY9;(/;1&D&-3Y$$.?(U(V@I<6X4K6P'4;I] MHA5+IVUG$5(U*IY&UE%#] %6)V\_CUSD6VHX FYH+3/MJ*#^D[T /*?Q9AFX M\)_W?]][#]3G8L7+Y)Q&T8'/+?]"_7W=107=OL@#M),)U(#5ZH@X@+O);^SJ MG+RXB"/^4!@M"$U(QHL(9G9"?&([./ '*QA9''T?J.?#Q90/873+A;EESC[B MDW@67[#[I/A7BE9U"-F9"G) ,#1+:2SO1@(Q2)AJ8IR/P*F2@NR"Y *'#NJK@*#1#3$(=)'>U,U3'B1E(H9*P88<+0GL1/V4)F"222QL$ H; M.*4% Y(%N\Z2"7]$M\;N7*)T6&><).K"A/K:J^_>*MT!.S2A=!.%.Q8EAQNN MC:B'P)<$.]A4_\3J1]#&+L@#34?A\IA9WQYQ&&J);3Y$2.(+(LC+"A<9@P7A M+&P-CQ,H+;1EA;;!J;93CX2-N(4_),M*G YZB,/L2,!A3T"F'-T&&M9L#V=7 M'KWW?+$XY?$ODA4VH>]RX L2 XMISL=NB./J:Z&4*-.MR_BN.RL@JG;*XSR M89"/$;8/C*SIK[+Z76H-%'"@=[S;V&$^(:]QT%O?>AYA/?1AJ$(:S[GOB/IF M*OH%"XLGP$O'"?=!$M_0 ^PQMVSMU#5&'J#-2I;FO94M$0=FB\#&\^*4+$GI MVCYT&5G+G:1K-0RC/7-/8:?>(+7M\0=CLZI'\5C=&'=(MLCMH3FRMMEY"*;9K/:T 7\\Z@7BK")P!&><+.1:MXU&4*Y\,J),3%&$ M7+L=9A5D+=$UC[ :,IZLA]% \8,B;CKOO,YYK[7;[NHL]U-'W$&LVC$DRR2) MO/N]3#A+0K[^0[$?,YD9F"!N<4/FAM-B?""6>\=-"?C5+9&';(-Z1PESQ\T0 M!VF3M#VRP23-[.:O(+L@EW',%T6V5GOC:AI+37O7KUFNQ8 M1&*X^4SH/MF$D?1(*#D0OFL.T] M)_#FM?CTC_]*7B_>_N'MXH]O_YAU](119<)=<;-:DY[%ZSO%]?/&FSJGS9"C M1)UBI?LW1VT0XT.MJ.:7H]6: .,C0_LEFI$T[(@(/TH\$)B@#0;_O'CS]LWB MS:NWHL7KWR]^_/&/BS^\^?T@X+ @G,2..8GWP'R+![)+UQ7W\ZE_0SWW,CBG M.X\O6I3?K6Y_3Z>'\V9T& !_$"DG)9E(J66#HR MFM0 D+A_Y@5GCN1B]2!IO]W[4"M#7%& :EL1V[ @Y@!T&3CAEEV%K M._I4OZG?D0IV!# SR]%15!<2F+'!4),>!SD9O_1.3XDCD2S)]\#T!Y'%3,(5 MX9RM'39;,T]ZW:=D'C\TKUO6'U ^LX1Z 7/?TRC@TYY8D?:"K3S'J]M8U.J( M'#;TE5>1HKT78G#H(+RIPV4,85)QTH3O@K,^7;SVWK MNB$/4UW%N]P,01S"VJ(/>Q/$>E;!.,J>I!H(E7%%=OF0B$/I=21*AKIB:_B& M1:*(K=8)4T-GY%'>S0CU9Y]U/1%'?$<%!CLAY9Q(&!')2YZ*P M;LF:RM;HA MTYKBY,#D>R\@;NC[-(J+0Y.3M94M<)#EK)?Y$8Z6&2LZS0H,ZI2N!X'C'K,) M_EK!!POZM"!ZP0)#H(^H=AK@6<9#K=IV(UJ>17>P5=YAAI%<5K8MBF7KF47P MD=!#1Z_-U(5)U"U'K5>IKMV(K7^91+_7#&.WYFT2S2XSB^(A7R>I"^6&ETGL MQ?,XBI>#.L3P)(N2WM!QW:W7$WF$=U"_)I5PALOM+M(/DW"(<*$]H1'0+[%/ M7J5J75\W]YA/T.NLK!N:SR/(!U]<5KXP9GM!/8'"^);2)THWKJ/K6\\M8NM7 MT#5-YQ2I RTFJZ(43=+_&)KB6C-W>,I3L\O<@K1EJ3RS1SP[B3ULS%I?(D^A M,\+%L>"VJ*G&;$U3Q.':)K&YUU8^-YHSBB$E_9JO[BC< M^+"8CWT>Q@GDEJ1/4;0]0=K0'+D;MRE:'GNJVR)VY%:1S3V9$Y:)4-E#(K:K M-XRF:QJ0P3HO$F:QWP.8JWSIPI@<8I080BOS:QJ2=WJQ.>>>O]'T?2X MR22 2Z"I# 2$&/@2A_ZU!B1F,YG/=E\JL8V M5>V0QVRM:FJ4GC1"')?ULO:?\[ZO*8P[3.2U77487C-YMR$\F=,CB+3BVG>; M-4HMYQ)MI^I5QEO1; X15R%M_Y@KU2JP''@#*@A$"#A'%GY6][@N S[NLSB1 M"HHB#+7;@54MD8==@WKES=F39HC#KDE:4Z_,:*91MR"YZ]NJ?SBJEIX@:G&T M W6D9G704VJ!/,PJU"F-:L77B,.J2DKC44P4E[FL]+)I5FO#:V,[9CZQI'5N M>-P&>=Q4JJ1&3JD!XMBIEM/4WZ L56GV-TG1"/VR-<-K6U5X:IHI[HQTT9@T M#*_-E=628%FQH"RQNN4(NJ$YN67 JP?08^F M:P8N(O/?27.?@(/%D^AC9=_1V'/@+,SS]TEM.G%[KYF%:XW:35%[U&5&P5LG M^7 QO"""ASP.EEQPQ/+0JA=JNI(B">J"'-W=G_]BWGK#15[R>0E=LT][J$9^ MO1)V4K(\]1#!F!ARH.AG)!4_S"@AAI6>"IF&7,:6I'R)9 Q)EZ?WBM$ D25C MG>+38V8^FIHOR,VGHA62/.P\J?9Z)==%W#85199;'R[K2@4Y*AF:I5S;LQ,) MQ#ADJLFH^=_ELN5V%^$ZIU\KU9G>8GG*8SB!V'XE25NOG--Y\\,/' MMHO)+5V0A[..PC4;,R?M$0>TEMCC;KEPMD3PM9KC!6+<1.&#YS+WW>%+#)<& M\V34);SN*L?\9I\W(H0\$LR-*0UX)_MX>.BLH7U[0\+UA.66P'(E.Y P"//.3.+FQW<%"LO:4@P M+35 CA>GRI3K+6??(H[O"B$'2RI=P#_32_5UZ^!/W,H\=+F#Z($6E4=4W# M61$*4"L7BYQFTO.O.\Y>K$]3YF#R*#=YGL#&/X6_';#V7AH8VW0GR^ECXL"? MKQ#%Q+1NA5K7&#D0-BM9VCJH;(D8C%H$-O5M0?8,_G:)2MA.^(^E)%3-3)5T M%,)9+01[47G!=AQ./"$-_]MGXB@C<)=;F*7^VA2CFEV11VP7 ZCQJ],/<31W M$M_4[54F"Y*SD=6&%$9V8GUR$\AJ0PIU^^'/9S41XX)>,/E?91YS3G=>0OWV MR-&!8,E#"OCR!9D.\S9C_ K+58%:0,K2\))K3)^8;W M@ZKXI=E['+.T]*OR0+3%F?RI06XBMJ.>>Y$^H966CN)8*O(KED(!;>MJ$IL= MF'0Q4C.PZ%":%;(JK0)>X0R9W0? MB4Q:6FD7F_BS=)QP'R3Q#3V(]*N(NG6U;K0[SPY?FHS0C"=5/6>%'XT*#(P7 M&2^2,EL0P0[+W&044^0Z[R159+$?[3F4%E.C+K8Z[3K'N*\Q0&O4'_6;6\S7 MB3]\Q ,GHK"R5ZAN C-D^O;8G=BZ:U^$\*NW;UZ) (9/ZL7/#KM%&F7VC\_, M8=[#R37V?I20AO< YH%H[T'&*PS?XG*[7D9CGPZ8?'SXA\9&FL>5EU2'3( ,> M>_'\]/T^(4&8D -+",S$%^)DCW?-NT2I;G -8$L3R/D_R 8/+#TF?#$*0%4! MM,W?I@JO+PN\SOC)1/+K5?X!R228=M)FTU3+([\S\JHYY.K6#)R="" =(\R- M89:3BW@Z:*"$_1Q<:T47IS15:PH*.A"Y% W0,)_,Z%Y@HJ&<33 I8'*_$!& M1YF1P"9G/=^$_S&M=YSP[^7F0I$!=T,/:6)A^D391QK]PD3^=W&_N,::NGV1 MHTPG$Y1N$.AT1(PEW>0W/KQ)N4 ^:,J'%(S(;>T%\:D.M28R Y=\0^'PBJ]? MMH7^&"[(BS<)F1M_X''Q42ZSN#SBU$V:!BIB4=^/KU=Y$8(/871+=4!B(-K8 M061($QY=4^I/&#,(#:J?^0FSE$*.T84<"Z)((HZ=A2P0PXT%1ZQ=D$)@2R G M;;7-9< (>L>PSZW'9ZK)X8;KG< 3TOQ3\9RJ[KC11 [?'4V1N-$J+8W9B#J MKL204Z*,&T<0SZIG+-',C48TBCI!VJ5LA!58QB/?(':]>!=RR)W%QDWO MM2A^^.AN#+,-&L3P8:"$_0T95+N_8YFJM/M;M?V"#D0^> $-G %V?YL)S1-4 M-(RC 2X-5.8',CK*C 0V.>OY[OZ.:;WCW=]5;JZ>N[\UR4SJ"O RCO><&;L6 M"[SK%4S5D@,W0E4*@&Y'I)C17?D\,TFK%_9$I&Y*],D[$J.I%X!/2Y>&K"(O M9:F^ @'7BQ=\(I_>#,@^2"##9!\=LG\7J?Q@'C'Y9T+@?++/(S&((5PX52>, M)T\DFL:V^0X4L"$9'W(=$> $F4+O4[-P;A9RA":V@CPK4]PJ=9''MBU Z_9".1IU5K]OPK^R$>'ZJ+_LP "%XD)0)R;G8WWT?67DN_]X7\2_, MP%(..4Z2<#?>^E[C2L#4?J :0)U_U-D!XPJ_]Z(%/QYV-X;92AXQ0AHH87_E MCFJ;<"Q3B87-3C%5U5K=XB,&7#SX'\PK'_@,,TCBSRQ.(L])F M?+ .W_('2 M\D;< 3E.\W__E);_Y'^((@^?:<+>KU:L=IMQ.6X/#L//%56Q@.0H0">OU;X/&M-G[)NO M$JL(30B#S<)5>CMX1 O=)C1*9FJC>[;V@@#&SUI+3?@.9;2F05JDL7C%1I:' MO.&_3W8\=+U*5TC4+]ZW:7N#=R#:R&%_4!.67HX<@C#B86!8_4QC595B0=[M M8R]@<2R/$.&A>G%XJ(HSTV"]\&+'#^-]Q.[84_*.B_G+&+]+-9OG',(-AATL MFBMX/-? ;E)UF!@OB23B7!4*PCT72WW,K1",? 71B)#-UAO;N$V,&D;3&F]\ M!G;#S>9H/'73U $YM+4K6WIVIK8U8KC1$-KXUM%^NZ61J YSZZT#;^4Y-$A( MP9%D+!'."D387:_4H,OB\H+%3N3MLCKP)P8TGB(,Q!-Y4$UBFP(BP^_[;EZ'(#X8NLBW-\GR_MPG_PC Z>6_8?63LBA M0$_IXY/O^AZ(0UY3\&'/KH6#:U6_LIH_PNU2502K;5 THS2#D# T3TN&2!L9 MY,%CJLW0V2"U(85@$,5C)XS((ZZ&;$+?Y69,[\N%2=V27+L3-]=O,.>55MK&0%[$T4.'\,8K?0P>B^* MB(%F(,5Z!=N9H$U4]C,(N'>J0=K&YOY4GTO(-9O-*.:J23Z'H&O1S#3JE)$] M7)7BCJ0B$"'#@@@ITOC,BX[:GPW8-B ^V#J',BY)7J-97,)>L\#1.:LVI8$< MDHQ,4MIQZT( ,=R8Z6&\>U1PD_7.57[( Z1U?[HKD><0(LV[TITHS#U(!MQC M;8H27$MO3):QB1]*1IQ(-3NTHT5C%_38T*YP&0GJVZ..>PVQS7VYE"/$V_)E0EWI@I-&R .U6BDU-,LM M$ =CC:"F+OA%%G3+">*+P)$5QI;\I#EN:O9%'I>=3-">$36C(;63_+T++U24 M-$(6Y98-8@\%JO)4I-HUEFKL@#S>VY55@[R^->+(UA#:U'LK,XOPA?+4%K 7 MNQ^H%_V%^GNFW"N_#.(D$E=DFL-8MR_RB.YD C6XM3HBCO-N\ILZ/' A@DVY M$(/""1\ H#&-/63XS&+&HPBF-!?L@?FA>%OO_1,<@[%&7-#KB1P5.JBO8H)& M-\2(T$5Z4Z?/>(A)K,*%I&SP@8%5JYR;/LM1]_033=K7Z,TMD4:NAGK%:TZ5 MS;!?3&Z1>IA$$5K>8Z M*R-QR0.9N]D#@S>"FQ<:9I20PM0 YBGEP7X-;9DR@M.74O%W$-APD. Q)D:2BNFDVVMV1QVY70QPEXFGU11S; MG57HD6)6,"*2$[ZHMV2.JS"VB 7O:03U\N&A%C%QT8. ]E[((U]3;37@6[H@ MCG-=R4W].:,/3QO)&RSX@GML&T#-1D=N&7K^'F[T0%P+BYS+]RT%6YOO6CXJ MY2*C,.!_.DPY0]&+? ,RR*' U##EERZ[T4 ,%L:JF#_8]5BJ*EIBB0]()K?/ M9P8;!O4FLKBMZ&R8NX>WTY=<,!=PCT]HBEP*^GPR]R)? M[T1.DW6DQ&CNHJAULN%&WR=0,5,\N!D7!@_"A'A!:G0O$$V=LMG==)(7L(3X M,-';]\E]_P[;H^SS" 8\+NZZMGM)HR2.Q9M M+X,'%LLK8L*W]/&Z!^'9X'-?XU7CL2G56>!O;^5&*+6G,$4(H=8LID"F(XQW M^NXB-QY]H)X/C,]68706\V_(MDBOC1&DUQ:FK#Z@$T=H\I0N3A^J/W0$NQZ$ M9P-V?8U7#7:F5&CN3!2$&VC-D@8&QL%:8IB.D M[#"@VJ=0# %,>7I76.9+X"6F@&9&O/AHN M<4N(@!FTK-BNP*M]9KFHL%RZ0.T!7C49S6U0G29J+WU!5*SUU:]%@K5X/-P) MUX'W*W-OQ!/>XO-&Z)J>.U*0L_0SY-G4?0Z[ M7C27#CYAHC9O.HETU"J&#DA%DI!0LO8>6$ X<4:\A&U)*/?//)GY%&XV7LS7C(=LYTWRW\*9AY F3*@OD:M.@$7:%7;SBLY\?9IPX+O? MRZ4HEY%19U-/:<>-*)>TP8&#IJS.F- G0TD36[DD26)8\L-1&RB9^ND)I(L=/O;,\. MYOS+Q$H)SE+ I Z.80WT)8ARJQS;+)^'+1]IY';=Q^Y#&>E4803S5:^*C,G. M8FW47[LAHE.5XA05%\H*2HIB'0JQ&G*O&A(OYN49ZMK%AIM[(,,B5BI"R[9@MM- MA1-K5RK$FW@).K5Y,GZ T1R7)"")[E>D9PKR=E:6 %.;9B_5'M)A8>0[RE? M06=.]@.&-5W?W#&8*HZ>H)8R08K=XQIUG'12X(!XKC:2HOC22$^6A=-A0$_+ MOCM4$U@^>765J,?EB!P=)C"W"A4CLD.,&U-H;0HB=<#Q%:BCPX%/=,LNPBWU MCJ?F';K-,B)/%6\/JZ+/[&*C0O2A'1Q8D*^2B:5M4%NZ+YJ5G_ >^G;GAP?& ME&R^CVQ[SZ(:@S6U1Q[6K:J6;IW7-484%[#)AVY%6P2IYY&$_M"$'7-_FM!&#R^ J#CVQ[[SE!2(1 M(1.J=8 ED^97E%%XICQ MM%R"Q=W#BI>!&H[YZELC]]X6-4LO8E4W1>RW;1(;/^U4\9B3]3.MNX@&\8J/ ME5#$@T4/GL-'HNH7KNZX+''U5XWG7P.S0!X:8QA4C:]7D8[<*()@S8%JQ^K#Q9T.N!%)TZJ)LG238XO=U1EP>;N M&7GTD@U?2+TA? F6;&+BQ?&>+]#N#\0-MWR.ZCF$^_HJC)BWAIO"J8#DGJ_- M A;'"W)/@U_DS=&0K]PB @^T"/) &O)A^8_IR:?>([:C![# Q,G4(]LU)R^A M0&%@Z6QG6J5=#;>"M3^TY?_=<34WU.;]KQK+-)[-MO5!BJ&=5"Z_T-'0 ?$< M3$_NP2/=\B'N5%HWA/IK_+S!'K@=U&V;_+Q!$;2FDY]C MZ4>8_-RSY)$Q<&&8Q?PH'+D8LC(W_J:F1D-9O18PWR"<&@VO=!5>UGJ;N'B( M9I*4/QW_[O"14;AQ#-X)+[4T70)I[X44;SNJ7=HM;NZ">+*D*[GQ1DE!E BJ MUK>.;Z#65!@LDUSU_(_B:GWC0J ;!>3>;F .U?,[=$<IL,>&F 8VB@Q>L/XMZ=0( M8FB6TE9#-Q*(D<14$_,'&20_DC%,DY-0 HHUXT"=#XL3Z?=\I;CET_KKE?&< MHR,)Y)!A8I#2K:X._1&#A9$:QG>_4F;B?!?WQ&-2NP@#6 8(9166__D?'HMX M2&T.5^R!1Z;6@KNY,W)0Z&:$FN5W0T_$0-!1@5ZN+H@O2$[>^H(\UUB9[<>G M9FA,UNI*8RZAT,4DE1&A0V .@=%)C_[QH:X\8W6,5,+&:C:4-<.T&\ "P(TE=2+)6Y[NCJFR($9>XXK1 MZDQ%O1XSC-&*3$6-YC.+T:&2RFIBU%8>W10JRQC]$=D5MJN6,@>MG9!'JI[2 MK=?9KF90:$!3\,&OM5W9+@@ 78B?])DTGNPO/?1K'WNI00.(R+N"J0*LCN?$J;N(#)R)DKT8*"QZD5KT1K%H)I$R501S:DV8)D@,QFC2@9W48@VJ M!^KY(,V',+KE0U\Y^7JYA20P\7Q9+%-0:T9L S)(QYJ^ABD5D>I( _$4U5B5 M7E=#U++.N01GJS ZB[D,HNR3Y"L>!1P'F^"9WJ;)ZN26^5B%( OQ."]:'''X MO&0O7A[^.0KC&%Y&I#Z8Y6?J!>\8W->YHT]F%M:F/6_$Z6;"#C"D1WB^V-11 MOW$!JQ"&"&E((0X!>1;D7D@$3WY9*F>'PIHU(+5"=$]-B ML;!1V6*:9F[H/C/D:C-$$SC5]9T1_K2J,"+$X)@DC6:!&E!8]4J1KROD0>/- MT9D+5';;\!7L'8NVRH'M,H'E;-5FG0$-I+'>RR1%^8^.!+ ?(!CK8UPR<>/% MQ$O8%JIQJ <&L-\AZH%DE?Z8K/2GALGCQG,V!$I8\RA@ZS 2PVC /%'Y@\9D MPWSW+ G/\M.'((Q($E$HH[T0%;$Y!^K^;9]E4,A:VG"#C3I.Q,!,"T+E)@^5 M_W)"WV=.5EW;$1D)7/('+]S'LN;(6;*AP1G7"2I21 ?B;7<\GB6#B#GA.A!R M>@%A:;'P17%(675:.75]DJF=H#JM0QI%L.7&C+9JJLL";G-/OREH*49 G-33 MCEU#V*CRT&%1:9^>X\?IL3W_I'ZTK-A#J#SE'HXT]M%F0 .6!J$!Z,YA;!I2 MS<&'K+58 !_O84&UJGIH+P4L3:! 5>@%B7C+P=NRGF.TW[>XU+9A ,.3)+P M\Q^9CO0XV_C4U6?ZYA!Z>KRNWCL3?9<5ET@ '*]BZ\_O*R9O.R$P&D MXY*Y,8XO#^CU1KP;;Z#$=/LPHP#W XONP_8K!!,9Q112,)2Y*:YCG8<^%P(J MY'H/;!E%W!:RA $WVR<>AS5?BS=@J-CMU'QB;T!&R+%I/.-6WX$YN$SB^;T'=9%/\N?<5MT$=+X'UCP>0O80(5 M4+WU)HD_[>O?+&GN@!1]])557BQI:(U^ITU+^('N+ :"*@S\#V'"Y,/9\L7L M9$.3_ UMQ9/%7AB#%T=\YL)%L8@YC(?3Y ^,C&DE29T(\D32)Y(!D1RLO"XR MIL:?!G,$BTO!_7WLN1Z-#K /=[T2MFHHG[H=BOO=Z!IHWE"IO:(X_I5E754*YMC#B" MVV4V]5J@3'+21-*V7*-P/&V7KNL!.>J36YAH#IDQ\YFMO9CKQMSKU8I%?+)< M_Y1G0UNDH::E8KX8KFN(?1W<*O< 2^ HY\%'"\EDXG7LB%KFJF64;;Z-.:6> M@XWS<90H8SS_U_'XSC_BZ_)]P/GO:)0<8#Y3L>!L:(848MH4 W2I:X-P[&X5 MU7RCJ" JI]H#+RBU7) C6EJY:;F.F-C2/M:VON M\O<8-[/Z8#DK4A$ 5A:7TYI"7^L>D]B?0]_=TN"6.IOX/*R?P-:T0QJLK:KE M$]>J1M@GK8TR#S!A3>D3P8#\$]WN_A7^Q\-PXGGK*(J6M3L/;4Y8)U#PG[*? MCEQ=G=O;G+KC#*Y7RG%XPY%)75ND8*.EHKHA5=D0XQ[3%U+"A8+?8M3\>FUM9@/ B?6EW&\9^[%'C:S94+V MB3V*KVH3FG0[(X4K,R.4B*>H714H%=N,I%\B&24/K*P2$]C%X1SDRTF M+@1[QB3F"_2R?U!Y,>*_,8AL[:5Y!>ISL]\FI,P]R[,'H,HSL6E MIE6(:$0%:=#W-$L^=>E. ON,IH=&IL&0/K2REHP@JS??\Z=%OH8,E(GG/!:L M44HC6V2OT/Q<&"=_@Z8UF66":9(% Q78Z=)#K.9[4*K-QT,M9@"3-@QZ(0^C+P+8T%1I-6T&3[(22 M, 4"]+ 7H3=1Z##FQO!$%DA&N:/#1>G\YDN-?73Z(8]8;=75R&WMA#B"]64W MGLRD'.0C9QD/>HC'1SG*=1O^^JTPEI:'=3NEC(M/5 OV[15F" M_5@O6(715L@"EQ83ZD&Y:3$%C;P'>-APYU-'[F%F.;[P;F*AZ -=W1/^B)%0",3:.SGECLBGN1TDW^,W5S! M"NUF[L"&D(^_#[V5.PP,G('R] M[-0OR*5XJ(?',_.]M7?O^5!=FJ]-P0;P5;WN M1_CV\9[Z9;X3'^%,8. "&E),3"U^O2K7\;&PZIE4^W0"E-9W*OWH@]8@>V3! M>?CBRG?J=W"J&F'&OEJEE/IB1RVP(UN]P+UW8.1V*B=?OLY ))_)JX(-K:=4 M32CE.S;W3,92;9Q+*'K75B'7M^:ZM/H=4K"H5"&_5II]@7"54BV?,1( )3O7 MGH%SY;AS^BUV'SH=:8Z^PNQ'0XTITI.L8.Q(N@Q=>4HK+C[2)V^[W]9&QO'W MB&.C4I4L.DI?(HV/:AE-O2JE9C%&1M%GP!7),KG;,/GD=':H#GEQL<9)LWY7 MI %C8H!\3:/9#_M*IZL:HYY T^0LV; S^7H*\;($%'CT/2[N#HFWK^"$(D[3 M38O3BM_%>>5=&RFW4QESF1#.B$A.1:*.X(7CQ'HZ2YQQ1F_#6[78N-CH M/MH:7Q"7W2=*X@XT>LE!]%'<'X;GO+)M]:A(1.<_/1?7$87O:4(BH1P!$(\> M.&4 X=4^V47IP9 (CD1EF:8H6*E):,DJN=/1+122JG6S<5X+ M6:[Y. */76;U$D5&>?6>8WLGS&BNK735RR'5/;!CMKX" \Q\ =:VZ9*49MR* M+$MYJZ"8S?*V!P&N\OA29&"FYU0<(R$7LX3$FL;7N&%J;1\C9?C=FER'.XD M@E#'"2.WVZP[A7 OXN,+U'&S]X#)2#]4Z1&3G$=1#59PL?N0R4B:?VSQR2'S M0QBW#8_'-5=!O/>;I?7?T .\?[>,BYE Y:%PM_Z8T=;$%$7V2(?.V#'82)>! MX'B7\P9,E6^BYW= =I(_/%M>7/\@KDP837M[H3MU5LB4YKHIV4<^,)[?$[HI M[%.PM)$I8L\B.AXS<#F$8A,%WC7V A%7G$$7G/D_GA!#[55$'0[8P;.SD8H MU3S0ZHD=,KLK,@!>!N7;Z_R_@>"6PJ#.M5X44D MLZP: K"S5.Q@&E-\*OD$;.8TN@2&E]!%PO4[+KW+QXD="V(AK%IQ[]VA:,,' M%5$Y])%&KMX#Z/WI(X7CT4Q9_=QY3^((C[S'T]$8R93'S06?,_C<):HTY7>/ M[P^EAJE(1,AD_U5S:1K.I:%*\W$;Y-%6J5*I *W: +'75\MI?!8H'$[48K9= M6]D\B N3!.X--T3M6R0CLT(> F,:^*34S\!\$ ?DJ.KV*C!$WK6,0N_242AM M6!Z%%&B JM(@H,W'5U";^_W?]W#VD [?UI\";;51G8FNO(!=)FQ;6RI@",)S MATEMXW4"Q5:J5Z 5[+M+MEU@W"$"$-5F@;WXQ?@H@YX3KP?LT285); M.:I-V1/\/SF (DC&GJ0*7,++^R .:;*%O&S*$N2EA#*I12'H$+. MF@I;A-I40/Y'(2+Y"D*25,JY[7!,8'+;CT8,8Q8Y)(UO_IS/ MMX.?9=..!)V2R;>!FD>Z(@/,;,8Z"E+*!?/[P)T(+0Y/=DW.SV89J^ M]KV7727_843;W28T2F9OO7NV]@)Q7T_;AO,9EL0B*+X,LI>BPGCP<\5&3L]\ M:&HP[Y"#4P6;9SP\-6F+88"2\A$OR(NO"QGG.9T?P]@IZ?R=.!Q(VO3,J/@R M%?O]$XL0X]O24S!&(91208U!.L/X31BGFP]YPC]DC#0C4G["@VGGF'G,U5L,&,@R-J MBP$H%?D00"5"8V=8ZL!1E_],'G&$%JO M*P8 5:0;=;]V]*7P\&96*!KMU2SC&U>9N2/-J-C&A\K;U:7WF>.\88.Z@$I[KB##MKU2=+?2LAH6*Q ; T-W,9[[T&#X MPPPZ.'24X3D/#Z:F0#% 5*8R/=Y#PK _ MPTA)5<]U !C8 AC.9DH)6/,$>R2_BG:^UG."_:7K>O ']2^\V/'#&(;4+&5C MI!^TC>305XKF.'KU^E$$&#R,)GN/8T<\0-BN>RU=M%,F) M$)TD7/9B8,G%KZCQ.^NBDQ9_N#FN(_3--DNS+_MC$?SZ5J M4[B?X96+R7^>HUL!MSSPF1@JW[Q: [/\F:%;2O^)PWV-#J0UPM29J?)C78O N3Z(^, MK3N3*/;,.DKYS8X2O7[6B1=?743\)L>?!%NJ1=TLU3>9Y[>7%99PY]EA_EY])'<(_BTY&!I8QB;UM/% M\F<6,QX'FV7@7K 'YH<[D/#]$\P V$?6D&>IUQ-Y7'=07XUNC6Z(8[R+]*8^ MG_$@G E1N)"4#?DJ&5D*^$E-0+D)W(*+O6#_F05\TNUSI9?NU@L\.(Q+O >F M$^ZZ?9$'?"<3J"&OU1%QT'>3W]3G4RXBZLM\D 3^M&: R*E-$2 MQ.-M$G)@"2DDM(.>> W^)8AR8B0&]/U6<%>>JWP(H_0C:/=ZZM^O3HAO%:$; M?Y1)8+M2@F\1RYL-@1;@%^FQ,5F%$5%$?V; /\ZOCEL"G$I))E\%-XN'167=K[R 729L6Y>^4-]Z5GY[HF:][^9-9^._IQ*; M^O"1MY*O0)H(VN-L]7)@OP^;!ZVQ=.5CVM9+9%#"%N]Y&"1\:&&!XYE5WMFZ M:U\$W:NW;UZ)D(-/_OHY&[0^>CX?5\. I8E7QR'7WAIIR&FJ"2'7TM1RR+FA M(YQ,S'.Z_3J]W?%NPPC=AGL>=7P 6>WA70FRS=B07]X"7< WTO[QD<[[G FY9=!DX_AZN)BSCF/'_<^_H4^WAO0DEI @X@'G* MF2F=R2">K/31QC2.KOCR-H"'ZE+FMA)4K&GNDET4NGLG(3'U;582O.&T6!0Q M5QRF-6:GU#1%'O--"JI!7=4.<=0VBFOJG#E1(JA:3B.90D5[@7=.8\B,@__ M[8X'#@-\ZM!P4Z&Q _(@;%=6#<7ZUH@#4D-HXZ4PIRG7P/"'0MWZ+87/?.8; M>4["W&KUJS]M2WGN0Q)Y( QAL*,D:6-ZB(-I$+5ZY!2GS&7 +:LBK_X;ZTG7 M]BS7 %36+V& 2(W 4VJ '$9.E3D>/]&'>(60O=S.;M@-K(V],/D8!NSPD4:_ ML.3#/G";Q^K:QLC#IUE)-92J6R(.JQ:!39U2D"62+A&$+0?Y:D9BEL M1M/'8NFB[*KON4_C^'HE]G,:]D^:VB,-(VU52Z5VZAHC##-]F8UG4T!0/'8D M=S0M;YBH^C76Z15HLRC*9?V*;?A#$7 M;K=AT'Z^5=4.>\35J58*N.-&F..M5M8^>61A@.) :S3E8M.CK)JE%ZP'S=^7%:"4$E-P MOLG'"Q8Y'O6]7V6YR"SQNG[R8DP):7P.8![E3H )&>SSG9Y:F2<8\)E/+,[% MO6 51EMY1W7'AZ_B[D FVZ)4V4W>A#F2C^0"DDK+0V"LRM*/H<. MGPQ]_YWX[W<_D,>-YVSD&S9\JD1B;B=!E,^W_'T,-:1\F:$*,J0%U19D'[,% MGV/Y_H)/MG@(B_NRD+DJ^GK;71B!; >2I[?>I.FM-.945E[ /[H_6+X"8>G' M3BO4J3_CLN5GM#AMLVRF3NX^X#"2QLP5%8%2/TC4M,,\!#2IE@-\52/L\-TH M\ZC@G'+. 79B*!M%\90HR0<-BR TIH)5PZ*JXI]>%N)<\;_XA]E'*:E_^_]0 M2P,$% @ CS!F3=%N: ;?)0 -,X" !4 !M9&=L+3(P,3@P.3,P7W!R M92YX;6SM75MSX[BQ?C]5YS_P3!Z25,4SDN_:VDU*8X\GSO'8*MNS29ZV:!*2 M<)8B'9#R97[] 4!*(B6 !$A0 "'59#,:";?N_M!H=#> G__V-@N<%X!B&(6_ M?.A_['UP0.A%/@PGOWR8QP=N[$'XX6]__>__^OE_#@Z<"P3%FM5YA,E_4^(^A/@..*&WJK61B]9O?Y@,/A$?UT6Q=W#D@$MF\;< MS!V:!L_)>_/X)'M/_]_KHPH)GK(SAQ@^>IB\M]]*+9)U+L MDUB+E$PACG]J2N)#@K%*1G(1A3X(,:;QAS@*H$\P_-D-"",?I@ DL1RE4@V; M2?#(1;C<%"30>7@71:WN,6'6P1091[#$,0Q MUM=XX8=X=",$8CS..FM K1ZTL.!A/INYZ/UN_ G(;95/!!)( D&]="^DW\#]SZ..5&0OD.U;6*'$A'E=]:DL:U$(@F5[DOR]X6"]N M0.8<'MDW%_T.$OJT(?TU.C+$ M",Z@2;YO.D&$VC:$['LP@7$"$/#OQF. \ Q63GU)%X8PX1_S$.#"9R.$09N M4>!ZU!^CG!65'1G"D&&23MGK.)X3IVWCA5:B!X,,+/KMW3/YJ((!0NT;1/X] MB!,$O81^JU(Y2O9D$$N^O)&/C4THH;8-(OM[B( 787/O!_#;9$%9/Z:Y7YI: M2@(M2Y/\G/.>W^ ?,SI)URHCM3F&@K<$A#[PE]_"A/35Z_4&/>? 6324_^B& MOI.VZM0+ %-:,;5!Y!7&$I#<@ A529=\\UL9A<,GK(U<+UDT%+A/($A;$JSW M26J(A.(8DTS)C8'W<1*]?/(!I)D1Y ,=_T&OGZ4H_ %_]5O:>VI;(;P%NW5G M8&W O&*_G1Z=GIWU>F>'QV=GYR>#H_.SW)#S&!JBXO!=Y"WZP!\W8%645U;B MTS.-]1YX4Q@L83)&T4R*H]DH(DFJ(H1-CE\^]#\X\QB/-:)K+8DX;TU"%Y@T MY ;7>)*\_2]XYXIHK9PM,A(A*Q/2H0XA+2A[Q.TR9)/_N?LBJ:0FD\213DF, M\!8QPC3YEWB'5"*20CE[9%--5B:D8QU"&N(A^F285X$[80BG\'OWA5)-3B:, M$YTSY@H;E6Z0 N<*?Q>7S)J-LD6J3C%5YQT3DAQIFT>X+2XJR3%KG&DWM=+CWX#E"9#=-\NJ8LZNL M>/>E)DU=)KF!/LE=P0"@"XRL283X6Z1"*5OD5$W48@_;TR>?+S. )AA$7U'T MFDR)Q\X-^7)BEK9%7N+$+>2FT?GP,'.#8)%DRY57H90M( MXWS9+OZ\;-K)M^UDC3O2YXFDT;T ]]B-GVA[\_A@XKK/*<)!D,2+;]:AGGW] MVY*!GZU0WFZ^X J;J&XD)$Q)OPJ$^Q)7 9OK@P("F.5Q%Z<(N9 MCD_)ZE\9>WD*1*X5JR"D@G9N*+%;8!HA\.S"10H,GE=WR12@ G,Y !*H:15H MZM++C71V"R@BD+!7^,)BWHR52HHY2MQ JSZ(G@%*WD>!F^ZF\1+[3*SV6\!7 M!/PJAH) >NI+4FC)XI RJW2RVR'@$EI4J6_-\_H&ND\PH%8-!C C2[Y\NRE: MO]#HT(MF3ZYW@@YI3@5S .%XWD6PH7$&* Y'NL&Y_A(8)>W$@P2I"I:-UX >HJ6B'A&,$)8 MH]&]B1G+B/#R81\@Y)!@D=59+7.3A:W81FC5:M0L<^F]18=V$XH146];T75/ MXF@Q6DI^67"+4=(X2#0&@2B1BHS%HG&@)=RYRK@IC6RN%;-/\D(4MN!+6%F$ MAYHV#+X/4S)&+O2OPPOW&>)%*\]+XLW#34V:N6<5NP45YK6S8EL8^Z @2"/WU&.W=K%5.[V:<3+C M8-&>CT.<_M92)PQ(Q5]_?B(GT9*\_),Z>?G.GPJ=_7F?IZ_9M8'%<8?H8'VZ MOQL!1(^8"'D[>)6-TR!U(^P-R+4D;E;D0'KZ:#A/IGAS_F.E%DI1LEZIR*[S MP=&@9P,ZA,BT).N"13FYNU(*$6D%J]%00J(EO@\6U?QCFX*UK,9$%9V6N#!R MOC])&T.@IC4 J4NK))$8Z?68Z0: MYDP:%UN.O<(KQ2VM9[K']+;O[+1BU=41O.+&3?,*D11GM@1-EGB4[K% ,#/) M^?A+\ *"B)Y2RSCPYD]Z E] QA@.KBIJV8:=.N1:XL_,5OMPLF = M!Q$;Y6S#@!B!EF3^+XE=)1=5R7U5TCC)2Y@=HN18DNU_'9+WUN(DI9;FEG'M MXXV279:S*#F*YK/^M&U*8DHM;R:O2G19LE5D6!)$N 5)I6XNE.FR3*L)4>7U MUZR/%XF:BPA'Q<:?5[S+LI:BR1+__CK-:X\B"TI_K99Q()"2;#4P1,BU9)/^ M3P G4TSC$-L1[@31":SM]_3&%PD&3O*51 M$5HXJA=:*'3G9/T9'&+(A:W2%8Z^T+EQ-D<$5:LE;V]V3#&*".L6G9H]X_Y MBIPS&Y$78[#\D@3!IWE"[LMYC-(L]@K(*VK=1HRUR1I;?-(<%BTO!AY'*"Y< M##ST_V\>)]F=CU4LE,2LHEZ-PW*;0!2'?9O<;6%WH/VZ)@8+*TY7E]0P#I,* M]*LLN:U%= RP[MUX>A5$KZ)6_7%-JQYWXRSZZ88UO^2,N.G.J*+)3BQ","'>'*. M_8\ MPR-R?5X^HUCE7026,!^L73PW'W:0 =%:U1V%D @76DF?;N 1(:_-4Y3T!D<] MBA'Z_CR7OD6:.(T0+/Z!31 7S;RJQJT9"^"5#.EA>SM%9SZIKOL&[OJC0-: M:\ZPACRQY!P7APO7X0N>: JB024-&0H$BDKG%X421_1@RI-CNLV=C1P_7 CZ\PQ[^Y248SW?"FO"%Y'6X0 MQ'=C_FOO_+!D\[9W"(VML-)4_/,&$4HSN#&AMGN M@*LA3UJ[T-X(:&7WJS6W_4L:,@YJBFQ_69*UQW\X_J[\FD\N3R3/$-S1)?UN MG+[T@!G ;5JL\+&[/$\MR@]S'>4:KB+V\ >3 NN?Z\HI[] M:&K&"CM?G19G;>Q60:UII<9/5/<8W)0L@=<*TM\-Q[E^A$ZZMCOX3_.@;/J M /\CW\=?G$4O?W'G-7AS32K.D]%[D;^U;%.CL=( M49M:[A1H,O053AXQHCX'_"?057=CS.JI%$Z%BP&VP;'6#J2TK_H>YK.9B][O MQ@]P$L(Q]$C$$WPQ,;M"+/+R^V2*]3>X:;:R]HGRBW7@[/JPLGU8;"^V^0) M1XF5%31*,S%6M\6J= EB#\'GQ2&9#8IJJRD5?1JCLZHA(:2(6N-)A[72#<06 MIT]>H [][Z$'$'F(/A%71$>;BFC9)+6XUAMM1?-PPB=@6^>I:#L;. MG\C]APE>2B^C^5,R?(KFR=>()/]&9+QAE?H0;\ 875!7L(43L,W([O!T9^Q( M,0O+4@0KYO_QYOPG[?\EO4PFUPU5!JN.G$)/!ILCV39]G6ELM5%5V!"_#D?D M5=JB1DO&J TQ,58X;VI1VV%M08.;TRC !,1II%Q0*YPPMB>YMO[H+%LS>.9O M4G\;)=5WQ)97TF(F,,^-P;5RHF_REG M\A^0B>P[:RT:K !R;NMQ?M3W("#9J/2=*GJ9"B5LD2G+41!-&]-R;XKHF#_G MQURE3AJV:HR240./PN4I+7"FP^8'>308)LNS#1'UR(!0PDUZQMB=K!JE6Y+U M9@W61R7\J'1H2-;5]79VY1 K]RA2C11G3!_/F"--VY,ZHEU_8+LAW1W6%&*Q M%:D8RV$/_ZD?8W'^M/CT9[.52F?#+077/AW2>[5RX%CQ,XPY81+_VH6*BC$A8@PI(#G&P?G>#4%JG;4034ITW[N28UP& Y75/R M.6C@5^@H!"0)LN3MU"L7HE_=8 YR.4/7(>;2?+:: 1P("-7M*!KJTZ;J^57- MP+C'@L%,)5KQ$KR (*(GT+.+%TMA(5"SHZ"H2YGVIUEY9U^QN5.Y_)>4[)@8 M92G)Q';6\9G,OHS\;I&)=1UZF"'P!9#K)LH5?HV6.@81U91F$#KO.(32VZ7I MLV(B.P5>\8Z"08J<3.*#CDN<\3182KVH&TBL>D<1T8B\A7NHUW&(K+\Z+8:, MBEH=!40=JA8XZ+J?\!:\YIB%HA!_]$!NFR0&#-EF.HH4)60NH-.==]9E TF/ MQ!$C%D8ZZAWVCIJ$D=*^]D&DEK8?WA3XOD \,E5 M+V1=G2_.L*WKU,H<.N4==53%;(D1'0YF2R0>R^BAXTT]))NIWQ%MU/F4_=4< M86/A81JAY!&@67I38IH%1E$$=9"=1LN3K9#/-F.-67,2"?TMT1\AS4-.\U7 M2JN<,JP;3K)O1[3'SF?]KN8)V]&8O_(NNXGL75+[U&W8&.VC/O>W)>98DNZS MXLYM1+4SR%V<0UGS/81)73C6:',GD*B*+]KSDS@AQJHYMWC)+Z"-TEU(_F?* M6WJ%DQ?A7?P/S%YZK1+]OA2"6^[=0K":P$%+LJM67/P>HB4KUAFUU 7#5Q?Y MLMN-VBU;"-VVN=-:\IG3]E?1N^ MG1%VS597(&@[.3DY.SH9],^.ST[.SP>:(_Z5QYX$:ABC86H*H"0E0)!8[7L$ MCGFV>% 94Y(^HHR79Y+:XDZPSB3YCZE4\.K^2N[T9]E8DDT8AP594:X92"K( M;_5,^Z%I:PNY(\PC*90D,(%)BV+",W*Z#F_!R?(NN^(T.4-V0.\K]:A#/AN0 M0T;DX"$YZ9@<.JC=7(Q.CH].#D_[QU@-'I]CV.HVGYL&M(AIUWKXD'1BG)J3 M%'.;444N?TKTH.9WB1N2_/F=W<#P#?(.UK78HW'8W *T-O&\;09SP6T.GF_= M&;B,9BX,I4"YJF8+$:H_VJ$'":#'::B"PBA99.@ MW"JJE(.XA(D=3E7DW_@NY8^5>ZZ@?;>J]H<+EB&ET^/3\T'_[*Q_HD'@ M_/3P[/RX?ZX[(+=^D*,RN+9>P1CMT4 $9<$R(7J-B@UP&, /5?$K&"=<2;EL M"E:25J,$N_$P[AH5[&\%_;/R31H'#DG9ECEP%7'#$H\_(;@41JL"QH%"N4S9 M.L5^$'R+0O">6G17\] OUROLPKL(#@E.6.(]9=RW66)\<$H;!Y7&EH<,H5PD MZ)#G(W+#&../'@ 'Z 7OF,,)^UK51SR6F/U3:5Z*RBZ,0XZ,X#=ATSIKM"]/ M' ?O182>(^0FX!($2OWP2%SW1&H81PN6I?L"DQUV;.=Q/9MWXS(9$.Y?5M6 M9Y>!59]!VHT=.;5S)*UVCO;HJ,N>%O)BM&>@+R^D__S^#;C$=T[X2 ZOE+GF M*FH9!Z[F5G(-@DO@HGFM&46(,C]9DK7\L(JAE.?-B;=@'!CJR)*13=>0 ]KM M6U4^.(3>L::^!UB;DK/N-(=%%DZ2K1@'J:9@8#GOFG/$$H@M7M#"*WY==273 MQ Z JS$[M%O)RHV?Y<>_0X"P;*;O-^0I%C$;J*1RD7W'F'VG]IA"LG1S[S?1 M*OR<$1!O4E3J()1JPS@H-)!D"2QJL\*2Y6I)\W7X/$]BRL=^Z>I44L-S>< (;U4?C-.*'7 M-BZJR2IY_U"M-T5 $O& M511A-1U=%J+[5B[$_.]=%F(E'6:N*/AQN QN@C<.(;C]Q4?AS'K\!$KG*ZN=;L M@WF6++"#5]<&!!RKR+T@"=@ M,?-@."-^_A_IA=0T&LG19++-V(4WI5Q0E=$1)6ZPH=>.C439ZI3I5Q3%,;G MW T(I[ZZ,/P,QA&YM^.M'O3$VMY)/#9@30NWPG<6I.1$?5L@+;2]!ZD<:TK< M<_6/I1L'T_SY]#SG!)'(J[X;8).BOH5=:P,T\9)RA5\C'";$$&&FZ4JV81=6 MU+$@ \Q9*Z;;^5%'31=Z>8-Z>V0"OMCB3H>[,)\9RK?_12=LG5TME[[>07[MR M;=0FHVZCA'<5855A12?:EH+Z-2(/B-S#R32);^?\ VTE%8R9Z&*,SAU#DR6J MPU>!;O+F'DQ@C(<"_+LQ'CRF7W;2;K[2Q)ZTJYZ<15=6SEVQ2LL["OM'IX<8 M88.>]BO?+J( DT".9,(7,$2(9$G,LJ7M-@H]SL_TW"BF"(-3\*HX51T9HW(: MB+PLPZ!5/AEU@]G#_"F&/G31.['-[\:4D25'/[CES8/$=J3)@)$4BP1>Z))V MP2B"QFKTY,&%NW&.(:5'0ZHKF@<6*9DQ9%Z/9.U)B!P#==,VX5^VP"N;)_B\ M=S(X[NF6<3T9K5FM4N2:E3RD1BW7R5[K(%GJ#BEK!(]P5/N>&76@Z;!&#ZTWCBXB_)625,TJJS<2SMB,4IM;&W2"YD/!NG%. )18_LVR14Z>8 M4^<[M@3(L\>HRV0V&>.R>5%J $JV8AQJQ(6W*7@5M)NZ9'P/\;A>2;Y/.%GJ M6O[*45+<.)&K$-O:4B)+OHTKB@*M>U-Q=%IE%\;!4MOZU3I7FQZT8.9NZ7&5 M1M[OUW$\!_[EG(00TL.C]"7<^!:\TI_X?E.1RL;!LG5TL-RGM3G5JF*5?JR6 ML[;FXA4I95\QLQ+@/T:+P\=#WX?IR%.B64NN?"N[C"V5+&LA\*,_:8"2FTZZ M$8(>6+SPS=-FO/*[#+)ZS&GUCGY-IQ!'*/( \&-RKP+A@QMZU+!9NM0YL*JL MMX=7728I.I/-RZ!?'NG3D9/[CWD(,!+/\&1[<1,P"ER/0 M#IVL1V?9Y3Y#]^SP?' Z&!SVC_JGFA8S.S)TC=!O-43.6!"WPR?[,W3-@,1V MI,F D12+=CY#UPRP2,F,(?-Z)&OWJZNRHXL&3?D+1\S"YB&BGD19=K PO9; MH:5<31- H6U-D6+1#N1JF@ &*9DP(AIB)%JB%!3E:AH@=T&YL4)8(J1IES?W M6'GX E "Z:VB"()XM!@/7ZCB%;LOY8:T6G).8Y^QI6S-E\[8:B5S=Y^QM<_8 M4KB*K.YG&JWGR/)7D,I*QHF_A>RM>DS8YW#M<[B,6=&VE<.E-GJXS^&R-D9M M30[7/KW&/&S52:]I)UM+4WH-9W;1=W%JZK!BW2(GSS G![L'L]J,:C6C2_K6 M,\Y^@9E%A-+@3!;H!\SKOX4J[C* &G*IY40M33'OHKMNY"+,#.+F3^=3Q7(H M5GF7,:> 4UM[KK;&MI3X?F,\G,QMG%H F4L8^'WN7K.BWAXQ=9G4B<"^B5Q!>1!]O J\L*VBMD%'R M;":8C:0@$5([$*D5F_Q$QW&4^_(W8X2M5:.7LX,;$MBJ))DS>.U78Z19S52& M +8[)[)N"5T&[=G7"L;J'R>,4%/U[)(X7"^17"E8U#@HJQ+EFJS=AA:G(V$;.K9UH MJ,<$2XYR=#K-]GQPW._MJ'G3.E?W:;9UDT<-@&7KZ!#.41/AE)5IMMO-B]QC M3HY1K:;B:GH-=DLWW>TFU.HQ25'Z;>5-=XT?:R1A#CQ_5K8PO4?\80J" M/O4XI.CR\W9OI,8KN$>D-\$$?451'"\4[\A])]NC84R(AS')$F6F3$K4WWD< M-696"[FWRNXU7[GS'@&:P9 *\C9*TE-:V$R\=-^YUYD+5=YY_#3C5*LYN,O$ M[2WEX'YV8^#CV?(,,"M)F_3;].5>N0S&77_;SI6W$M)-D&AC#%BWXZP&#'D2FX8 M)>#Z3%D1&OJCP VY:;MM=F413Y?%^#I MQ]NA7B7Y1!EMR^*KTR$3.A1]_>0/(@S'@FB_2#>UQ*WQV19Q_34V1 M00K+D.9S^AU6R9C[8P"3.;D;7<"?HK:G/;15JF11!C=-1V=BWPQW8O>M\@&6 M47\_"5IFKZ+\^M0J_Q)V>0'(UDGBN&H5]QO]['&O$O=B[-5^", ,S.EC-2<"#VS!J-CLHFO&[U,)^NEX&VPUJ]D\B> MF:,6T-IF6MGT4N\O-3]*QDU!8;K79VL)M:;HO!95)*:NL9P\6:T-D$Z;UN+;K9Y9$?([TQTLW 5#UG*$=5TH=P^P#*!';[M:7O\I>[7%9KW]RHNMV^KH3-'T!^3K$],PI:7?)%*#' MJ1MF4_=U0E-O;)^L*;W]Y(Q^!;$#[2"*@G76QDP'L_3-I#,7=RDWN.K5O5YY)6U-K M9KRBU>R9-",6W5:%M0F.:FX8)>#Z3#'OF303X%8M?I4']B098TG:23O/I)F MGJTA81.$?Z5$&AU!XJK6,<'&3%(RQ@^^T5K!@!9O04*]9+\ *" MZ)G0GWE>JM::38!<-NV;EIB82LO5FIQ- :T<>"S&97-89X'4JBR M>1AL!Q,,GV1]_K2VHNJ*J7T/$?"B20A_ +]F?.U8(KZ6[VX?;-L'V_;!MGVP M;1]LVP?;]L&V?;"M$YO*?;!M'VS;!]N,0]#.!=OVSBUSS;!VG5OMY.QK>CUQ MJ?D!>H$>8'-NF1A-F10_1HD;Y'\GVZC;*/DW2.Z7SH6JY5AU?^:!?EO>M.VR MU)+%OS6FI8>"KB*4?47*];<]&9B#V,\0C7SN\%6'Y&)!F*2.L1"S+$P@ED_H M01#+>:K/>OUU3W6N;<<-B;]D_[9T5G_ MK'^(_]*C12_!4[(Z4%7F6F:4-$X?-9?!INH1I=LHOR#9"-Z-8[1B^WK)4+7*6%&_Z3J%OG0QWPXTB-B*4$5Y=N, M6.U3F[-"_#T:CV=N>./>1]Z4G>[++6>45)N)9TVG"U.K7:QM;/:JPABZ'Z# 8B3* 2++"BVA<% MJ_T6XGMLJH9S0)Y)(JX0XO/X)TRF%W/,$&RU7H=>,"?OZPWC&.#_^8_N&S=X M+MV2)6A2S8%6(Y#'I2[EGS^EHLW\K'_]?U!+ 0(4 Q0 ( (\P9DV# Y D M290 -(,# 1 " 0 !M9&=L+3(P,3@P.3,P+GAM;%!+ M 0(4 Q0 ( (\P9DUX=T P[@H &UE 1 " 7B4 !M M9&=L+3(P,3@P.3,P+GAS9%!+ 0(4 Q0 ( (\P9DUGYSEMZP@ ,EL 5 M " 96? !M9&=L+3(P,3@P.3,P7V-A;"YX;6Q02P$"% ,4 M " "/,&9-)>4=^DX3 !Q3P$ %0 @ &SJ ;61G;"TR M,#$X,#DS,%]D968N>&UL4$L! A0#% @ CS!F35^9UNV / HMH# !4 M ( !-+P &UD9VPM,C Q.# Y,S!?;&%B+GAM;%!+ 0(4 Q0 M ( (\P9DW1;F@&WR4 #3. @ 5 " >?X !M9&=L+3(P D,3@P.3,P7W!R92YX;6Q02P4& 8 !@"* 0 ^1X! end